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BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that sends a signal
from the surface of a cell to the nucleus of a cell via phosphorylation cascades. This pathway regulates cell
growth, differentiation, and survival. BRAF is known to be mutated in about 50% of melanomas, and less
frequently in a wide variety of other cancers, making BRAF a bona-fide target for therapy. In melanoma, a
single V600E activation segment mutation (BRAFV600E) accounts for ~90% of BRAF mutant malignant
tumors. BRAFV600E selective inhibitors, such as vemurafenib, extend the survival of patients in the clinic,
however most patients develop drug resistance and progress at a median of 6 months. One mode of resistance
is “paradoxical activation” of RAF heterodimers. In this mechanism, a drug-bound BRAF protomer dimerizes
with either BRAFWT or CRAFWT, allosterically stimulating kinase activity and leading to hyper-activation
of the MAPK pathway.
The first part of this thesis involves my efforts to develop bivalent BRAF inhibitors to target paradoxical
activation of active RAF dimers. We successfully chemically linked two BRAFV600E selective vemurafenib
inibitors and found that this bivalent inhibitor stabilized an inactive face-to-face BRAF dimer conformation.
We then extended this strategy to pan-RAF inhibitor TAK632 to target BRAFWT and CRAFWT in cells.
Interestingly, this bivalent molecule was unable to “trap” two BRAF molecules in the same face-to-face
conformation as the bivalent vemurafenib inhibitor, but also uncovered that the monovalent TAK632
depends on induction of active conformation BRAF dimers to be able to potently inhibit RAF.
The last part of this thesis involved the development of a high throughput screen to discover novel inhibitors
that can disrupt the complex between BRAF and its downstream substrate MEK. We were able to design a
high throughput TR-FRET assay to identify 15 novel inhibitors that can inhibit BRAF/MEK dimerization.
Together, our studies identify novel RAF dimer inhibitors that can be used as chemical probes to further
understand BRAF signaling through RAF dimerization in melanoma and other BRAF-related cancers. These
studies also highlight a novel method of targeting paradoxical activation and RAF dimerization for melanoma
therapy.
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ABSTRACT 
DEVELOPMENT AND CHARACTERIZATION OF NOVEL RAF DIMER 
INHIBITORS TO TARGET BRAFV600E INHIBITOR RESISTANCE 
Michael J. Grasso 
Ronen Marmorstein 
 
 
 BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a 
pathway that sends a signal from the surface of a cell to the nucleus of a cell via 
phosphorylation cascades. This pathway regulates cell growth, differentiation, and 
survival.  BRAF is known to be mutated in about 50% of melanomas, and less frequently 
in a wide variety of other cancers, making BRAF a bona-fide target for therapy.  In 
melanoma, a single V600E activation segment mutation (BRAFV600E) accounts for ~90% 
of BRAF mutant malignant tumors.  BRAFV600E selective inhibitors, such as vemurafenib, 
extend the survival of patients in the clinic, however most patients develop drug resistance 
and progress at a median of 6 months.   One mode of resistance is “paradoxical activation” 
of RAF heterodimers.  In this mechanism, a drug-bound BRAF protomer dimerizes with 
either BRAFWT or CRAFWT, allosterically stimulating kinase activity and leading to hyper-
activation of the MAPK pathway.   
The first part of this thesis involves my efforts to develop bivalent BRAF inhibitors 
to target paradoxical activation of active RAF dimers.  We successfully chemically linked 
two BRAFV600E selective vemurafenib inibitors and found that this bivalent inhibitor 
stabilized an inactive face-to-face BRAF dimer conformation.   We then extended this 
strategy to pan-RAF inhibitor TAK632 to target BRAFWT and CRAFWT in cells.  
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Interestingly, this bivalent molecule was unable to “trap” two BRAF molecules in the same 
face-to-face conformation as the bivalent vemurafenib inhibitor, but also uncovered that 
the monovalent TAK632 depends on induction of active conformation BRAF dimers to be 
able to potently inhibit RAF.    
 The last part of this thesis involved the development of a high throughput screen to 
discover novel inhibitors that can disrupt the complex between BRAF and its downstream 
substrate MEK.  We were able to design a high throughput TR-FRET assay to identify 15 
novel inhibitors that can inhibit BRAF/MEK dimerization.   Together, our studies identify 
novel RAF dimer inhibitors that can be used as chemical probes to further understand 
BRAF signaling through RAF dimerization in melanoma and other BRAF-related cancers.  
These studies also highlight a novel method of targeting paradoxical activation and RAF 
dimerization for melanoma therapy. 
 
 
 
 
 
 
 
 
 
 
 
  
 
vii
Table of Contents 
 
Acknowledgements ............................................................................................................................... iii 
Abstract ...................................................................................................................................................... v 
Table of Contents ................................................................................................................................. vii 
List of Tables ............................................................................................................................................ x 
List of Figures ......................................................................................................................................... xi 
Chapter 1-the MAPK Signaling Pathway and Cancer ........................................................... 1 
1.1 Phosphorylation .......................................................................................................................... 2 
1.2 Kinase inhibitor development ............................................................................................... 4 
1.3 MAPK/ERK Signaling Pathway .......................................................................................... 8 
1.4 BRAF and Cancer ................................................................................................................... 12 
1.5 BRAF Inhibitors and Cancer ............................................................................................. 23 
1.6 Dissertation Objectives .......................................................................................................... 28 
Chapter 2- Chemically Linked Vemurafenib Inhibitors Promote an Inactive 
BRAFV600E Conformation ................................................................................................................ 31 
2.1 Introduction ............................................................................................................................... 32 
2.2 Results .......................................................................................................................................... 33 
2.2.1 Chemically linked vemurafenib molecules specifically and potently disrupt 
active BRAFV600E dimers ............................................................................................................. 33 
2.2.2 Crystal structures of Vem-6-Vem and Vem-3-Vem demonstrate that linked 
vemurafenib inhibitors force BRAFV600E subunits into a face-to-face inactive dimer 
conformation ................................................................................................................................. 38 
2.2.3 Functionalization of the linker can increase the potency of chemically linked 
vemurafenib over unlinked PLX .............................................................................................. 43 
2.2.4 Crystal structure of BRAFV600E/Vem-BisAmide-2 complex reveals the 
molecular basis for inhibition of BRAFV600E dimers .......................................................... 48 
2.2.5 Vem-BisAmide-2 can promote the formation of BRAFV600E dimers in solution
 ........................................................................................................................................................... 52 
2.2.6 Vem-BisAmide-2 is able to enter melanoma cells to selectively target 
BRAFV600E over BRAFWT ............................................................................................................ 54 
2.3 Discussion ................................................................................................................................... 56 
2.4 Methods ....................................................................................................................................... 58 
2.4.1 Plasmids ............................................................................................................................... 58 
2.4.2. Protein Purification ......................................................................................................... 59 
  
 
viii
2.4.3 Crystallization, Data Collection, and Structural Analysis .................................... 61 
2.4.4. In Vitro Kinase Assay ...................................................................................................... 63 
2.4.5. Thermal Stability Assays ................................................................................................ 64 
2.4.6. Analytical Ultracentrifugation (AUC) ....................................................................... 65 
2.4.7.Cell Viability Assays ......................................................................................................... 66 
2.4.8 Small Molecule Inhibitors ............................................................................................... 66 
2.4.9. Western Blotting ............................................................................................................... 66 
2.4.10 Inhibitor Synthesis .......................................................................................................... 67 
Chapter 3- TAK632 promotes inhibition of BRAF through the induction of 
inhibited dimers ................................................................................................................................... 68 
3.1 Introduction ............................................................................................................................... 69 
3.2 Results .......................................................................................................................................... 70 
3.2.1. Bivalent TAK inhibitors have reduced potency relative to monovalent TAK in 
vitro .................................................................................................................................................. 70 
3.2.2 Monovalent TAK inhibitors promote BRAF dimers while bivalent TAK 
inhibitors do not ........................................................................................................................... 74 
3.2.3 The bivalent nature of the linked TAK inhibitors is required to reduce inhibitor 
potency and to promote BRAF monomers ............................................................................ 80 
3.2.4 Bivalent TAK inhibitors display distinct BRAF properties ................................... 83 
3.2.5 Trp450, Arg506 and the αC-helix play a significant role in dimer formation 
via TAK binding ............................................................................................................................ 85 
3.2.6 Type II αC-in and Type I αC-out inhibitors promote BRAF dimers and 
monomers, respectively .............................................................................................................. 90 
3.3 Discussion ................................................................................................................................... 93 
3.4 Methods ....................................................................................................................................... 97 
3.4.1. Plasmids .............................................................................................................................. 97 
3.4.2 Protein Purification .......................................................................................................... 98 
3.4.3. In Vitro Kinase Assay .................................................................................................... 100 
3.4.4. Analytical Ultracentrifugation (AUC) ..................................................................... 101 
3.4.5. Limited Proteolysis. ....................................................................................................... 102 
3.4.6. Differential Scanning Calorimetry (DSC) .............................................................. 102 
3.4.7. Small Molecule Inhibitors............................................................................................ 103 
3.4.8. General Chemistry Information ................................................................................. 103 
3.4.9. Synthesis of TAK-X-TAK dimers ................................................................................ 104 
3.4.10. Synthesis of TAK-L ...................................................................................................... 107 
  
 
ix
3.4.11. Synthesis of TAK-L-C 14: 2-(2-(2-(2-oxo-2-(thiazol-2-
ylamino)ethoxy)ethoxy)ethoxy)acetic acid. ........................................................................ 108 
3.4.12 Synthesis of TAK-L-C. ................................................................................................. 109 
Chapter 4- A High-Throughput Approach to Identifying Novel Small Molecule 
Inhibitors that Target BRAF/MEK Heterodimerization .................................................. 110 
4.1 Introduction ............................................................................................................................. 111 
4.2 Results ........................................................................................................................................ 112 
4.2.1 Mutations in the solubilized E. Coli construct of BRAF allows for restoration 
of MEK complex formation and kinase activity in vitro. ................................................ 112 
4.2.2. Development and optimization of a Time-Resolved Fluorescence Resonance 
Energy Transfer (TR-FRET) assay to identify small molecules disrupting a 
BRAF/MEK complex. ................................................................................................................ 115 
4.2.3 Plumbagin and thymoquinone can selectively disrupt a BRAF/MEK complex
 ......................................................................................................................................................... 121 
4.2.4 ChemDiv and ChemBridge 136 plate screen set up and analysis ..................... 126 
4.3 Discussion ................................................................................................................................. 136 
4.4 Methods ..................................................................................................................................... 137 
4.4.1. Plasmids ............................................................................................................................ 137 
4.4.2 Protein Purification ........................................................................................................ 139 
4.4.3. In Vitro Kinase Assay .................................................................................................... 144 
4.4.4 Differential Scanning Fluorimetry (DSF) assays .................................................. 146 
4.4.5 Differential Scanning Calorimetry (DSC) assays .................................................. 146 
4.4.6 TR-FRET assay 50:50 screen ...................................................................................... 147 
4.4.6 TR-FRET assay Natural Product Pilot Screen ....................................................... 148 
4.4.10 High Throughput screening ....................................................................................... 149 
4.4.11 Data Analysis using Tibco Spotfire Software ....................................................... 150 
4.4.12 Inhibitors ......................................................................................................................... 150 
4.4.13 Library ............................................................................................................................. 151 
Chapter 5- Conclusions and Future Directions ..................................................................... 152 
References ............................................................................................................................................ 156 
 
 
 
 
 
 
 
  
 
x
  List of Tables 
 
 
Table 1 Summary of crystallographic statistics………………...………….………….39 
Table 2 Natural Product pilot screen results…………………...…………………….121 
Table 3 ChemBridge and ChemDiv screen results………...…………...…………….130 
Table 4. ChemBridge and ChemDiv screen results IUPAC names…………………132 
Table 5 Initial hits…………………………………………...…………...…………….133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
xi
List of Figures 
Figure 1 The human kinome.............................................................................................................. 3 
Figure 2 DFG-in versus DFG-out. ................................................................................................... 7 
Figure 3 MAPK/ERK signaling pathway. ................................................................................. 11 
Figure 4 Mutations in BRAF. ......................................................................................................... 14 
Figure 5 RAF homologues and conserved regions. ................................................................ 15 
Figure 6 Crystal structure of the BRAF kinase domain. ..................................................... 17 
Figure 7 Inactive vs. active forms of BRAF. ............................................................................. 18 
Figure 8 R509 dimerization stabilization in BRAF. .............................................................. 20 
Figure 9 Monomeric BRAF crystal structure shows αC-helix shift. .............................. 21 
Figure 10 BRAF:MEK complex. ................................................................................................... 22 
Figure 11 BRAF:MEK complex interactions........................................................................... 23 
Figure 12 Resistance in melanoma patients treated with vemurafenib......................... 24 
Figure 13 Vemurafenib binding. ................................................................................................... 26 
Figure 14 Transactivation model. ................................................................................................. 27 
Figure 15 Structure of BRAF kinase domain and rationale for linked vemurafenib 
BRAF inhibitors. ................................................................................................................................. 34 
Figure 16 PLX4720 (PLX) vs PLX4032 (Vem) ........................................................................ 36 
Figure 17 Potency of first generation linked vemurafenib inhibitors. ........................... 37 
Figure 18 Structure of BRAFV600E/Vem-6-Vem complex. ................................................... 41 
Figure 19 Structure of BRAFV600E/Vem-3-Vem complex. ................................................... 44 
Figure 20 Vem-BisAmide inhibitors against BRAFWT. ........................................................ 46 
Figure 21 Development of second generation linked vemurafenib inhibitors. ........... 48 
Figure 22 Simulated annealing omit map of Vem-BisAmide-2 and Q461. .................. 50 
Figure 23 Structure of BRAFV600E/Vem-BisAmide-2 complex and functional 
characterization of Vem-BisAmide-2. ......................................................................................... 51 
Figure 24 AUC sedimentation velocity of Vem-BisAmide-4 vs. Vem-BisAmide-2 
complexed with BRAFV600E/R509H. .................................................................................................. 54 
Figure 25 Activity of Vem-BisAmide-2 against melanoma cell lines. ............................. 55 
Figure 26 Structure of TAK632 bound BRAF and rationale for linked TAK 
inhibitors. ................................................................................................................................................ 72 
Figure 27 Potency of first generation bivalent TAK inhibitors. ....................................... 74 
Figure 28 Sedimentation velocity experiments of bivalent TAK inhibitors. ............... 76 
Figure 29 Bivalent TAK inhibitors versus bivalent vemurafenib inhibitors. ............. 77 
Figure 30 Sedimentation velocity and sedimentation equilibrium experiments of 
bivalent TAK inhibitors.................................................................................................................... 79 
Figure 31 Biochemical and biophysical properties of TAK-linker compounds. ........ 82 
Figure 32 Determination of bivalent TAK inhibitor binding modes to BRAF. ......... 84 
Figure 33 BRAFR509H dimer interface via TAK632 binding. ............................................. 88 
Figure 34 Sedimentation velocity experiments of dimerization mutants and αC-
in/αC-out inhibitors. .......................................................................................................................... 92 
Figure 35 Superposition of BRAFV600E/Vem-BisAmide-2 with BRAFWT/TAK632. . 95 
Figure 36 BRAF and MEK complexation in vitro. .............................................................. 114 
Figure 37 E667F mutation restores complexation and activity. ..................................... 115 
  
 
xii
Figure 38 TR-FRET assay diagrams. ........................................................................................ 117 
Figure 39 Optimization of high-throughput screen............................................................. 120 
Figure 40 Confirmation of hits. ................................................................................................... 123 
Figure 41 Confirmation of hits using DSF and DSC. ......................................................... 125 
Figure 42 Fluorophore concentrations halved. ..................................................................... 127 
Figure 43 44,000 compound screen results. ............................................................................ 128 
Figure 44 Dose response repeat. .................................................................................................. 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1-the MAPK Signaling Pathway and Cancer 
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1.1 Phosphorylation 
 
Protein kinases are enzymes that modify other proteins by adding phosphate groups 
to them to either regulate activity, localization, or interactions between various molecules.   
Kinases are involved in a large percentage of the signal transduction within eukaryotic 
cells, sending signals either from the surface of a cell to the nucleus of a cell, or managing 
cross talk between different cell types (Manning, Whyte, Martinez, & Hunter, 2002).  One 
of the first protein kinases to be discovered was cAMP-dependent protein kinase (PKA) in 
1968, leading the way for  further analysis and classification of these essential and complex 
enzymes (Walsh, Perkins, & Krebs, 1968).  The further discovery of Src led to the 
elucidation that while existing kinases were known to phosphorylate serine and threonine, 
Src was a tyrosine kinase, opening the door for different mechanisms of phosphorylation 
(Hunter, 2009).  Furthermore, in 1982, sequence screening led to the discovery that PKA 
is related to Src gene kinases, establishing that these proteins stemmed from a common 
ancestor (Barker & Dayhoff, 1982).     
 These discoveries led to the illumination of the protein kinome, one of the largest 
eukaryotic families of proteins, corresponding to close to 2% of the entire genome (Figure 
1) (Taylor & Kornev, 2011).  As more kinases were discovered through the surge of cloning 
technologies, a study was performed to map conserved regions of the catalytic domains 
through alignment and amino acid sequence similarities to elucidate properties and 
functions of the catalytic core (S. Hanks, Quinn, & Hunter, 1988).  This study revealed 11 
highly conserved subdomains within the catalytic region of the kinase, later expanded to 
12 regions (S. K. Hanks & Hunter, 1995).   With primary structure alone, a phylogenic tree 
was adapted, allowing predictions of function and substrates just by looking at conserved 
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residues, as well as reflecting evolution stemming from gene duplication events or from 
speciation.    
 
Figure 1 The human kinome. 
Black circles represent publicly available structures.   The 7 subfamilies are as follows:  
AGC (Containing PKA, PKG, PKC families), CAMK (Calcium/calmodulin dependent 
protein kinase), CK1 (Casein kinase 1), CMGC (Containing CDK, MAPK, GSK3, and 
CLK families), STE (Homologs of yeast sterile 7, sterile 11, sterile 20 kinases), TK 
(tyrosine kinases), and TLK (tyrosine kinase-like).  Figure taken from (Taylor & Kornev, 
2011). 
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In 1991, the first crystal structure of a kinase, PKA, was solved, allowing for the 
previously classified subdomains to be mapped to corresponding secondary structure 
(Knighton et al., 1991).   This crystal structure resolved the now common kinase catalytic 
domain, consisting of a smaller N-terminal lobe (N-lobe) and a larger, C-terminal lobe (C-
lobe) with a cleft being formed between the two lobes.  This cleft is the site of catalysis, 
with substrate, ATP and Mg binding between the two lobes.  Five β strands encompass the 
majority of the N-lobe, with an α helix on the surface.  The C-lobe, in contrast, is composed 
mostly of α helices (Knighton et al., 1991).  While kinase structures may differ slightly 
from enzyme to enzyme, the main structural motifs are present in all human kinase 
structures (Taylor & Kornev, 2011).  Because kinases regulate signal transduction, they are 
often linked to disease as mutations in these enzymes can cause aberrant cell growth, as 
well as halt or hyper activate important mechanisms needed for survival (Ochoa, Bradley, 
& Beltrao, 2018).  These initial studies on kinase structure and function paved the way for 
drug development to target a wide variety of diseases and enzymatic pathways.     
 
1.2 Kinase inhibitor development 
One of the first molecules developed for the inhibition of kinase activity is 
Staurosporine, a natural product isolated from bacteria Streptomyces (Omura et al., 1977).  
It was discovered to hit important kinases such as PKA and v-src p60 with half maximal 
inhibitory concentration (IC50)’s in the low nanomolar range (Nakano et al., 1987).   This 
inhibitor was later found to be an ATP-competitive inhibitor, binding in the pocket ATP 
binds to trigger a phosphorylation event.  However, it was also found to lack selectivity, 
hitting many kinases known in the human kinome (Karaman et al., 2008).  While this 
inhibitor lacks the selectivity needed to be a fruitful molecule in the clinic, it brought about 
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the need for selectivity testing, as the initial sequence alignments and structure studies shed 
light on the similarities of structures within the human kinome, despite very different 
targets and pathways.  Staurosporine is also a useful tool in research, and even led to the 
FDA approval of Midostaurin, a semi-synthetic stauro sporine analog used for treatment 
of acute myeloid leukemia (AML) (Weisberg et al., 2002).   
In 2001, the first kinase small molecule inhibitor, imatinib (Gleevec) was approved 
by the FDA (Müller, Chaikuad, Gray, & Knapp, 2015).   The clinical success of imatinib 
led to optimism in the field of drug discovery and kinase inhibition, as it was shown to treat 
patients with chronic myelogenous leukemia (CML) (Jänne, Gray, & Settleman, 2009).  
While success in the clinic is not easy to come by, kinase inhibitors’ impressive results in 
a variety of cancers as well as the potential that comes from such a large enzyme family 
lends to the importance in the field of medicinal chemistry and pharmacology (Knapp & 
Sundström, 2014).   
 Out of the class of inhibitors currently available, there are four classes of kinase 
inhibitors.  ATP mimetic inhibitors that bind in the ATP active site cleft make up the first 
two classes of kinase inhibitors, whereas those that stabilize an “active” state are type I 
inhibitors and those that stabilize an “inactive” state are type II inhibitors (Müller et al., 
2015).  The classification of “active” versus “inactive” comes from the position of the DFG 
motif, a conserved three residue patch in almost all kinases that is involved in magnesium 
binding and stabilization near the active site pocket.  When the motif is flipped inward, this 
is considered an active conformation, whereas the flipping outward to open up an allosteric 
pocket refers to a type II, inactive conformation (Figure 2) (Treiber & Shah, 2013).  
Kinases are known to be highly dynamic and thought to alternate between the active and 
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inactive states when not bound to any substrate or inhibitor.  These different classes of 
inhibitor can stabilize either state through by extending to occupy not only the ATP binding 
region but also an accompanying allosteric pocket within the binding cleft (Treiber & Shah, 
2013).  Type III kinase inhibitors are allosteric inhibitors that bind to a region other than 
the ATP site.  While these are less common than types I and II, there have been examples 
of type III that have been approved by the FDA, such as Trametinib    (Salama & Kim, 
2013).  Type IV inhibitors, meanwhile, bind to surface pockets of the kinase to block 
protein-protein interactions.  This class of kinase inhibitor is the least studied of the four 
(Müller et al., 2015).  Through the utilization of these four different classes, more selective 
inhibitors can be developed to produce highly potent and selective molecules targeting 
specific pathways involved in diseases such as many different types of cancer.   
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Figure 2 DFG-in versus DFG-out. 
Figure A, left, shows protein kinase ABL bound to inhibitor VX-680, a type I inhibitor that 
stabilizes a DFG-in, active conformation, flipping the activation segment (yellow) to the 
right.   Figure B, right, shows ABL bound to type II inhibitor Imatinib, stabilizing a DFG-
out, inactive conformation, flipping the activation segment (yellow) to the left.   Both 
figures show the inhibitors in black sticks.  The gatekeeper residue is shown by an orange 
circle, and the DFG motif is shown by a magenta circle.  Figure taken from (Treiber & 
Shah, 2013). 
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1.3 MAPK/ERK Signaling Pathway 
The mitogen-activated protein kinase (MAPK) signaling pathway is a family of 
kinases that help to send a signal from the surface of a cell to either the nucleus or 
cytoplasm of a cell to regulate cell growth, survival, and differentiation (Wellbrock, 
Karasarides, & Marais, 2004).    These signals are sent through the activation and process 
of a cascade of three kinases that trigger one another in succession.  The most upstream 
kinases are MAPK kinase kinases (MAPKKK) which are serine/threonine kinases that 
phosphorylate and activate the MAPK kinase (MAPKK) dual specificity 
serine/threonine/tyrosine kinases, which then phosphorylate the final kinases in the 
cascade, the MAPKs, which have many different substrates within the nucleus as well as 
the cytoplasm (Acosta & Kadkol, 2016; Wellbrock et al., 2004).  Within the MAPK 
signaling pathway family lies four distinct cascades, named after their downstream 
MAPKs; the extracellular signal regulated kinases 1/2 (ERK1/2), Jun amino-terminal 
kinases 1/2/3 (JNK1/2/3), p38-MAPK, and extracellular signal regulated kinase 5 (ERK5).     
These pathways are usually regulated by growth factors binding to receptor tyrosine 
kinases (RTKs) but can also be initiated via stress (Acosta & Kadkol, 2016).  RTK’s 
contain an extracellular binding region capable of binding growth factors, as well as a 
transmembrane domain and an intracellular domain that contains a kinase domain.   Growth 
factor binding activates the intracellular kinase domain, allowing for dimerization and 
trans-phosphorylation to trigger recruitment of adaptor proteins to further initiate pathway 
activation (Katz, Amit, & Yarden, 2007).   Adaptor proteins can bind to phosphorylated 
regions of RTKs as well as guanine-nucleotide exchange factors (GEFs), which bind 
GTPases and allow release of GDP and, in turn, initiate binding of GTP.  This GTP binding 
  
 
9 
can activate the GTPase, which allows for activation of the MAPKKK, triggering the 
phosphorylation cascade (Acosta & Kadkol, 2016). 
One of the most studied MAPK signaling pathways is the ERK1/2 pathway, due to its 
heavy involvement in cancer and disease, and the terms “ERK1/2 pathway” and MAPK 
signaling pathway” are often used interchangeably referring to ERK1/2  (Wellbrock et al., 
2004).  In 1983, the isolation of the v-raf oncogene from a mouse retrovirus was reported, 
and was later found to be a serine/threonine kinase (Moelling, Heimann, Beimling, Rapp, 
& Sander, 1984; Rapp et al., 1983). V-raf’s cellular homologue, CRAF, was later 
discovered in human cells and characterized as a proto-oncogene (Bonner et al., 1985).  
The corresponding protein CRAF would later be characterized as a MAPKKK in the 
ERK1/2 MAPK signaling pathway, however the discovery of the CRAF gene paved the 
way to this discovery (Hugo Lavoie & Therrien, 2015; Wellbrock et al., 2004).  While 
human homologues ARAF and BRAF were discovered shortly thereafter, little was known 
other than that they were proto-oncogenes whose corresponding proteins had kinase 
activity (Huleihel et al., 1986; Ikawa et al., 1988).   In 1987, ERK, then known as MAP-
kinase due to its ability to phosphorylate microtubule associated protein 2 (MAP-2), was 
discovered and characterized as being activated by growth factors such as insulin (Boulton 
et al., 1991; Ray & Sturgill, 1987; Rossomando, Payne, Weber, & Sturgill, 1989).  
ERK1/2’s MAPKK, MEK1, was soon discovered, and this was connected to the RAF 
proteins when MEK1 was found to be a substrate of CRAF (Crews & Erikson, 1992; 
Kyriakis et al., 1992).  ERK1/2 activation was found to be initiated by insulin, and this was 
corroborated with studies connecting CRAF with receptor tyrosine kinases and RAS, the 
upstream GTPase (Chuang et al., 1994; Kolch, Heidecker, Lloyd, & Rapp, 1991; Morrison, 
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Kaplan, Rapp, & Roberts, 1988).  The relationship between RAS and RAF was further 
elucidated when RAS was found to interact directly with the amino (N) -terminus of RAF, 
activating it, and soon a clearer picture of the ERK1/2 signaling pathway was revealed 
(Dent, Reardon, Morrison, Sturgill, & Iol, 1995; Vojtek, Hollenberg, & Cooper, 1993; X. 
F. Zhang et al., 1993).  Upon binding of growth factors, receptor tyrosine kinases can 
dimerize and activate one another, initiating bonding of adaptor protein GRB2, which can 
then bind guanine-nucleotide exchange factor SOS, which can interact and stimulate GTP 
binding and activation of RAS.  This activation stimulates N-terminal binding to the RAF 
proteins, triggering the phosphorylation cascade of RAF phosphorylating MEK and MEK 
phosphorylating ERK (Figure 3). (Acosta & Kadkol, 2016; Hugo Lavoie & Therrien, 
2015; Wellbrock et al., 2004).  
 
 ERK1 is the first of the MAPK proteins to be discovered, and ERK2 was cloned 
shortly thereafter (Boulton et al., 1991).  These proteins share 83% amino acid sequence 
identity (Boulton et al., 1991; Cargnello & Roux, 2011).  After activation via RTK and 
RAS stimulation of the RAF-MEK-ERK phosphorylation cascade, ERK proteins can either 
phosphorylate their targets in the cytoplasm or be imported to the nucleus to phosphorylate 
nuclear substrates (Cargnello & Roux, 2011; R. H. Chen, Sarnecki, & Blenis, 1992).  A 
recent proteomics study reported that ERK has over 600 direct target sites, highlighting the 
immense scope of ERKs functionality (Ünal, Uhlitz, & Blüthgen, 2017).  ERK mainly 
controls cell proliferation through its target phosphorylation, and can do so by multiple 
mechanisms, but is also known to regulate transcription factors such as Elk-1 (Cargnello 
& Roux, 2011).   
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Figure 3 MAPK/ERK signaling pathway. 
A schematic illustrating the ERK1/2 signaling pathway, in which growth factor binding 
stimulates RTK dimerization and activation of the RTK kinase domain.  This allows 
adaptor GRB2 to bind and recruit SOS, which can bind and activate RAS by promoting 
GTP binding.  RAS-GTP binding to RAF proteins then stimulates a phosphorylation 
cascade in which RAF proteins activate MEK and MEK activates ERK.  This figure is 
adapted from (Wellbrock et al., 2004). 
 
 
 
 
  
 
12
 
1.4 BRAF and Cancer 
 
 The ERK1/2 pathway has been heavily studied since its discovery due to its 
involvement in cell proliferation, as well as its hyper-activation in about 30% of tumor cell 
lines (Hoshino et al., 1999).  In the late 1990’s and early 2000’s, RAS was the focal point 
of many researchers’ studies due to its mutations in 15% of all human cancers. However, 
it was soon discovered that BRAF, one of the three homologues of the RAF proteins, had 
a high frequency of mutations in cancers such as melanoma (60%), colorectal cancers 
(18%) and gliomas (11%), among others (Davies et al., 2002; Wellbrock et al., 2004).  
While many different BRAF mutations can be found in cancers, a majority of them are 
found in the kinase domain. Of these mutations, 98.4% occur at the specific residue valine 
600.  Of those mutations, 97.8% of them are one specific point mutation:  a glutamate 
instead of the valine (V600E) (Figure 4) (Hugo Lavoie & Therrien, 2015).   
 While BRAF has become a focus due to its major role in cancer, particularly 
melanoma, the other RAF homologues, ARAF and CRAF, also play an important role in 
ERK1/2 signaling.   Although the three homologues differ in protein sequence, they have 
three conserved regions, CR1, CR2, and CR3 (Figure 5).  CR1 consists of two particular 
regions, a RAS binding domain (RBD) that acts as an auto regulatory domain and frees up 
the kinase domain for activation after binding RAS, and a cysteine rich domain (CRD) 
(Tran, Wu, & Frost, 2005).  The CR2 domain acts as regulatory domain that can bind 14-
3-3 proteins upon phosphorylation by kinases such as PKA (Cook & McCormick, 1993; 
Muslin, Tanner, Allen, & Shaw, 1996), and CR3 is the kinase domain (Hugo Lavoie & 
Therrien, 2015). 
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 Interestingly, BRAF mutations are much more predominant in cancer patients than 
in CRAF or ARAF, and this is due to sequences within the kinases right before the kinase 
domain (Forbes et al., 2011; Wellbrock et al., 2004).  The RAF kinases are regulated not 
just by RAS binding but also by multiple phosphorylation events, and one of these occurs 
on an N-terminal acidic (NtA) region right before the kinase domain that requires a 
negative charge in order to activate the kinases.  In ARAF and CRAF, these sequences are 
SSYY (residues 299-302 in ARAF and 338-341 in CRAF), and must be phosphorylated 
by SRC kinases on the tyrosine residues and casein kinase 2 (CK2) on serine residues (Diaz 
et al., 1997; Ritt et al., 2007; Williams, Roberts, & Li, 1992).  In contrast, BRAF has the 
sequence SSDD in its NtA region, resulting in less phosphorylation events needed for 
activation (Marais, Light, Paterson, Mason, & Marshall, 1997).  Moreover, negative charge 
is needed for CK2 to phosphorylate the serine residue in the NtA region, meaning its 
phosphorylation of BRAF is unregulated whereas ARAF and CRAF are SRC-dependent 
(Figure 5)  (Ritt et al., 2007).  BRAF, therefore, only needs RAS binding to its N-terminus 
and phosphorylation on its activation segment to be activated (Hugo Lavoie & Therrien, 
2015).  This “priming” of RAF activation leads to a more activated kinase than ARAF or 
CRAF (Wellbrock et al., 2004).  This also explains BRAF’s V600E mutation, as this 
mimics activation segment phosphorylation, which is otherwise required on residues T599 
and S602 in BRAF (B. H. Zhang & Guan, 2000).  While all three RAF isoforms are known 
to phosphorylate MEK, to what degree and how these three kinases function together is not 
completely understood.   Many studies have shown evidence that BRAF:CRAF 
heterodimers exist in cells and exhibit higher activity than respective RAF homodimers, 
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and one particular study suggests that ARAF can act as a scaffolding protein to regulate 
these heterodimers (Hugo Lavoie & Therrien, 2015; Rebocho & Marais, 2013). 
 
 
Figure 4 Mutations in BRAF. 
Pie graph showing the prevalence of point mutations at residue 600, primarily V600E.  
Taken from (Hugo Lavoie & Therrien, 2015) 
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Figure 5 RAF homologues and conserved regions. 
The three RAF homologues, ARAF, BRAF, and CRAF, shown via conserved regions in 
their protein sequences.  CR1 contains a Ras Binding Domain (purple) and a cysteine rich 
domain (orange).   CR2 contains a serine/threonine rich region (cyan) that can be 
phosphorylated to promote binding by 14-3-3 proteins.  CR3 is the conserved kinase 
domain (red).   NtA residues needed for activation in all three homologues are shown.  
Figure is adapted from (Wellbrock et al., 2004). 
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 In 2004, the first crystal structure of the BRAF kinase domain was solved by co-
crystallizing with one of the first kinase inhibitors, Sorafenib (Wan et al., 2004).   The 
kinase domain, crystallized with an inhibitor, was well resolved except for the N terminus 
(Q433-S447) and the activation segment from residue K601 to Q612 (Wan et al., 2004).   
This crystal structure confirmed that BRAF adopts the canonical kinase structure shown in 
Figure 2, with an N-lobe and a larger C-lobe, and the inhibitor inhabiting the cleft between 
the two lobes.  Due to structural comparisons to a previous c-Abl crystal structure, it was 
determined that this inhibitor was establishing an inactive form of the kinase, with a DFG-
out conformation (Wan et al., 2004) (Figure 6).   Despite being in the inactive 
conformation and the activation segment being mostly disordered, the authors proposed 
that BRAFV600E is able to initiate an active conformation by forming a salt bridge with 
lysine 507 in the αC-helix, stabilizing an activation segment flipped in the active 
conformation. Further crystal structures bound to inhibitors stabilizing the active form later 
confirmed this (Wan et al., 2004; Xie et al., 2009) (Figure 7).   
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Figure 6 Crystal structure of the BRAF kinase domain. 
Crystal structure of BRAFWT kinase domain, color coded with different structural domains 
of kinases.   PDB accession code 1UWH.    
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Figure 7 Inactive vs. active forms of BRAF. 
Crystal structure of BRAFWT kinase domain in the inactive conformation (left, PDB ID 
1UWH) compared to BRAFWT kinase domain in the active conformation (right, PDB ID 
3Q4C), demonstrating the possibility of V600E mutations forming salt bridges with K507.      
 
 
 When the RAF kinases were first discovered, little was known about their complex 
activation mechanism.  As mentioned above, RAS interaction with the RAS binding 
domain (RBD) of RAF proteins are known to activate RAF, but despite a crystal structure 
of the RAF RBD interacting with RAS being solved in 2015, the exact mechanism as to 
how this activation occurs is not clearly understood (Fetics et al., 2015). In 1996, it was 
discovered that artificial induction of RAF dimerization in cells stimulated its activity 
(Farrar, Alberola-Ila, & Perlmutter, 1996).  RAS was later found to promote dimeric 
complexes between BRAF and CRAF as well as respective homodimers, and oncogenic 
mutations other than V600E were found to impair kinase activity but stimulate CRAF 
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activation in vivo, hinting at a dimerization dependent mechanism for activation 
(Rushworth, Hindley, Neill, & Kolch, 2006; Wan et al., 2004).   As more crystal structures 
of BRAF became publicly available on the PDB, it became evident that the asymmetric 
unit of these crystals comprised two kinase domains making notable contacts with one 
another in a conserved manner.  While this was first thought to be an artifact of crystal 
packing, the conserved nature of this interaction hinted at biological relevance 
(Rajakulendran, Sahmi, Lefrançois, Sicheri, & Therrien, 2009).  A key residue, R509, lies 
at the center of this interface and forms contacts to the partner subunit’s backbone residues 
of R506 and T508 (Rajakulendran et al., 2009) (Figure 8).  Mutation of this residue to a 
histidine (R509H) has been shown to deplete dimerization in vitro (Rajakulendran et al., 
2009).  While the exact mechanism of dimerization-dependent RAF mechanism is still not 
completely understood, it is thought that the stabilization of a closed conformation between 
the N and C lobes and the alignment of two regions of hydrophobic residues spanning 
several kinases can lead to kinase closure and activation (Kornev, Haste, Taylor, & Ten 
Eyck, 2006).  In RAF, the stabilization of this closed conformation is thought to be 
governed by the αC-helix (light grey in Figures 6 and 7), as R509 lies on the C terminal 
tip of this helix (Hugo Lavoie & Therrien, 2015; Rajakulendran et al., 2009).   
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Figure 8 R509 dimerization stabilization in BRAF. 
Figure (a) Illustrates the side to side dimerization interface of the RAF kinases, while (b) 
is a close-up of R509 interactions with T508 and R506.  This figure is taken from (Grasso 
et al., 2016).    
 
The crucial nature of αC-helix conformation in dimerization activation of BRAF 
was further elucidated with the first monomeric structure of the BRAF kinase domain, 
which illustrated an αC-helix conformation significantly shifted “outward” compared to 
those of known dimeric crystal structures (Thevakumaran et al., 2014) (Figure 9).  This 
crystal structure also demonstrated that, despite the activation segment being in a DFG-in, 
active, conformation, the activation segment was more resolved than other structures and 
displayed a helical conformation(AS-H1) that is thought to be inactive, as it forms multiple 
contacts with the αC-helix, therefore stabilizing its inactive form (Thevakumaran et al., 
2014) (Figure 9).   
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Figure 9 Monomeric BRAF crystal structure shows αC-helix shift. 
Monomeric BRAF crystal structure (blue, PDB ID 4WO5) aligned with dimeric BRAF 
(purple, PDB ID 1UWH), showing a shift in the αC-helix and the formation of AS-H1. 
 
 A recent study from 2013 helped elucidate BRAF’s interactions on downstream 
activity of the MAPK pathway by crystallizing the complex of BRAF with its substrate 
MEK (Haling et al., 2014).  The crystal structure demonstrated that at high concentrations, 
the complex is a hetero-tetramer, with two BRAF molecules forming a side-to-side dimeric 
interaction, and MEK molecules on each BRAF molecule, making face-to-face interactions 
(Figure 10).  The interactions are stabilized mostly through the activation segments of both 
kinases (magenta, Figure 11) , as well as their G-helices (cyan, Figure 11) (Haling et al., 
2014).  The activation segment of BRAF is stabilized in an active, DFG-in conformation 
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despite no inhibitor binding, and the conformation demonstrates that V600E mutations can 
indeed stabilize this conformation with a salt-bridge to K507 and thereby strengthen the 
complex.  Interestingly, this complex has a very strong interaction with a KD of ~43 nM, 
and it is thought that phosphorylation of MEK1 by BRAF weakens the interaction (Haling 
et al., 2014).    
 
 
 
Figure 10 BRAF:MEK complex. 
The crystal structure of MEK (blue) bound to a biologically relevant BRAF dimer 
(salmon), forming a hetero-tetrameric structure (PDB ID 4MNE).     
  
 
23
 
Figure 11 BRAF:MEK complex interactions. 
The crystal structure of MEK (blue) bound to BRAF (salmon) shows their activation 
segments (magenta) make extensive contacts, as well as their G-helices (cyan) (PDB ID 
4MNE).  
 
 
 
1.5 BRAF Inhibitors and Cancer 
  As it was being discovered that RAF kinases would be a suitable target in cancer 
treatment, the first available inhibitor, Sorafenib (BAY43-9006) was being developed by 
Bayer (Lyons, Wilhelm, Hibner, & Bollag, 2001; Wan et al., 2004).  Sorafenib is a pan-
RAF inhibitor, targeting CRAFWT, BRAFWT, and BRAFV600E.  Sorafenib was found to be 
extremely potent against the RAF kinases, with recorded IC50 values in the low nanomolar 
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range (S. Wilhelm & Chien, 2002).  The inhibitor bound the DFG-out, inactive 
conformation, and is ATP-competitive, binding in the cleft between the N and C lobes of 
the kinase.  However, its lack of selectivity within the RAF kinases, as well as its ability to 
hit certain RTK’s upstream, led to issues in the clinic and side effects (S. M. Wilhelm et 
al., 2004).  The need for a mutant specific RAF inhibitor was apparent, and after extensive 
“scaffold-like” drug discovery techniques, vemurafenib was first synthesized in 2005 
(Figure 12) (Bollag et al., 2012).  Vemurafenib binds to BRAF in the active, DFG-in 
conformation, thus displaying selectivity for the BRAFV600E mutant over BRAFWT (Bollag 
et al., 2010, 2012; Tsai et al., 2008a).  However, in the clinic, patients receiving high 
enough doses of vemurafenib often regressed after 6 months, and tumors return (Figure 
12) (Bollag et al., 2010, 2012).   
 
Figure 12 Resistance in melanoma patients treated with vemurafenib. 
Image of patient treated with vemurafenib and after ~6 months, developed cutaneous 
metastatic deposits due to inhibitor resistance.  Adapted from (Wagle et al., 2011). 
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Interestingly, the crystal structure of BRAF-bound vemurafenib consists of BRAF 
in the biologically relevant dimer conformation, but one protomer is bound to inhibitor 
while the other is not (Figure 13) (Bollag et al., 2010).  A difference in the αC-helix is 
present between the two protomers, and it is thought that inhibitor binding promotes 
dimerization, and this dimerization forces the αC-helix in the conformation shown in grey 
in Figure 13, keeping a second vemurafenib molecule from binding in that active site 
(Bollag et al., 2010, 2012; P. I. Poulikakos, Zhang, Bollag, Shokat, & Rosen, 2010).  
Indeed, at sub-saturating concentrations of inhibitor, ERK signaling in cells is increased, 
and this phenomenon is called “transactivation” or “paradoxical activation” (P. I. 
Poulikakos et al., 2010; P. Poulikakos & Rosen, 2011).  Further studies have shown that in 
the presence of oncogenic RAS, kinase dead BRAF mutants can bind and activate CRAF 
and other BRAF protomers.   This mechanism is also true for inhibited BRAF molecules 
(Heidorn et al., 2010).  Examining the process of transactivation, it was found that BRAF 
has the potential to transactivate other BRAF and CRAF molecules while CRAF cannot, 
and this is due to the NtA motif that is “primed” with its sequence SSDD, whereas CRAF 
and ARAF require phosphorylation to activate their NtA motifs (Hu et al., 2013).  
Furthermore, this activation is dimerization dependent, as R509H mutations block any 
ERK activation (Hu et al., 2013).  The current model of transactivation is shown in Figure 
14, in which inhibitor bound RAF can allosterically activate another RAF molecule that is 
not bound to inhibitor when active RAS is present (P. Poulikakos & Rosen, 2011).    
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Figure 13 Vemurafenib binding. 
Crystal structure of Vemurafenib bound to BRAFV600E shows only one molecule of the 
BRAF dimer bound to vemurafenib, and the other is left free with its αC-helix in a 
conformation promoting dimerization but blocking inhibitor binding (PDB ID 3OG7). 
 
 
 
 
 
  
 
27
 
Figure 14 Transactivation model. 
Illustration of transactivation, in which without activated RAS, RAF is mainly monomeric 
and has low activity.  When active RAS is present, MEK phosphorylation is elevated to 
basal level.  At sub-saturating levels of inhibitor such as vemurafenib, one molecule of a 
RAF dimer can activate the other molecule allosterically, inducing MEK phosphorylation 
and ERK signaling.  Figure is taken from (P. Poulikakos & Rosen, 2011). 
 
 
 
 Resistance to BRAF inhibitors develops ~6 months after melanoma cell lines are 
persistently exposed to these drugs, and interestingly, these resistant cell-lines also 
demonstrate resistance to other BRAF inhibitors, indicating that most existing BRAF 
inhibitors act under the same mechanism to promote resistance (Villanueva, Vultur, & 
Herlyn, 2011).  Some common resistance pathways are RTK, N-RAS, and CRAF 
upregulation, N-RAS mutations, and expression of a specific splice variant of BRAF 
(Nazarian et al., 2010; P. I. Poulikakos et al., 2011; Villanueva et al., 2011).  All of these 
resistance mechanisms go hand in hand with transactivation and dimerization, as the 
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increase in RTK’s, RAS, and CRAF, as well as N-RAS mutations, increase the presence 
of RAF dimers in cells.   Also, the splice variant of BRAF cuts out the RBD of the BRAF 
N-terminus, hindering RAS regulation and allowing for aberrant dimerization of BRAF (P. 
I. Poulikakos et al., 2011).  In 2015, “paradox breaker” inhibitors were developed, which 
modify vemurafenib to reduce the amount of transactivation of the ERK pathway in cells 
(C. Zhang et al., 2015).  Despite these positive results, however, the crystal structures of 
these inhibitors bound to BRAF still demonstrate one protomer bound and the other 
unbound in an activated αC-helix conformation, leading to the possibility of inhibitor 
resistance developing (Karoulia et al., 2016; C. Zhang et al., 2015).  Extensive studies of 
RAF inhibitors have concluded that certain inhibitors can induce dimerization by favoring 
a “closed” conformation of the N- and C- lobes of the kinase, and αC-helix-“in” favoring 
inhibitors such as sorafenib promote dimerization while αC-helix-“out” inhibitors such as 
vemurafenib do not (Karoulia et al., 2016; H Lavoie et al., 2013).  These studies shed a 
light on the current mechanisms of transactivation, however there is a current need for not 
only inhibitors that can circumvent transactivation but also more information on how this 
pathway functions and how to avoid further resistant pathways.    
 
1.6 Dissertation Objectives 
 While much work has been done to elucidate BRAF as a cancer target and develop 
drugs targeting RAF kinases, many questions still need to be answered due to the discovery 
of inhibitor resistance in BRAF-mutant cancers.   Can small molecule inhibitors be 
developed to target transactivation?   If so, which means would be most effective?   Would 
these small molecule inhibitors have downstream effects on the MAPK pathway, and could 
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they elucidate more intricacies in ERK signaling that have yet to be discovered?  
Answering these questions will not only provide options for clinical treatments for 
melanoma as well as many other cancers but will also provide useful molecular probes to 
elucidate inhibitor mechanisms in vitro and in cells.    
 The focus of my dissertation is to develop and characterize novel small molecule 
inhibitors targeting BRAF-mutant melanoma and other cancers.   Exploiting BRAF’s 
propensity for transactivation via dimerization, I aimed to develop two novel classes of 
inhibitors that utilize different techniques to target inhibitor resistance within the MAPK 
signaling pathway.   I first characterized and used structure-based inhibitor design to 
improve upon a bivalent class of BRAF inhibitors that can target two BRAF molecules at 
once using type I, mutant specific inhibitor vemurafenib.   I then utilized the same 
technique to develop a class of bivalent BRAF inhibitors using a type II, pan-RAF inhibitor 
TAK632.  Finally, I developed and optimized a high-throughput screen to identify small 
molecules that can disrupt the interaction between BRAF and its downstream substrate 
MEK.  Through these studies, I have: 
 
(1) Determined that chemically-linked dimeric vemurafenib inhibitors can stabilize 
a biologically irrelevant dimeric form with an inactive αC-helix conformation 
 
(2) Bivalent TAK632 inhibitors cannot stabilize this biologically irrelevant 
conformation, but monovalent TAK632 can stabilize the biologically relevant 
dimeric form even in the presence of mutations within the dimer interface 
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(3) Small molecule inhibitors identified in my FRET-based high throughput screen 
affect BRAF/MEK dimerization. 
 
In conclusion, these small molecules can be used to further probe BRAF dimerization and 
its role in MAPK signaling and inhibitor resistance.   
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Chapter 2- Chemically Linked Vemurafenib Inhibitors 
Promote an Inactive BRAFV600E Conformation 
 
 
 
 
 
 
 
 
 
 
 
 
This research was performed in collaboration with Dr. Michelle Estrada, Dr. Minu Samanta, Dr. Christian 
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performed the synthesis of inhibitors, Dr. Samanta carried out cell-based experiments, and Dr. Maksimoska 
performed initial first-generation enzymatic assays.  Repeated with permission from Grasso, M., Estrada, M. 
A., Ventocilla, C., Samanta, M., Maksimoska, J., Villanueva, J., Winkler, J., and Marmorstein, R. (2016). 
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation. ACS Chemical 
Biology, 11, 2876–2888. Copyright 2016 American Chemical Society. 
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2.1 Introduction 
BRAF is a notable oncoprotein within the MAPK signaling pathway due to its 
proclivity to mutations in cancer as compared to other RAF proteins ARAF and CRAF.   
60% of melanomas in particular carry a BRAF mutation, and 90% of those mutations are 
a particular point mutation of valine to glutamic acid at residue 600 (V600E) (Davies et 
al., 2002; Wellbrock et al., 2004).  BRAFV600E -selective inhibitors have therefore become 
a topic of interest in the fields of drug discovery, and two inhibitors in particular, 
vemurafenib and dabrafenib, have been approved by the FDA based on overall extended 
survival in patients with metastatic BRAFV600E melanoma (Bollag et al., 2012; King et al., 
2013; Rheault et al., 2013).  However, almost all patients develop drug resistance within 
about 6 months of treatment through diverse mechanisms (Anforth et al., 2012; P. 
Poulikakos & Rosen, 2011; Villanueva et al., 2013).  While combination therapies of MEK 
and BRAF inhibitors have been approved by the FDA to help counteract MAPK 
reactivation, resistance can still develop and this strategy has limited activity in a subset of 
melanomas with acquired resistance to RAF or MEK inhibitor monotherapy, particularly 
in the context of increased MAPK signaling (Flaherty et al., 2012; Johnson et al., 2014).   
Resistance pathways, while diverse, appear to stem from the phenomenon of 
 “paradoxical activation” or “transactivation” in which drug-bound BRAF in an inactive 
conformation is able to allosterically shift the associated non-drug bound wild-type BRAF 
or CRAF subunit into an activated conformation to promote MAPK signaling (P. I. 
Poulikakos et al., 2010).  Consistent with the importance of RAF dimerization, a single 
R509H mutation that disrupts BRAF dimerization is shown to prevent transactivation 
(Rajakulendran et al., 2009).  These studies highlight the importance of RAF dimerization 
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and suggest that novel approaches to specifically target RAF dimers may have therapeutic 
value.  In the study reported here, we used BRAFV600E dimers in the active conformation 
as a model system to ask if chemically linked vemurafenib inhibitors could shift RAF 
dimers into an inactive conformation.   We show that chemically linked vemurafenib 
inhibitors promote an inactive BRAFV600E dimeric conformation, implicating that a similar 
strategy can be employed to target BRAFV600E/RAFWT dimers for inhibition of 
transactivation in the MAPK pathway.    
2.2 Results 
2.2.1 Chemically linked vemurafenib molecules specifically and potently disrupt active 
BRAFV600E dimers  
 Vemurafenib was the first selective BRAF inhibitor approved to treat BRAFV600E 
melanoma based on efficacy and improved overall survival; however, responses are 
transient due to the emergence of resistance in virtually all patients, demonstrating the 
necessity for more effective drugs/therapies, particularly those that directly address the 
issue of transactivation (Bollag et al., 2010; Tsai et al., 2008a).  Therefore, we hypothesized 
that two vemurafenib molecules chemically linked in an appropriate fashion could inhibit 
a RAF dimer and thus prevent paradoxical activation.   Of the 45 BRAF kinase domain 
crystal structures available in the PDB, only one (4WO5) (Thevakumaran et al., 2014) is 
not present in what is presumed to be a biologically relevant dimer (Figure 15a).  In the 
BRAF dimer, residue Arg509 makes dimer-stabilizing H-bonds to the backbone carbonyl 
oxygens of T508 and R506 of the other BRAF subunit of the dimer, which contributes to 
orienting the αC-helix in a conformation that facilitates catalysis (Figure 15b) 
(Thevakumaran et al., 2014). The dimer structures reveal that the kinase active sites face 
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away from each other and are separated by about ~30Å (Figure 15a).  Based on this 
observation, we reasoned that a linker of ~ 30Å could enable an inhibitor to bind both 
active sites of the observed dimer simultaneously, while a shorter linker might also be able 
to “trap” BRAF into another, potentially inactive dimer conformation. With this in mind, 
we prepared linked vemurafenib molecules in which the tether contained 2 (~10Å) to 6 
(~30Å) polyethylene glycol (PEG) units (Figure 15c). 
 
 
Figure 15 Structure of BRAF kinase domain and rationale for linked vemurafenib 
BRAF inhibitors. 
 (a) Structure of the BRAFWT kinase domain crystallized with Sorafenib (accession code 
1UWH).  The αC-Helix and R509 residue are highlighted in orange.  (b) Close up of BRAF 
dimer interactions mediated by R509.  (c) Initial scaffold for vemurafenib linked inhibitors 
where n equals the number of polyethylene glycol moiety groups.   
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 The potencies of the linked vemurafenib inhibitors against BRAFV600E and 
BRAFWT were evaluated in vitro using an ELISA assay that measures phosphorylation of 
the BRAF substrate GST-MEK1.  We found that all but the linked compound with the 
fewest PEG units (Vem-2-Vem) had potencies within 2-fold of unlinked PLX4720 (an 
analogue of vemurafenib without a phenyl group, referred to herein as PLX) inhibitor 
against BRAFV600E. In control studies, we also demonstrated that PLX4720 (PLX) and 
PLX4032 (Vemurafenib, or Vem) have potencies within about 2-fold of each other (Figure 
16). Interestingly, all of the linked compounds had considerably poorer potency against 
BRAFWT (Figures 17a and 17b, respectively). These data demonstrate that the potency of 
the chemically linked vemurafenib inhibitors against BRAFV600E is relatively insensitive to 
linker length between 3 and 6 units.  Unexpectedly, linkers of all lengths significantly 
reduced the potency of vemurafenib against BRAFWT, suggesting that the linked 
vemurafenib inhibitors are binding to two BRAFV600E subunits in a way that differed from 
the active dimer conformation.  This hypothesis was also corroborated by the data showing 
that all the linker lengths, except the shortest 10Å length, did not significantly affect linked 
inhibitor potency.   
 As RAF dimerization is predicted to increase the thermal stability of the protein, 
we performed a thermal stability assay of BRAFV600E with and without inhibitors as a 
readout for BRAFV600E dimerization. We carried out these studies by measuring the 
fluorescence of the reporter molecule sypro orange as it binds hydrophobic residues of 
BRAF, which becomes exposed as thermal denaturation occurs (R. Zhang & Monsma, 
2010).  These studies reveal that while unlinked PLX increased the melting temperature of 
BRAFV600E by about 18 oC, the linked vemurafenib compounds produce a significant but 
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more modest 2-9 oC increase in melting temperature (Figure 17c). These results are 
consistent with a model whereby the linked vemurafenib compounds change the 
conformation of the two BRAFV600E molecules relative to the conformation  of the active 
dimer conformation. 
 To evaluate the cellular activity of the linked vemurafenib compounds, we treated 
melanoma cells that harbored BRAFV600E (Mel1617) or BRAFWT (WM3918) with unlinked 
or linked vemurafenib compounds.  Consistent with the in vitro studies, the unlinked and 
linked (Vem-3-Vem and Vem-6-Vem) vemurafenib compounds showed comparable 
inhibitory activity on cell viability in BRAFV600E- mutant melanoma cells, but showed no 
significant inhibitory activity in BRAFWT-melanoma cells (Figure 17d). These results also 
demonstrate that the linked vemurafenib compounds are able to enter cells and exhibit on-
target activity.   
 
Figure 16 PLX4720 (PLX) vs PLX4032 (Vem) 
BRAFV600E was assayed against Vem and PLX using the previously described ELISA 
assay.   IC50 values were 119 nM for PLX and 42.8 nM  Vem.  Assay performed in 
duplicate, +/- SEM shown. 
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Figure 17 Potency of first generation linked vemurafenib inhibitors. 
 (a)  Dose response curves of the Vem-Vem class of linked inhibitors against BRAFV600E 
with unlinked PLX4720 (PLX) as a control.  Calculated IC50 values are indicated. The data 
is the average of two separate experiments, each performed in duplicate with +/- SEM 
shown.  95% Confidence Intervals are:  PLX (75.8 nM to 195 nM), Vem-6-Vem (97.8 nM 
to 291 nM), Vem-5-Vem (111 nM to 356 nM), Vem-4-Vem (114 nM to 295 nM), Vem-3-
Vem (186 nM to 364 nM), and Vem-2-Vem (391 nM to 994 nM).  (b)  Dose response 
curves of Vem-6-Vem and Vem-3-Vem against BRAFWT with PLX as a control, carried 
out in triplicate for PLX and Vem-6-Vem and in duplicate for Vem-3-Vem with +/- SEM 
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(from previous page) shown.  The 95% Confidence Intervals are:  PLX (335 nM to 883 
nM), Vem-6-Vem (1.87 μM to 8.75 μM) and Vem-3-Vem (1.69 μM to 4.50 μM).  
 (c) Thermal shift assay measurements of melting temperature for BRAFV600E with no 
inhibitor, and with 50 μM of Vem-6-Vem, Vem-3-Vem, Vem-2-Vem, and PLX as a 
control, with calculated melting temperatures listed (n=6) with +/- SEM shown.  95% 
Confidence Intervals are as follows:  DMSO Control (35.4 oC to 36.2 oC), PLX (54.0  oC 
to 55.1 oC), Vem-6-Vem (43.7 oC to 45.0 oC), Vem-3-Vem (39.1 oC to 45.0 oC), and Vem-
2-Vem (36.5 oC to 37.1 oC).  (d)BRAFV600E (Mel1617 cell line, solid line) and BRAFWT 
(WM3918, dashed line) cell lines were treated with the indicated doses of Vem-6-Vem or 
Vem-3-Vem for 72h. Cell viability was determined by MTT assays and calculated relative 
to DMSO-treated cells, Average cell viability taken from 3 separate experiments (n=7) and 
averaged together with +/- SEM  shown.   
  
2.2.2 Crystal structures of Vem-6-Vem and Vem-3-Vem demonstrate that linked 
vemurafenib inhibitors force BRAFV600E subunits into a face-to-face inactive dimer 
conformation 
 To determine the molecular basis for BRAFV600E inhibition by the linked 
vemurafenib compounds, we determined the crystal structure of the BRAFV600E kinase 
domain bound to Vem-6-Vem.   The crystals formed in the space group P21 with two 
BRAFV600E molecules in the asymmetric unit, and the structure was determined by 
molecular replacement using 4WO5 as a search model and was refined to 2.3 Å resolution 
with good geometry and refinement statistics (Table 1).  As expected, the refined  
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Crystal BRAFV600E/ 
Vem-6-Vem 
BRAFV600E/ 
Vem-3-Vem 
BRAFV600E/ 
Vem-BisAmide-2 
Resolution 
Range (Å) 
29.21-2.29 (2.34-
2.29) 
138.00-2.19  
(2.24-2.19) 
50-2.70 (2.75-2.70) 
Space Group P21 P212121 P212121 
Unit Cell 
(a, b, c, α, β, γ) 
56.84, 67.75, 67.88  
90, 90.32, 90 
64.61, 68.26, 
276.01 90, 90, 90 
65.10, 68.44, 275.60 
90, 90, 90 
Total Reflections 59,386 82,6367 192,419 
Unique 
Reflections 
22,352 63,307 34,634 
Redundancy 2.7(2.7) 12.9 (12.100) 5.5 (5.8) 
Completeness 
(%) 
95.31 (90.21) 98.94 (96.12) 99.72 (99.50) 
Mean I/sigma (I) 13.19 (2.76) 15.64 (1.37) 16.23 (2.62) 
Wilson B Factor 32.72 51.44 57.32 
R-merge 0.097 (0.521) 0.104 (2.323) 0.110 (0.862) 
R-work 0.1947 0.2072 0.2122 
R-free 0.2538 0.2597 0.2729 
RMS (bonds) 0.008 0.009 0.009 
RMS (angles) 1.18 1.19 1.28 
Ramachandran 
Favored (%) 
95 96 96 
Ramachandran 
Outliers (%) 
0.41 0.39 0.42 
Clashscore 9.50 6.31 6.22 
Average B 
Factor 
27.20 50.10 41.10 
Table 1. Summary of crystallographic statistics 
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BRAFV600E/Vem-6-Vem structure shows a vemurafenib molecule bound in each enzyme 
active site, although electron density is not observed for the PEG linker, which was 
presumably disordered in the crystal structure (Figure 18a).  Indeed, the last resolvable 
atom closest to the PEG linker, a carbon attached to the first oxygen in the linker portion, 
has a B factor of 34 Å2, while the average B factor of the structure is 24 Å2.  As expected 
from the solution studies, the BRAFV600E/Vem-6-Vem structure did not adopt the active 
RAF dimer conformation typically seen in RAF crystal structures, where the active sites 
are facing away from each other (Figure 15a).  Instead, the BRAFV600E/Vem-6-Vem dimer 
structure reveals that one protein subunit of the dimer is flipped about 180° relative to its 
position in the active RAF dimer such that the active sites are facing towards each other 
(Figure 18a).  Figure 18b shows one subunit of the Vem-6-Vem structure superimposed 
with one subunit of the 1UWH biologically relevant dimer, demonstrating the different 
positions of the associated protein pair and αC-Helix, highlighted in orange, in both 
structural configurations.  As a consequence of the altered configuration of the 
BRAFV600E/Vem-6-Vem structure, key elements of the active RAF dimer are absent.  
Notably, R509 is surface exposed and thus does not participate in dimer interactions. 
Significantly, both BRAF molecules in the BRAFV600E/Vem-6-Vem dimer structure are in 
an inactive dimer conformation as characterized by a shift of the C-helix to a more open 
configuration and an ordering of the activation segment into a helical conformation, 
referred to as AS-H1 (Thevakumaran et al., 2014) (Figure 18c).  A similar inactive kinase 
conformation was noted in a recently reported BRAF monomer bound to vemurafenib 
(accession code 4WO5) (Thevakumaran et al., 2014) (Figure 18c).  Notably, while the 
same inactive kinase configuration is observed between BRAFV600E/Vem-6-Vem and 
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4WO5, the contact areas between both subunits in the asymmetric unit are different, despite 
being crystallized under similar conditions (details found in the methods section).  This 
observation suggests that the crystallographically observed inactive kinase conformation 
results from a destabilization of the active BRAF dimer by Vem-6-Vem rather than by 
crystal contacts.   
 
Figure 18 Structure of BRAFV600E/Vem-6-Vem complex. 
 (a) Structure of BRAFV600E bound to Vem-6-Vem. The αC-helix and R509 residues are 
highlighted in orange.  (b) Overlay of one subunit of the BRAFV600E/Vem-6-Vem dimer 
with an active dimer conformation (accession code 1UWH).  (c) Superposition of 
BRAFV600E/inhibitor structures (indicated by color-code) highlighting the position of the 
αC-helix and presence or absence of the AS-H1 helix. (d)  Comparison of the αC-helix in 
active and inactive conformations highlighting the disposition of key residues, shown as a 
stereoimage.  
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 Based on previous crystallographic and solution studies demonstrating that the 
BRAFV600E kinase domain favors a dimeric state, while BRAFWT favors a monomeric state, 
as well as analogies with other kinases, it was proposed that the AS-H1 helix is a driver of 
the inactive monomeric BRAFWT conformation (Thevakumaran et al., 2014).   Based on 
this model, interactions between the AS-H1 helix and the C-helix are proposed to force the 
C-helix into an inactive conformation.   BRAFWT activation loop phosphorylation or 
BRAFV600E mutation is proposed to destabilize interactions between the AS-H1 helix and 
the C-helix, causing the C-helix to shift into the active and dimeric form.  The 
BRAFV600E/Vem-6-Vem structure reveals that the AS-H1 helix is formed, even with the 
glutamate present in the BRAFV600E mutant.  While the glutamate is within close contact 
to Ala497 (3.5 Å) (Figure 18d), the inactive conformation is still favored, and present in 
both BRAF molecules in the asymmetric unit.  Alignment of the BRAFV600E/Vem-6-Vem 
complex with 1UWH in Figure 18d reveals that the BRAFV600E mutation is still able to 
facilitate formation of AS-H1 helix and the inactive kinase conformation because Glu501 
shifts away from Glu600, thus avoiding potentially destabilizing interactions.  These 
observations argue against the AS-H1 helix being a driver of BRAFV600E activation and 
instead for the inherent ability of the linked Vem-6-Vem inhibitor to drive formation of the 
inactive BRAFV600E kinase conformation.     
 
To determine if the inactive kinase conformation observed in the BRAFV600E/Vem-6-Vem 
structure was dependent on the linker length between the vemurafenib molecules and to 
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potentially capture the path of the linker, we prepared crystals of BRAFV600E bound to 
Vem-3-Vem.  Vem-3-Vem is estimated to have a linker length of ~15 Å, compared to the 
estimated linker length of ~30 Å, for the Vem-6-Vem compound. Crystallization of the 
BRAFV600E/Vem-3-Vem complex under the conditions that produced the BRAFV600E/Vem-
6-Vem structure was unsuccessful, and we hypothesize that the lack of a highly dynamic 
linker altered crystal contacts.  We were able to crystallize the BRAFV600E/Vem-3-Vem 
complex in the P212121 space group containing four BRAF protomers (two inhibitor-linked 
dimers) in the asymmetric unit cell.  The structure was determined by molecular 
replacement using the BRAFV600E/Vem-6-Vem structure and refined to 2.19 Å with good 
geometry and refinement statistics (Table 1).  Despite the fact that the BRAFV600E/Vem-3-
Vem complex was in a different crystal environment than the BRAFV600E/Vem-6-Vem 
complex, the two BRAFV600E/Vem-3-Vem complexes in the asymmetric unit show the 
same face-to-face and inactive kinase conformation as BRAFV600E/Vem-6-Vem (RMSD of 
1.98 Å2 for all common atoms) (Figure 19a). In particular, the BRAFV600E/Vem-3-Vem 
complex shows the same C-helix shift and presence of the AS-H1 segment characteristic 
of the inactive kinase conformation (Figure 18c). This observation further supports the 
conclusion that the inactive kinase conformations observed in the BRAFV600E crystal 
structures bound to the chemically linked vemurafenib inhibitors are promoted by the 
linked inhibitors themselves and not crystal packing forces.   
 
2.2.3 Functionalization of the linker can increase the potency of chemically linked 
vemurafenib over unlinked PLX 
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 Unlike the ~30 Å, linker of the Vem-6-Vem compound in the BRAFV600E/Vem-6-
Vem structure, which was disordered, the shorter ~15 Å, linker of the Vem-3-Vem 
compound could be reliably traced into the electron density map (Figure 19b).  
 
Figure 19 Structure of BRAFV600E/Vem-3-Vem complex. 
 (a) Overlay of BRAFV600E/Vem-6-Vem (green) and BRAFV600E/Vem-3-Vem (cyan) 
structures. (b) Close-up of Vem-3-Vem inhibitor (magenta) and the simulated annealing 
omit map in green contoured at 2.5 sigma.   (c) Close up of BRAFV600E residues Q461 and 
H539 (purple) highlighting their proximity to the Vem-3-Vem linker (pink), shown as a 
stereo image.   
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 Interestingly, the linker region is in proximity to residues Gln461 and His539 of 
both BRAFV600E subunits of the dimer (Figure 19c). We reasoned that functionalization of 
the linker region to introduce hydrogen bond acceptors and/or donors could introduce 
stabilizing protein-linker interactions to increase the potency of the linked vemurafenib 
inhibitors for BRAFV600E.  With this in mind, we designed a set of second-generation 
inhibitors, in which the linker region was functionalized. We reasoned that adding amide  
functional groups within the linker would add the hydrogen bond acceptors and/or donors 
with which Gln461 and His539 could interact, potentially strengthening the interaction of 
the inhibitor and, in turn, further stabilizing the forced inactive BRAFV600E conformation.  
We prepared three new diglycolic diamide linked-dimers, in which the number of 
methylenes between the diglycolic amide nitrogens and the phenyl ring of the vemurafenib 
core was varied.  The three analogs synthesized consisted of an n-aryl diamide, as well as 
n-benzylic, and n-homobenzylic diamide linkers (Figure 21a).  These compounds allowed 
us to examine the effect of linker length, in addition to increasing electronic density of the 
carbonyl functions due to amide resonance.  We reasoned that this effect would facilitate 
increased interaction of the dimers with Gln461 and His539, relative to the analogous 
ketone linkers.  
 We assayed the inhibitory activity of the three bis amide-linked vemurafenib 
compounds against BRAFV600E and BRAFWT in vitro using the ELISA assay used for first 
generation inhibitors and found that all three amide-linked vemurafenib compounds lacked 
potency against BRAFWT, as expected (Figure 20).  However the ability of the compounds 
to inhibit BRAFV600E varied significantly (Figure 21b).  Vem-BisAmide-1 inhibited 
BRAFV600E poorly compared to PLX, with an IC50 of ~3.62 μM compared to 115 nM for 
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PLX measured under identical conditions, and Vem-BisAmide-3 demonstrated an IC50 
value of 195 nM, mimicking Vem-3-Vem and Vem-6-Vem.  Vem-BisAmide-2 showed the 
greatest potency of the bis amide-linked vemurafenib compounds for BRAFV600E, with an 
IC50 of 33.5 nM, about 3-5 fold higher than PLX and the PEG-linked vemurafenib 
inhibitors, but comparable to vemurafenib alone (Figure 16).  We hypothesized that the 
geometry of Vem-BisAmide-2 is most optimal for inhibiting the inactive BRAFV600E dimer 
conformation, through more restricted movement of the linker and interactions with 
residues Gln461 and/or His539 of BRAFV600E.  Consistent with the findings of the activity 
assay, a thermal stability assay demonstrated that Vem-BisAmide-2 increases the thermal 
stability of BRAFV600E more than Vem-6-Vem and on the same level as unlinked PLX 
(Figure 21c).   These results demonstrate that judicious functionalization of the linker can 
significantly increase BRAFV600E inhibitor potency.   
 
Figure 20 Vem-BisAmide inhibitors against BRAFWT. 
BRAFWT was assayed against Vem-BisAmide-1, Vem-BisAmide-2, Vem-BisAmide-3, 
and PLX using the previously described ELISA assay.   IC50 values were 2.68 μM for Vem-
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BisAmide-2, 1.35 μM for Vem-BisAmide-3, 697 nM for Vem, and N/A for Vem-
BisAmide-1.  Assay performed in duplicate, +/- SEM shown  
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(from previous page)  
Figure 21 Development of second generation linked vemurafenib inhibitors. 
(a) Second generation linked vemurafenib inhibitors utilizing bis-amide linkers.  (b) Dose 
response curves of second generation inhibitors against BRAFV600E with unlinked 
PLX4720 (PLX) as a control.  Calculated IC50 values are indicated. The data is the average 
of two separate experiments, each performed in duplicate with +/- SEM shown.  95% 
Confidence Intervals are:  PLX (70.0 nM to 191 nM), Vem-BisAmide-1 (2.28 μM to 5.75 
μM), Vem-BisAmide-2 (23.7 nM to 47.5 nM), Vem-BisAmide-3 (114 nM to 332 nM), and 
Vem-3-Vem (165 nM to 352 nM)  (c) Thermal stability assay of linked vemurafenib 
inhibitors with calculated melting temperatures listed (n=6) with +/- SEM shown.  95% 
Confidence Intervals are as follows:  DMSO Control (35.5 oC to 36.3 oC), PLX (54.0  oC 
to 55.1 oC), Vem-6-Vem (43.7 oC to 45.0 oC), and Vem-BisAmide-2 (52.0 oC to 53.3 oC),  
 
2.2.4 Crystal structure of BRAFV600E/Vem-BisAmide-2 complex reveals the molecular basis 
for inhibition of BRAFV600E dimers 
 We were able to successfully crystallize Vem-BisAmide-2 bound to BRAFV600E. 
The crystals were isomorphous to the BRAFV600E/Vem-3-Vem structure and thus contained 
four BRAF protomers (two inhibitor-linked dimers) in the asymmetric unit.  The structure 
was determined by molecular replacement using the BRAFV600E monomer from the 
BRAFV600E/Vem-3-Vem structure and refined to 2.70 Å resolution with good geometry 
and refinement statistics (Table 1). As predicted, each enzyme active site was occupied by 
a vemurafenib molecule and the C-helix and the AS-H1 helix mimicked the conformation 
shown in the other structures with inactive conformations.  The Vem-BisAmide-2 linker 
density was more pronounced than that of Vem-3-Vem despite the more limited resolution, 
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consistent with a more rigid linker.  The linker region of Vem-BisAmide-2 shows that the 
amide carbonyls are making interactions with Gln461 and His539 residues.  While the 
His539 residues make van der Waals contact to methyl groups in the linker, Gln461 
residues hydrogen bond to the amide carbonyl groups of the linkers, with the nitrogen of 
the amide groups of the glutamine within close proximity of the carbonyl groups of the 
inhibitor’s amide linker  (Figure 23a). In the two BRAFV600E dimers in the asymmetric 
unit, the electron density for Gln461 is weak or unclear for one of the two dimer subunits 
(Figure 22).  This observation suggests that stabilization of one Gln461-linker interaction 
does not synergistically nucleate the second Gln461-linker interaction and thus the 
interactions are independent.  Nonetheless, the biochemical data argues for the importance 
of the Gln461-linker interaction in increasing inhibitor activity of the linked vemurafenib 
molecules, and we therefore hypothesize that only one Gln461/linker interaction 
contributes to formation of the protein/inhibitor complex.  
 To evaluate the contribution of the second vemurafenib molecule of the Vem 
BisAmide-2 compound on inhibitor potency and promotion of the inactive dimeric 
BRAFV600E conformation, a control inhibitor (Vem-BisAmide-4, Figure 21a) containing 
the BisAmide-2 linker but only one vemurafenib molecule was synthesized and tested 
against BRAFV600E and BRAFWT in activity and thermal stability assays. These data 
revealed comparable potency to PLX and Vem-BisAmide-2 (Figure 21b), but a thermal 
melting temperature closer to PLX than Vem-BisAmide-2 (Figure 21c).  These data 
suggest that PLX and Vem-BisAmide-4 are promoting comparable BRAFV600E 
configurations that are distinct from the BRAFV600E complex with Vem-BisAmide-2, and 
consistent with the conclusion that the second vemurafenib molecule in the bivalent Vem-
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BisAmide-2 inhibitor plays a key role in promotion of the inactive dimeric BRAFV600E 
conformation.  
 
Figure 22 Simulated annealing omit map of Vem-BisAmide-2 and Q461. 
Simulated annealing omit map of the BRAFV600E/Vem-BisAmide-2 co-crystal with the 
omit map in green contoured at 2.0 sigma.  Density for one Q461 residue within the off-
state dimer is observable, however the other is not.   
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Figure 23 Structure of BRAFV600E/Vem-BisAmide-2 complex and functional 
characterization of Vem-BisAmide-2. 
 (a) Structure of BRAFV600E (violet) bound to Vem-BisAmide-2 (pink) with a simulated 
annealing omit map in green contoured at 2.5 sigma, highlighting close proximity between 
the carbonyls of the linker amide and Q461, shown as a stereo image (b) Dose response 
curves of Vem-BisAmide-2 against BRAFV600E (blue) and BRAFV600E/Q461A (cyan) with 
PLX4720 (PLX) against both proteins as a control.  Calculated IC50 values from duplicate 
measurements are indicated with+/- SEM shown.  95% Confidence Intervals are as 
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(continued from previous page) follows:  BRAFV600E/Vem-BisAmide-2 (29.8 nM to 106 
nM), BRAFV600E/Q461A/Vem-BisAmide-2 (286 nM to 755 nM), BRAFV600E/PLX (83.8 nM 
to 184 nM), and BRAFV600E/Q461A/PLX (54.7 nM to 108 nM).  (c) Sedimentation Velocity 
of BRAFV600E (blue) and BRAFV600E/R509H (red) as a function of added Vem-BisAmide-
2.  (d) Log plots of Sedimentation Equilibrium experiments showing theoretical monomer 
(red) and theoretical dimer (blue) slopes compared to BRAFV600E/R509H with equimolar 
concentrations of protein and Vem-BisAmide-2 (purple) and PLX (cyan).   
 
 Mutagenesis studies were performed to probe the importance of Gln461 for 
BRAFV600E inhibition by Vem-BisAmide-2.  We prepared the BRAFV600E/Q461A mutant and 
assessed its ability to be inhibited by Vem-BisAmide-2 relative to BRAFV600E/Q461A. IC50 
curves of Vem-BisAmide-2 against BRAFV600E and BRAFV600E/Q461A demonstrated that the 
Gln461A mutation shifts the IC50 from ~56 nM to ~464 nM, respectively, an almost 10 fold 
difference (Figure 23b).  In contrast PLX shows a comparable IC50 of ~80-130 nM for 
both BRAFV600E and BRAFV600E/Q461A (Figure 23b).  These studies highlight the 
importance of the role of BRAF Gln461 for inhibition by Vem-BisAmide-2.  
 
2.2.5 Vem-BisAmide-2 can promote the formation of BRAFV600E dimers in solution 
In order to validate that Vem-BisAmide-2 can mediate an inactive BRAFV600E dimer in 
solution as was observed in the crystal structures, we performed analytical 
ultracentrifugation experiments with and without Vem-BisAmide-2.   For these 
experiments, we utilized an R509H point mutation, previously shown to disrupt the active 
BRAFV600E dimer (Rajakulendran et al., 2009).  Control sedimentation velocity 
  
 
53
experiments demonstrated that while 10 μM BRAFV600E sediments as a dimer, 
BRAFV600E/R509H sediments as a monomer.  However, the addition of 5 μM of Vem-
BisAmide-2 to BRAFV600E/R509H shifts the sedimentation coefficient of BRAFV600E/R509H to 
two distinct populations, matching both a monomer and a dimer (Figure 23c).  Vem-
BisAmide-2 concentrations of 10 μM and 15 μM were also tested, and increasing 
concentrations of inhibitor were correlated with more dimer formation for BRAF V600E/R509H 
while BRAFV600E consistently sediments as a dimer, regardless of whether Vem-
BisAmide-2 is added or not.  To further quantify the sedimentation velocity experiments, 
sedimentation equilibrium experiments were performed.  Log plots of the data are shown 
in Figure 23d, where the slope of the line is proportional to the estimated molecular weight 
of the species in solution.  BRAFV600E/R50H with no inhibitor bound gives a single species 
with an estimated molecular weight of 40kD, where the predicted molecular weight of the 
monomer is ~35kD, indicative of predominantly monomer formation.  This species also 
has a slope that corresponds to that of the predicted line of an ideal monomer.  However, 
when Vem-BisAmide-2 is added, the single species molecular weight is ~70kD, precisely 
the predicted molecular weight of a BRAF dimer.  When BRAFV600E/R509H is incubated 
with PLX, the ideal fit molecular weight is 40kD, demonstrating that the presence of the 
unlinked inhibitor is not able to alter the monomeric state of the kinase.  These studies 
validate the promotion of BRAFV600E dimer formation by Vem-BisAmide-2, consistent 
with the crystallographic data demonstrating that it promotes the formation of BRAFV600E 
dimers in the inactive conformation.  We also performed sedimentation velocity 
experiments with BRAFV600E/R509H and Vem-BisAmide-4, which contains a single 
vemurafenib moiety, and demonstrated that the BRAFV600E/R509H/Vem-BisAmide-4 
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complex adopts a monomeric configuration (Figure 24) supporting our conclusion that the 
second vemurafenib molecule in the bivalent Vem-BisAmide-2 inhibitor plays a key role 
in promotion of the inactive dimeric BRAFV600E conformation.    
 
Figure 24 AUC sedimentation velocity of Vem-BisAmide-4 vs. Vem-BisAmide-2 
complexed with BRAFV600E/R509H. 
Sedimentation Velocity experiment shows a difference in Sedimentation Coefficient (s) for 
BRAFV600E/R509H complexed with Vem-BisAmide-4 and Vem-BisAmide-2.   
 
2.2.6 Vem-BisAmide-2 is able to enter melanoma cells to selectively target BRAFV600E over 
BRAFWT 
To determine if Vem-BisAmide-2 can selectively inhibit BRAFV600E in cells, we treated 
BRAFV600E (WM983B) or BRAFWT (WM3000) melanoma cells with Vem-BisAmide-2, 
vemurafenib and other selected linked vemurafenib inhibitors.  We observed that each of 
the inhibitors tested showed comparable dose-response inhibition of cell growth (Figures 
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25a and 25b) in cells harboring mutant BRAFV600E (WM983B) but not in cells harboring 
BRAFWT (WM3000). Furthermore, we found that the linked compounds blunted MAPK 
signaling (assessed by pERK and pMEK levels) (Figure 25c, top), but less potently than 
the unlinked PLX or the MEK inhibitor PD901.  Of note, none of the RAF inhibitors 
tested blocked MAPK signaling in BRAFWT cells (Figure 25c, bottom). These studies 
demonstrate that Vem-BisAmide-2 can enter cells to selectively inhibit BRAFV600E.  The 
fact that BRAFV600E homodimer species are unlikely to exist in BRAFV600E –mutant 
melanoma cells (Hu et al., 2013) is consistent with the observation that unlinked and 
linked-vemurafenib inhibitors show comparable BRAFV600E inhibitory potency in cells. 
 
Figure 25 Activity of Vem-BisAmide-2 against melanoma cell lines. 
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 (from previous page)(a-b)  Effect of Vem-3-Vem (cyan), Vem (black), Vem-BisAmide-2 
(blue) and Vem-BisAmide-1 (pink) on viability  of BRAFV600E  (WM983B; a) and 
BRAFWT (WM3000; b) melanoma cell lines treated as in figure 2.  Average cell viability 
taken from 3 separate experiments (n=7) and averaged together with +/- SEM is shown. 
(c) WM983B (top) and WM3000 (bottom) melanoma cells were treated with the 
indicated compounds for 18 hr. Total protein lysates were analyzed by immunoblotting 
using antibodies against phospho-ERK and phospho-MEK.  Actin was used as a loading 
control. Quantification of bands were performed using Odyssey software (Licor) and 
normalized to the  DMSO treatment band.   
 
2.3 Discussion 
 In summary, we demonstrate that appropriately covalently linking two vemurafenib 
molecules produces an inhibitor with enhanced potency and selectivity for targeting 
BRAFV600E over BRAFWT, and most significantly, a shift from an active to inactive 
BRAFV600E conformation, which is trapped in a dimeric state that cannot undergo 
paradoxical activation.  To our knowledge, this is the first inhibitor shown to promote such 
an inactive BRAFV600E dimeric conformation.   While other sulfonamide inhibitors have 
been shown to favor an inactive monomeric state of BRAFWT, the same is not true for 
BRAFV600E, where sulfonamide inhibitors such as vemurabenib can promote an active 
dimeric conformation.   In addition, recently reported “paradox breaker” inhibitors, such 
as PLX7904, PLX7922 and PLX5568, were shown to disfavor dimerization (C. Zhang et 
al., 2015).  However, crystal structures of these inhibitors bound to BRAFV600E (4XV1 and 
4XV3) and BRAFWT (4XV9) still demonstrate packing in a biologically relevant dimer in 
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the active conformation, characterized by the active conformation of the C-helix and the 
absence of the AS-H1 helix (C. Zhang et al., 2015).  The two BRAFV600E co-crystal 
structures also have only one inhibitor molecule bound per dimer pair, with the second 
protomer binding site inhibitor-free and in the active conformation, suggesting that these 
inhibited dimers may be susceptible to paradoxical activation. 
 The studies reported here have important implications for developing analogous 
linked inhibitors to target BRAFV600E/RAFWT heterodimers through the substitution of a 
pan RAF inhibitor for one of the vemurafenib molecules and appropriate alterations of the 
linker properties.  Such inhibitors would be useful as molecular probes to study the 
biological importance of RAF dimerization in MAPK signaling and have the potential as 
novel molecules to target BRAFV600E resistant melanomas.  Targeting heterodimers with a 
linked inhibitor rather than combinations of inhibitors has the potential to demonstrate 
more selectivity, leading to lower doses and potentially a more prolonged response.   
 The linked kinase inhibitor strategy described herein also has the potential to be 
extended to other kinase systems that utilize dimeric forms for signaling and allosteric 
regulation, such as RTKs, or two different interacting kinases such as RAF and MEK.  This 
strategy could enhance inhibitor synergy or dosing issues that usually come with 
combination therapies (Flaherty et al., 2012; Greger et al., 2012; Johnson et al., 2014; 
Villanueva et al., 2013).  While these dimeric structures are larger than 500 Da (1067 Da 
for Vem-BisAmide-2) and therefore do not follow the Lipinski rules (Lipinski, C.A.; 
Lombardo, F.; Dominy, B.W.; Feeney, 1997), our studies demonstrate that such molecules 
have good uptake into cells, can engage their substrates and show potent cellular activity.  
In another example of successfully employing linked inhibitors, Illendula et. al. recently 
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reported on PEG-linked inhibitor of the dimeric transcription factor CBFβ-SMMHC fusion 
protein to delay leukemia in mice (Illendula et al., 2015).   
 Taken together, the studies reported here demonstrate that chemically linked RAF 
inhibitors hold promise for eliciting a prolonged response to BRAFV600E-driven melanoma, 
either administered alone or in combination with immunotherapy, and have implications 
for targeting other kinase dimers for therapy (Hu-Lieskovan et al., 2015).     
 
2.4 Methods 
2.4.1 Plasmids 
DNA encoding the BRAF kinase domain residues 448-723 containing 16 solubilizing 
mutations (Tsai et al., 2008)  (I543A, I544S, I551K, Q562R, L588N, K630S, F667E, 
Y673S, A688R, L706S, Q709R, S713E, L716E, S720E, P722S, and K723G) permitting 
kinase domain overexpression in bacteria was ordered from Epoch Biolabs and cloned into 
a Pet28a(+) vector encoding an N-terminal His tag and a thrombin cleavage site between 
the protein and His tag.  This construct was used as a template to create His-tagged 
BRAFV600E-16M, BRAFR509H-16M and BRAFV600E/R509H-16M mutants.  These proteins were 
used in Analytical Ultracentrifugation Sedimentation Velocity and Sedimentation 
Equilibrium experiments, and Thermal Stability assays.   DNA encoding the BRAFV600E-
16M construct was sub-cloned into a PRSF vector containing a TEV protease-cleavable 
GST-tag and used for crystallization.   
 
DNA encoding the BRAF kinase domain residues 442-724 was used as a template to 
prepare BRAFWT, BRAFV600E and BRAFV600E/Q461A were cloned into a Pfastbac dual vector 
with mouse p50cdc37 full length as an expression chaperone for protein expression in 
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baculovirus infected Sf9 insect cells and used for in vitro kinase assays. Full length human 
MEK1 with an N-terminal GST fusion tag and a C-terminal His tag in a pGex-3t vector 
was provided by Dr. Michael Olson (Beatson Institute for Cancer Research, Glasgow, UK) 
and was used for our in vitro kinase assays.     
 
2.4.2. Protein Purification  
His-tagged BRAF-16M proteins were expressed in Rosetta2 BL21 bacterial expression cells 
at 37 oC and induced with 1mM IPTG overnight at 18oC, spun down the next day and lysed 
in Lysis Buffer (50 mM Potassium Phosphate, pH 7.0, 250 mM NaCl, 5 mM Imidazole) 
and 1 mM PMSF.  The lysate was then spun down at 19000 r.p.m. and the supernatant was 
added to 5 mL TALON metal affinity resin (Takara) and left to incubate at 4oC for 1 hour.  
The supernatant was then eluted, the column washed with 1L of Lysis Buffer and the 
BRAF-16M proteins eluted with Lysis Buffer supplemented with 250mM Imidazole.   
Protein were then dialyzed into Lysis Buffer without imidazole but with 5 mM EDTA and 
NaCl adjusted to 5 mM NaCl, prior to application on a 5 mL SP Sepherose anion exchange 
column, followed by washing in the same buffer and elution in lysis buffer with 0 mM 
NaCl to 1 M NaCl gradient.  Peak fractions were pooled, concentrated, and applied to a 
Superdex S200 gel filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM 
NaCl, 10 mM Dithiothreitol and 5% glycerol.  Protein was flash frozen in liquid nitrogen 
and stored for future use.    
  
GST-tagged BRAFV600E-16M protein was expressed in bacteria as described for the His-
tagged proteins, lysed Lysis Buffer 2 (50 mM KPi pH 7.0 and 250 mM NaCl) and incubated 
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on Glutathione Resin at 4 oC for 1 hr.   The protein on resin was then washed and left on 
the resin and cleaved with TEV protease overnight and eluted the next morning in Lysis 
Buffer 2 with 25 mM NaCl, run over both SP Sepharose and Q Sepharose ion exchange 
columns in tandem and the flow through collected.  The protein was then concentrated 
using a 10kDalton cutoff centrifugal filter unit (Millipore) and chromatographed on a 
Superdex S200 gel filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM 
NaCl, 10 mM Dithiothreitol and 5% glycerol.  Protein eluted as a mix of dimer and 
monomer and both species were pooled together, concentrated to 10mg/mL (~320 μM) and 
used immediately for crystallization.    
  
BRAFWT, BRAFV600E, and BRAFV600E/Q461A were overproduced as N-terminally His-
tagged proteins in insect cells essentially as previously described (Qin et al., 2012).  
Briefly, protein constructs were coexpressed with p50cdc37, pelleted, suspended in Lysis 
Buffer 3 (25 mM Tris 8.0, 250 mM NaCl, 5 mM Imidazole, and 10% glycerol) treated with 
Complete EDTA-free protease inhibitor cocktail tablets (Roche) and DNAseI, lysed, 
centrifuged at 19,000 r.p.m and added to TALON metal affinity resin and incubated for 1 
hr at 4 oC.  The protein on the resin was then washed extensively with Lysis Buffer 3 and 
then eluted with 25 mM Tris pH 7.5, 250 mM NaCl, 250 mM Imidazole, and 10% Glycerol.   
The protein was then diluted in low salt buffer containing 1 mM EDTA and 1 mM 
Dithiothreitol and run on an SP Sepharose column, eluted with a salt gradient from 0 mM 
NaCl to 1 M NaCl.   Peak fractions were pooled and run on a Superdex S200 gel filtration 
column and stored in a final buffer of 25 mM Tris 8.0, 300 mM NaCl, 1 mM Dithiothreitol 
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and 10% glycerol.   Protein was concentrated to ~0.5mg/mL and flash frozen in liquid 
nitrogen and stored for later use for ELISA kinase assays.    
  
GST-MEK1 fusion protein used as substrate in ELISA assays was prepared essentially as 
previously described (Qin et al., 2012).  Briefly, protein was expressed in BL21 (Gold) 
cells at 37 oC and induced with 0.5 mM IPTG at 15 oC overnight.   The cells were then 
harvested and resuspended in Lysis Buffer 4 (20 mM Hepes pH 7.5, 500 mM NaCl, 10 
mM BME, 10 mM Imidazole, 5% Glycerol) supplemented with 1 mM PMSF and DNAseI.  
The lysate was sonicated and spun down, and the supernatant was added to Ni-NTA resin 
and incubated for 1 hr at 4 oC.  The resin was then washed extensively with Lysis Buffer 4 
and eluted with Lysis Buffer 4 supplemented with 250mM Imidazole.  Peak fractions were 
then concentrated as described above and loaded onto a Superdex S200 gel filtration 
column in a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 10 mM BME, and 5% 
glycerol.  The protein eluted off the sizing column in two separate populations, and the 
second peak corresponding to a GST-MEK dimer was collected, concentrated to 
~20mg/mL, and flash frozen in liquid nitrogen and stored for later use.   
 
2.4.3 Crystallization, Data Collection, and Structural Analysis 
  BRAFV600E-16M at 10 mg/mL was mixed with a  10 mM (in 100% DMSO) stock solution 
of inhibitor (Vem-6-Vem, Vem-3-Vem, and Vem-BisAmide-2, respectively) to a final 
inhibitor concentration of 500 μM and trays were set up screening around a crystallization 
condition of 100 mM Tris pH 8.5, 14% PEG Monomethyl Ether 2000, and 200 mM 
Trimethyl Amine N-oxide Dihydrate for Vem-6-Vem and a condition of 100 mM Tris 8.5, 
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5% ethanol, and 2% Benzamidine HCl for Vem-3-Vem and Vem-BisAmide-2 using the 
hanging-drop vapor diffusion method at 4oC.  Crystals were flash frozen in cryo-protected 
mother liquor containing 20% glycerol.  X-ray diffraction data were collected at a 
wavelength of 0.98 Å at the Advanced Photon Source (beamline 24-ID-E) for BRAFV600E-
16M inhibitor crystals with Vem-6-Vem and Vem-3-Vem, and with Vem-BisAmide-2 was 
collected in house using the Rigaku MicroMax-007HF with a mar CCD 165mm detector.  
The BRAFV600E-16M inhibitor crystal with Vem-6-Vem was processed using HKL-2000 
(Otwinowski & Minor, 1997), Vem-3-Vem was processed using XDS (Kabsch, 2010) and 
Vem-BisAmide-2 was processed using HKL-2000 (Otwinowski & Minor, 1997).  
 All three co-crystal structures were determined by molecular replacement in 
PHENIX using phaser (Adams et al., 2010; McCoy et al., 2007).  The BRAFV600E-16M/Vem-
6-Vem structure was determined using PDB 4WO5 (Thevakumaran et al., 2014) as a search 
model in Phaser and the  BRAFV600E-16M/Vem-3-Vem and BRAFV600E-16M/Vem-BisAmide-
2 structures were determined using the BRAFV600E-16M/Vem-6-Vem structure as a search 
model.  Molecular Replacement search models had the inhibitor removed from them, and 
for the structure determination of BRAFV600E-16M/Vem-6-Vem, the C-helix was removed 
from the search model.   For the structure determinations of BRAFV600E-16M with Vem-3-
Vem and Vem-BisAmide-2, the C-helix was included in the molecular replacement model 
but deleted during refinement and rebuilt manually after PHENIX refinement.  Model 
building and refinement were performed using Coot and PHENIX (Afonine et al., 2012; 
Emsley, Lohkamp, Scott, & Cowtan, 2010).  For all three structures, NCS was used, as 
multiple BRAF monomers were present in the asymmetric unit.   Simulated Annealing 
omit maps were generated by taking the fully built model, deleting the inhibitor, and 
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running through PHENIX refine using simulated annealing in the refinement.   The 
coordinates for the Vem-6-Vem inhibitor were generated by downloading the PDB file for 
Vemurafenib, editing it using the REEL program in PHENIX to edit the molecule, and then 
running through ELBOW (Moriarty, Grosse-Kunstleve, & Adams, 2009).  The coordinates 
for the inhibitors Vem-3-Vem and Vem-BisAmide-2 were generated using ChemDraw, 
saving as a pdb file and running through ELBOW to generate a cif file.  Table 1 statistics 
were generated using PHENIX validation tools (V. B. Chen et al., 2010).    The two sets of 
“dimers” in the asymmetric unit of the BRAFV600E-16M/Vem-3-Vem and BRAFV600E-
16M/Vem-BisAmide-2 structures are also making interactions with one another, with a 
Benzamidine molecule buried within the protein-protein interface.  Benzamidine 
Hydrochloride was a crystal additive, and we reason that it facilitated crystallization by 
stabilizing crystal contacts in this crystal form.  
 
2.4.4. In Vitro Kinase Assay 
 Compound inhibition of BRAFWT and BRAFV600E were assessed using an ELISA assay 
performed essentially as previously described (Qin et al., 2012).  Briefly, GST-MEK fusion 
protein was diluted 3:1000 in Tris-Buffered Saline treated with 0.05% Tween-20 (TBST) 
and diluted MEK was added to a glutathione-coated 96 well plate (Pierce #15240) and 
incubated at room temperature for 1 hour with shaking. BRAF was diluted from 0.5 mg/mL 
frozen stocks 1:1000 in 50 mM Hepes pH 7.0 and 50 mM NaCl and treated with inhibitor 
at various concentrations and incubated with GST-MEK.  Glutathione plates were washed 
extensively, and the protein-inhibitor mixture was then added to the plate with 100 μM 
final concentration of ATP in a buffer containing 50mM HEPES pH 7.0, 200 mM NaCl, 
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and 10 mM MgCl2.  The plate was then incubated at 37oC for 30 minutes, the reaction was 
then discarded, and the plate was washed with TBST extensively and a 1:8000 dilution of 
primary antibody (p-MEK1/2 (S217/S221) Rabbit Antibody (Cell signaling)) was added 
to the plate and incubated for 1 hour.  The plate was then treated with stringent TBST 
washes and then incubated with a 1:10000 dilution of secondary antibody (Goat Anti-
Rabbit IgG (H+L)-HRP (BioRad)) for 1 hour.  The plate was then washed and Supersignal 
ELISA Pico Chemiluminescent Substrate (Pierce #37069) was added and the plate read on 
a Perkin Elmer EnVision.  Each curve was repeated in duplicate or triplicate, normalized 
using GraphPad Prism by selecting the largest value as the maximum and the lowest value 
as the minimum, and used to calculate IC50 values by using a log (inhibitor) vs. response 
fit on Prism 5.0 (GraphPad).  IC50 values of PLX monomer, first generation Vem-linked 
inhibitors, and Vem-BisAmide-2 against BRAFV600E were calculated using data from two 
separate experiments, each performed in duplicate.  Error bars are indicative of the SEM 
of each point, and 95% confidence intervals of the IC50 values are listed in the figure 
legend, as calculated using GraphPad Prism.    
 
2.4.5. Thermal Stability Assays 
 Frozen aliquots of BRAFV600E-16M proteins were thawed and diluted in Thermal Stability 
Buffer (25 mM Hepes  pH 7.0, 150 mM NaCl) to a final concentration of 5 μM (0.2 mg/mL) 
and 15 μL were added to the selected wells of a MicroAmp Optical 384 well plate (Applied 
Biosystems).   Sypro Orange (5000X stock, ThermoFisher Scientific) was diluted 1:300 
and 4 μL of that diluted stock was added to each well.  1 μL of inhibitor in 100% DMSO 
was added to each well to a final concentration of 50 μM and the plate was spun down and 
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heated from 20 oC to 95 oC using a qPCR (ABI 7900 RealTime PCR) with a 2% ramp rate.   
Fluorescent readings were recorded every 2 minutes.  Melting curves were generated from 
this data and analyzed by taking the first derivative of the curve.  Data were analyzed and 
plotted using GraphPad, with error bars indicating as SEM of each sample and 95% 
confidence intervals of the Tm values listed in the figure legend, both metrics were 
calculated using GraphPad Prism with an n=6.   
 
2.4.6. Analytical Ultracentrifugation (AUC) 
 Sedimentation Velocity AUC was performed with a Beckman Optima XL-I at 42,000 
r.p.m.  Data were obtained over ~8 hours of centrifugation at 20 oC by monitoring 
absorbance.  Concentrations of BRAFV600E/R509H-16M and BRAFV600E-16M were at 10 μM 
while inhibitor concentration ranged from 5 μM to 15 μM in AUC buffer (25 mM Tris pH 
7.5, 150 mM NaCl).   Data was analyzed using SEDFIT to calculate a continuous c(s) 
distribution and data was graphed using GraphPad.    
 
Sedimentation Equilibrium AUC was performed with the same Beckman Optima XL-I at 
three speeds (12,000 r.p.m, 18000 r.p.m., and 26000 r.p.m.) at three different 
concentrations (15 μM, 10 μM, and 5 μM) of BRAFV600E/R509H-16M supplemented with a 1:1 
molar ratio of inhibitor at either concentration.  AUC buffer from sedimentation velocity 
experiments was used for equilibrium experiments.   Data was analyzed using 
Heteroanalysis to calculate an Ideal fit molecular weight of the species in each cell and log 
plots of the data were subsequently graphed using GraphPad Prism.  Ideal monomer and 
dimer fits were calculated using Heteroanalysis. 
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2.4.7.Cell Viability Assays  
The protocol is not included in this text, but is listed in (Grasso et al., 2016).  These assays 
were performed by Minu Samanta in the Villanueva lab.   
 
2.4.8 Small Molecule Inhibitors  
Inhibitors were purchased from Selleck Chem: BRAF inhibitor PLX4720 (cat# S1152), 
and MEK inhibitor PD0325901 (cat#S1036).  BRAF inhibitor PLX4032 was purchased 
from Santa Cruz Biotechnology (cat# sc-364643).  EC50 calculation: The EC50 (the 
concentration of a drug that gives half-maximal response) values for BisAmide inhibitors 
are calculated from relative viability data from three separate experiments with seven 
replicates each.  The EC50 values for Vem-x-Vem dimers are calculated from relative 
viability data from one experiment with seven replicates each.  EC50 values for Mel1617 
cell line (BRAFV600E melanoma cell line) are shown in Figure S8 and was calculated from 
relative viability data from three separate experiments with seven replicates each.  Relative 
viability values were input in GraphPad and calculated using log (inhibitor) vs normalized 
response curve.   
 
2.4.9. Western Blotting 
The protocol is not included in this text, but is listed in (Grasso et al., 2016).  These assays 
were performed by Minu Samanta in the Villanueva lab.   
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2.4.10 Inhibitor Synthesis  
The protocol is not included in this text, but is listed in (Grasso et al., 2016).  Inhibitor 
synthesis and purification analysis was performed by Michelle Estrada in the Winkler lab.   
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Chapter 3- TAK632 promotes inhibition of BRAF through the 
induction of inhibited dimers 
 
 
 
 
 
This research was performed in collaboration with Dr. Michelle Estrada, and Kiara Berrios of the University 
of Pennsylvania.  Dr. Estrada performed the synthesis of inhibitors, Kiara Berrios performed initial 
sedimentation velocity experiments of vemurafenib against BRAFWT and BRAFV600E.  Repeated with 
permission from Grasso, M., Estrada, M. A., Berrios, K. N., Winkler, J. D., Marmorstein, R. (2018) N-(7-
Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl) 
cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited 
Dimers. J. Med. Chem. DOI: 10.1021/acs.jmedchem.8b00499. Copyright 2018 American Chemical Society. 
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3.1 Introduction  
 Due to inhibitor resistance via transactivation in patients with BRAF-mutant 
melanoma, it is important to understand different BRAF inhibitor binding modes and 
their effects on BRAF dimerization and activation.  A prior study characterized several 
RAF kinase inhibitors that can induce dimerization in vitro and in cells, and correlated 
this to the stabilization of a closed conformation of N and C lobes of the kinase (H 
Lavoie et al., 2013). A more recent study comparing eight diverse RAF inhibitors led to 
their classification according to their ability to promote an active or inactive αC-helix 
conformation, αC-in versus αC-out, respectively (Karoulia et al., 2016).  The authors 
determined that the more BRAF mutant specific αC-out inhibitors (such as vemurafenib) 
are correlated with inhibitor resistance due to negative allostery, whereas the less BRAF 
mutant selective pan-RAF αC-in inhibitors can occupy both active sites of a BRAF dimer 
and are therefore less correlated with drug resistance during treatment (Karoulia et al., 
2016).   
 We previously reported on the development of bivalent vemurafenib (Type-I) 
inhibitors as a novel approach to potently inhibit active BRAFV600E dimers (Grasso et al., 
2016). We found that these inhibitors promote an inactive BRAFV600E/BRAFV600E 
homodimeric conformation with both protomers in αC-out conformations and with 
improved vemurafenib potency and selectivity for BRAFV600E in vitro (Grasso et al., 
2016).  To evaluate the BRAF dimerization and inhibition properties of bivalent 
inhibitors that contain a monovalent compound that promotes an αC-in conformation, we 
employed the type-II αC-in inhibitor TAK632 (Okaniwa et al., 2013).  We hypothesized 
that a bivalent TAK inhibitor would further stabilize an inactive dimeric BRAF 
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conformation and be more useful in a cellular environment due to resistance involving 
BRAFWT and CRAFWT as well as BRAFV600E.  Surprisingly, we found that while 
monovalent TAK632 promotes dimerization and potently inhibits BRAF dimers in vitro, 
bivalent TAK inhibitors cannot induce dimers, and concomitantly reduce inhibitor 
potency.  This study indicates that the promotion of an αC-in/αC-in BRAF dimer 
conformation is integral to the ability of TAK632, and likely other Type-II BRAF kinase 
inhibitors, to inhibit RAF kinases.  These studies have implications for the more effective 
targeting of BRAF dimers with bivalent BRAF inhibitors to target paradoxical activation 
for more durable treatment of melanoma.  
3.2 Results  
3.2.1. Bivalent TAK inhibitors have reduced potency relative to monovalent TAK in vitro 
 The pan-RAF inhibitor TAK632 targets wild-type or mutant BRAF and CRAF with 
IC50 values in the low nanomolar range (Okaniwa et al., 2013).  We used the crystal 
structure of BRAFWT complexed with TAK632 (accession code 4KSP) to determine where 
to link the two TAK632 molecules without compromising TAK632 potency.  The TAK632 
inhibitor binds both subunits of a BRAF dimer with the αC-helix of both protomers in the 
αC-in conformation.   While the trifluoromethylphenyl moiety of TAK632 is located near 
the hydrophobic pocket of the binding site, the cyclopropyl amide makes minimal protein 
contacts, i.e., no interaction between the cyclopropane ring and the protein surface is 
observed, although there is an interaction between the amide N-H and Cys532 (Figures 
26a and 26b).  The amide moiety is exposed to solvent, suggesting it would be an 
appropriate place to link the monomers, with the caveat that the amide N-H bond is retained 
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in the bivalent molecule (Figure 26a).  We therefore prepared a series of PEGylated amide 
dimers, where n equals the number of PEG units present in the oxydiacetic acid linker of 
the dimeric structure (Figure 26c).    Superposition of the BRAFWT/TAK632 structure with 
BRAFV600E/Vem-BisAmide-2, (BRAFV600E bound to a bivalent vemurafenib inhibitor, 
accession code 5JT2), suggests that the amide-linking site on TAK632 would produce 
bivalent TAK inhibitors with similar topology as Vem-BisAmide-2 and related compounds 
(Figure 26d).  The distance between the two TAK632 molecules within a BRAF dimer of 
the BRAFV600E/Vem-BisAmide-2 structure would be predicted to be about 10Å.  Based on 
this docking exercise, we synthesized a series of bivalent TAK-n-TAK molecules where 
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n=0, 2, 3, 4, and 6 to account for various possible protein dimer orientations (Figure 26e).  
 
 
Figure 26 Structure of TAK632 bound BRAF and rationale for linked TAK inhibitors. 
(from previous page)  (a) Structure of BRAFWT/TAK632 (accession code 4KSP), 
highlighting the exposed cyclopropane ring.  (b)  Structure of monovalent TAK632, and 
where it interacts with residue Cys532 of BRAF (c) Initial scaffold for bivalent TAK 
inhibitors where n equals the number of ethylene glycol moiety groups present.  (d) 
Alignment of BRAFWT/TAK632 (pink and grey) with BRAFV600E/Vem-BisAmide-2 
structure (blue) (5JT2).  (e). Preparation of bivalent TAK-n-TAK structures 
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 The requisite dimers were prepared by reaction of the known TAK 
aminobenzothiazole 1 with the requisite oxydiacetic acids 2-6 in the presence of BEP and 
DIPEA in DMF, in which the tether length was increased by incremental addition of 
ethylene glycol moieties to generate the TAK-n-TAK series, in which n represents the 
number of ethylene glycol moieties in the linker between the two TAK ligands.  The 
inhibitor potency of each molecule was then evaluated in vitro against both BRAFWT and 
BRAFV600E using an ELISA assay that measures the level of phosphorylation of GST-
tagged MEK by purified BRAF kinase domain.  While all inhibitors showed comparable 
potency against BRAFWT and BRAFV600E, their inhibitory potencies were 15- to 400- fold 
reduced relative to monovalent TAK632 (Figure 27a and 27b).  Compounds TAK-2-TAK 
and TAK-4-TAK showed the greatest potencies of the bivalent inhibitors, with IC50 values 
of 132 nM and 90.2 nM, respectively, against BRAFWT and 73.9 nM and 73.8 nM, 
respectively, against BRAFV600E.  The other bivalent TAK inhibitors (TAK-0-TAK, TAK-
3-TAK and TAK-6-TAK) had IC50 values ranging from 168 nM to 732 nM. In comparison, 
monovalent TAK632 had IC50 values of 3.23 nM and 4.46 nM against BRAFWT and 
BRAFV600E, respectively. These experiments reveal that although the bivalent TAK 
inhibitors show some dependency on linker length, they are considerably less potent than 
monovalent TAK632 and therefore likely binding BRAF in a different mode than bivalent 
Vem-BisAmide-2 and related compounds. 
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Figure 27 Potency of first generation bivalent TAK inhibitors. 
 (a)  Dose response curves of bivalent TAK inhibitors against BRAFWT with TAK632 as a 
control.  Calculated IC50 values are indicated. The experiments were performed in triplicate 
with +/- SEM shown.  95% confidence intervals are:  TAK632 (1.47 nM to 7.47 nM), 
TAK-2-TAK (69.6 nM to 249 nM), TAK-4-TAK (48.4 nM to 168 nM), TAK-0-TAK (347 
nM to 832 nM), TAK-3-TAK (351 nM to 1.08 µM), and TAK-6-TAK (277 nM to 1.94 
µM).  (b)  Dose response curves of bivalent TAK inhibitors against BRAFV600E with 
TAK632 as a control, carried out in triplicate with +/- SEM shown.  The 95% confidence 
intervals are:  TAK632 (2.67 nM to 7.45 nM), TAK-2-TAK (47.5 nM to 115 nM), TAK-
4-TAK (59.7 nM to 91.1 nM), TAK-0-TAK (323 nM to 549 nM), TAK-3-TAK (128 nM 
to 219 nM), and TAK-6-TAK (199 nM to 621nM).  
 
3.2.2 Monovalent TAK inhibitors promote BRAF dimers while bivalent TAK inhibitors do 
not 
 Our previous studies revealed that bivalent vemurafenib inhibitors promoted an 
inactive “face-to-face” αC-out/αC-out BRAF dimer configuration that differed 
significantly from the ”side-to-side” active αC-in/αC-out BRAF dimer configuration as 
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bound to monovalent vemurafenib or αC-in/αC-in BRAF dimer configuration not bound 
to inhibitor (Grasso et al., 2016). To determine if bivalent TAK inhibitors also promoted 
BRAF dimers, we performed analytical ultracentrifugation (AUC) sedimentation velocity 
experiments to compare the oligomeric state of BRAF as a function of added TAK 
inhibitors.  We first utilized an R509H BRAF mutant protein that disrupts the side-to-side 
active dimer interface to promote the formation of BRAF monomers (Rajakulendran et al., 
2009).  As expected, unliganded BRAFR509H migrated with a sedimentation coefficient of 
~ 3 corresponding to an apparent protein monomer (Figure 28a).  Surprisingly, however, 
the addition of a molar excess of bivalent TAK inhibitors did not alter the apparent 
monomer migration position of BRAFR509H, irrespective of linker length (Figures 28a – 
28c). The bivalent TAK inhibitors were therefore unable to shift BRAF into an inactive 
dimeric configuration as anticipated.  This differed from chemically linked Vemurafenib 
inhibitors such as Vem-BisAmide-2, which were able to shift BRAFV600E/R509H into a 
dimeric configuration in solution (Figure 29).   
 In contrast to the effect of adding bivalent TAK inhibitors to BRAFR509H, the 
addition of a molar excess of monovalent TAK632 to BRAFR509H led to the formation of 
an apparent BRAFR509H dimeric species (sedimentation coefficient of ~ 4, Figure 28a – 
28c).  While the literature demonstrates that TAK632 can induce dimers at lower 
concentrations than vemurafenib (Nakamura et al., 2013), the fact that TAK632 can induce 
dimers in vitro despite a R509H point mutation that is known to disrupt dimers was 
unexpected. These studies demonstrate that monovalent TAK632 actively promotes the 
formation of BRAF dimers. 
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Figure 28 Sedimentation velocity experiments of bivalent TAK inhibitors. 
 (a)  BRAFR509H (10 µM) in the absence and presence of TAK632 and TAK-2-TAK 
inhibitor at different concentrations.  (b) BRAFR509H (12 µM) in the absence and presence 
of TAK632 and TAK-4-TAK inhibitor at different concentrations. (c) BRAFR509H (12 µM) 
in the absence and presence of TAK632, TAK-3-TAK and TAK-6-TAK inhibitors at 20 
µM.  
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Figure 29 Bivalent TAK inhibitors versus bivalent vemurafenib inhibitors. 
Sedimentation velocity curves for 12 µM BRAFV600E/R509H either in the presence of 12 
µM Vem-BisAmide-2, 12 µM TAK-2-TAK, or no inhibitor.  These curves demonstrate 
Vem-BisAmide-2 can induce inactive dimers while TAK-2-TAK cannot.   
 
  
 To determine whether higher concentrations of the bivalent TAK inhibitors are able 
to shift BRAFR509H into a dimeric configuration, we titrated 20 µM protein with 25 – 200 
µM TAK-4-TAK and found that even the highest concentration of bivalent inhibitor was 
unable to fully shift the protein into a dimeric configuration, although at the highest 
concentration of TAK-4-TAK (200 µM), BRAFR509H gives a more broad sedimentation 
curve, indicating that at these high concentrations the protein/inhibitor complex begins to 
shift towards a dimeric species (Figure 30a). Consistent with the results above, we also 
demonstrated that BRAFWT and BRAFV600E form dimeric species in the presence of 
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monovalent TAK632 and form either monomers or mixed monomer/dimer populations in 
the presence of bivalent TAK inhibitors (Figures 30b  and 30c). To confirm these findings, 
we ran sedimentation equilibrium experiments of BRAFR509H in the absence and presence 
of monovalent TAK632 and bivalent TAK inhibitors.  Log plots of the data are shown in 
Figure 30d, where the slope of the line is proportional to the estimated molecular weight 
of the species in solution.    BRAFR509H/TAK632 gave an ideal molecular weight fit of ~69 
kDa, aligning with the simulated dimer of ~70 kDa.  In contrast, BRAFR509H/TAK-4-TAK 
gave an ideal molecular weight fit of ~40kDa, aligning with the simulated monomer of ~35 
kDa.  BRAFR509H without inhibitor also aligns with the simulated monomer, giving an ideal 
molecular weight fit of ~36 kDa.  Taken together, the observation that monovalent 
TAK632 inhibitors promote the formation of BRAF dimers and that the bivalent TAK 
inhibitors cannot, coupled with our earlier findings that monovalent TAK632 is much more 
potent than bivalent TAK for BRAF inhibition (Figure 27), leads to the conclusion that 
TAK632 promotes inhibition of BRAF through the induction of inhibited dimers. 
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Figure 30 Sedimentation velocity and sedimentation equilibrium experiments of 
bivalent TAK inhibitors. 
 (a) BRAFR509H (20 µM) in the absence and presence of TAK632 and TAK-4-TAK 
inhibitor at different concentrations. (b) BRAFWT (10 µM) in the absence and presence of 
TAK632 and TAK-2-TAK. (c) BRAFV600E (10 µM) in the absence and presence of 
TAK632 and TAK-2-TAK and TAK-4-TAK inhibitors at different concentrations. (d) Log 
plots of sedimentation equilibrium experiments showing theoretical monomer (purple) and 
theoretical dimer (blue) slopes of BRAF compared to BRAFR509H in the absence and 
presence of TAK632 and bivalent TAK-4-TAK at a 2:1 molar ratio of inhibitor to protein. 
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3.2.3 The bivalent nature of the linked TAK inhibitors is required to reduce inhibitor 
potency and to promote BRAF monomers  
To determine whether the two TAK632 ligands or the glycol linker was responsible 
for promoting the formation of the BRAF monomers, we prepared two compounds with 
the linker intact and only one TAK632 molecule (TAK-L and TAK-L-C, Figure 31a).  
TAK-L, included the PEG portion of the linker, while TAK-L-C included the PEG and the 
1,3-thiazole-2-amide moiety of the second TAK632 molecule as a cap.  Coupling of the 
TAK molecule 1 (Figure 26e) with commercially available 2-(2-methoxyethoxy)acetic 
acid 12 led to the formation of 13 TAK-L.  The TAK-L-C 14 was prepared from 3,6,9-
trioxaundecandioic acid 3, first by anhydride formation with DCC, followed by ring 
opening with 2-aminothiazole, and coupling of the TAK molecule 1 with the resulting 
monoacid intermediate to give 14 (TAK-L-C).  Both molecules were evaluated in ELISA 
kinase activity assays and sedimentation velocity experiments to assess the effect of these 
two linker regions on TAK potency and the ability to promote BRAF dimers, respectively. 
Dose response kinase inhibition experiments demonstrated that TAK-L had similar 
inhibitor potency to TAK632, with IC50 value of 5.75 nM and 7.11 nM, respectively, and 
TAK-L-C showed only about a 4-fold reduced potency (20.3 nM) relative to TAK632 
(Figure 31b).  In contrast, the bivalent TAK inhibitors, TAK-2-TAK and TAK-4-TAK, 
showed about a 12-fold reduction in potency (> 85 nM) relative to TAK632 (Figure 31b). 
These data demonstrate that the second TAK632 ligand in the bivalent TAK inhibitor plays 
a significant role in the reduced potency of the bivalent TAK inhibitors relative to 
monovalent TAK632.  These results also indicate that linker placement does not 
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significantly hinder the ability of the bivalent inhibitors to inhibit BRAF relative to 
monovalent TAK632. 
 Sedimentation velocity experiments with BRAFR509H in the presence of monovalent 
TAK-L and TAK-L-C or the bivalent TAK-2-TAK, reveal that the TAK inhibitors 
containing linkers and a single TAK632 ligand promoted the formation of protein dimers, 
while TAK-2-TAK could not alter the oligomerization state upon binding (Figure 31c), as 
previously shown (Figure 28a). These data demonstrate that the second TAK632 ligand in 
the bivalent TAK inhibitor plays a driving role in preventing the formation of inhibited 
BRAF dimers, which appears to be correlated with the reduced potency of the bivalent 
TAK inhibitors relative to monovalent TAK632.  
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Figure 31 Biochemical and biophysical properties of TAK-linker compounds. 
(a) Preparation of monomeric TAK control compounds, TAK-L (TAK with linker) and 
TAK-L-C (TAK with linker and cap).  (b). Dose response curves of TAK control 
compounds along with bivalent TAK-2-TAK and TAK-4-TAK and TAK632 against 
BRAFWT.  Calculated IC50 values are indicated. The experiments are performed in 
duplicate with +/- SEM shown.  95% confidence intervals are:  TAK-L (3.33 nM to 9.91 
nM), TAK-L-C (10.3 nM to 40.2 nM), TAK-2-TAK (50.2 nM to 151 nM), TAK-4-TAK 
(56.7 nM to 129 nM), and TAK632 (3.32 nM to 15.2 nM). (c). Sedimentation velocity 
experiments with BRAFR509H (15 µM) in the presence of TAK-L, TAK-L-C, and TAK-2-
TAK at 20 µM. 
 
 
  
 
83
3.2.4 Bivalent TAK inhibitors display distinct BRAF properties 
 To further explore the mechanism by which bivalent TAK inhibitors bind BRAF, 
we performed a limited proteolysis experiment in which trypsin was added to BRAFWT in 
the presence and absence of TAK632, TAK-2-TAK, TAK-L-C, and vemurafenib (Figure 
32a).  When no ligand is present (lane 1), the major digested band (species A), is very close 
in size to undigested BRAF, with the appearance of two smaller minor bands (species B 
and C).   In the presence of TAK632 and TAK-L-C (lanes 2 and 3 respectively), BRAFWT 
species A becomes a minor band, while species B and C become major bands.  In contrast, 
in the presence of TAK-2-TAK (lane 4), BRAFWT had a digestion pattern resembling that 
of unliganded BRAFWT, producing BRAFWT species A as a major band but with slightly 
larger amounts of species B and C.  In the presence of vemurafenib (lane 5), BRAFWT 
produces species A as the major band, with negligible amounts of species B and C.  These 
results demonstrate that in the presence of the bivalent TAK-2-TAK, BRAF has a digestion 
pattern that is somewhere in between BRAFWT alone and monomeric TAK632/TAK-L-C.  
These observations indicate that bivalent TAK inhibitors cannot fully promote a 
conformation allowing for degradation to species B and C, whereas monovalent TAK 
molecules can.   
 To further dissect the mode of bivalent TAK inhibitor binding to BRAF, we 
performed Differential Scanning Calorimetry (DSC) experiments in which BRAFWT 
protein (37 µM) was heated in the presence and absence of ligands to determine melting 
temperatures (Figure 32b).   When no ligand is present (black), we observe a single melting 
temperature of 37.84 oC, which we interpret as melting of a BRAFWT monomer.   In the 
presence of TAK632 or TAK-L-C (125 µM) (violet and cyan, respectively), we observe 
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single melting temperatures of 68.74 oC and 63.29 oC, respectively, which we interpret as 
melting of BRAFWT dimers bound to monovalent TAK inhibitors.  In contrast, in the 
presence of TAK-2-TAK (125 µM) (pink), two broad melting temperatures are observed 
of 38.72 oC and 59.6 oC, and titration of TAK-2-TAK between 75-250 µM produces more 
of the higher melting temperature species at the expense of the lower melting temperature 
species.  We interpret this observation to indicate that while bivalent TAK inhibitors do 
have a capacity to promote BRAF dimers at high concentration of bivalent inhibitor, they 
do so significantly more poorly than monovalent TAK632.  Taken together, both the 
limited proteolysis (Figure 32a) and DSC (Figure 32b) studies reveal that bivalent TAK 
inhibitors promote BRAF species in solution that act as a combination of both unbound 
BRAF and BRAF bound to monovalent TAK, indicating that the bivalent TAK inhibitors 
cannot fully stabilize the dimeric TAK632-mediated BRAF configuration.  
 
Figure 32 Determination of bivalent TAK inhibitor binding modes to BRAF. 
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 (from previous page) (a) Limited proteolysis experiment of BRAFWT in the presence and 
absence of 200 µM inhibitors after exposure to trypsin for 30 minutes (lanes 1-5) and lane 
6 shows BRAFWT without ligand or trypsin.   (b) Differential Scanning Calorimetry (DSC) 
experiments in which BRAFWT is heated in the presence and absence of inhibitors ranging 
in concentration from 25 µM to 250 µM.  Melting temperatures are as follows:  125 µM 
TAK632-68.7 oC;  125 µM TAK-L-C- 63.3 oC;  75 µM TAK-2-TAK- 38.4 oC, 58.7 oC;  
125 µM TAK-2-TAK- 38.7 oC, 59.6 oC; 250 µM TAK-2-TAK- 40.1 oC, 62.6 oC;  No 
ligand- 37.8 oC.   
 
 
3.2.5 Trp450, Arg506 and the αC-helix play a significant role in dimer formation via TAK 
binding 
 Given our surprising finding that the monovalent TAK632 inhibitor promotes 
formation of αC-in/αC-in BRAF dimers, even in the presence of the R509H dimerization 
defective mutant, we set out to better understand the nature of the BRAF dimer that is 
stabilized by monovalent TAK632. R509 is able to stabilize the active “side-to-side” αC-
in/αC-in configuration by making hydrogen bond interactions with backbone carbonyls of 
T508 and R506 (Grasso et al., 2016; Rajakulendran et al., 2009).  To assess what additional 
changes are necessary to facilitate TAK632-induced dimerization, we superimposed 
different subunits of the BRAFWT/TAK632 (accession code 4KSP) (Okaniwa et al., 2013),  
BRAFV600E/AZ628 (accession code 4G9R) (Wenglowsky et al., 2012), and 
BRAFR509H/AZ628 (accession code 4RZW) (Karoulia et al., 2016) crystal structures. 
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AZ628 is another Type-II, αC-in inhibitor, and was also shown to be able to induce 
dimerization in the presence of an R509H mutation, however at a higher concentration 
(Karoulia et al., 2016).   This superposition revealed that the inhibitor complexes with 
BRAFWT and BRAFV600E contain highly super imposable αC-in/αC-in configurations 
(RMSD of 0.596 Å2 for BRAFWT/TAK αC segments and 0.463 Å2 for BRAFV600E/AZ628 
αC segments), while the BRAFR509H/AZ628 structure contains more variable αC-in 
configurations (RMSD of 1.713 Å2 for corresponding αC segments) where one of the αC 
segments orients further away from the αC-out configuration while the other moves closer 
towards the αC-out configuration  (as seen in the BRAFV600E/Vem complex, Figure 33a). 
This observation suggests that while the R509H mutation destabilizes the active αC-in/αC-
in dimer and favors an inactive, αC-out configuration, Type-II inhibitor binding is able to 
compensate for the destabilizing R509H mutation to further strengthen the dimer by 
biasing the kinase towards an αC-in/αC-in dimer configuration.  
 In comparing the three crystal structures described above, we noted that W450 
participates in van der Waals interactions with the aliphatic region of R509 but that W450 
adopts a distinct conformation in one of the protomers of the BRAFR509H/AZ628 structure, 
which appears to be facilitated by a pi-stacking interaction with the R509H mutation of the 
other protomer (Figures 33b and 33c), and accompanied by a movement of D448 to 
hydrogen bond to W450 of the opposing subunit (Figure 33d). Reinforcing the importance 
of W450 for active BRAF dimer formation, a W450A mutation was previously 
demonstrated to impair transactivation in cells. (Hu et al., 2013; Jambrina et al., 2016) 
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These results indicate that W450 plays a critical role in the ability of TAK632 (and possibly 
other Type-II αC-in inhibitors such as AZ628) to induce dimerization.   
 R506 is another residue previously noted to play a significant role in inhibitor-
induced dimerization based on the unique conformations that it adopts in co-crystal 
structures of BRAF bound to αC-in (ie. AZ628) and αC-out (ie. vemurafenib) inhibitors 
(Karoulia et al., 2016).  Specifically, R506 adopts an “in” position in the 
BRAFR509H/AZ628 structure, but adopts an “out” position in BRAFV600E/Vemurafenib 
(Vem) (3OG7, yellow) structures (Figure 33e). R506 lies close to W450, and the distinct 
W450 shift present in the one BRAFR509H/AZ628 protomer that shifts closer to the R506 
“out” conformation, further supporting the role of R506 in dimerization (Figure 33f).  
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Figure 33 BRAFR509H dimer interface via TAK632 binding. 
 (a) Overlay of BRAFWT/TAK632 (light pink and magenta), BRAFV600E/AZ628 (light grey 
and dark grey), BRAFR509H/AZ628 (blue and teal), and BRAFV600E/Vemurafenib (yellow) 
structures, highlighting the  shift within the aC-in position.  Different subunits of the crystal 
structures are denoted with subscript 1 and 2, respectively.  (b) Overlay of 
BRAFWT/TAK632 (light pink, PDB ID: 4KSP), BRAFV600E/AZ628 (grey, PDB ID: 4G9R), 
and BRAFR509H/AZ628 (blue, PDB ID: 4RZW) highlighting a shift in the W450 residue 
in the BRAFR509H structure.  (c). Crystal structure of BRAFR509H bound to AZ628 
demonstrates that W450 forms pi- stacking interactions with His509. (d) Residue D448 
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(continued from last page) accompanies the shift in the W450 residue, hydrogen bonding 
with the other static W450.   (e) R506 residues in both subunits of BRAFWT/TAK632 (light 
pink and magenta), BRAFV600E/AZ628 (light grey and dark grey), and BRAFR509H/AZ628 
(blue and teal) aligned with one subunit of BRAFV600E/Vemurafenib (yellow) 
demonstrating “in” and “out” positions of R506.  (f).  W450 lies within close proximity of 
R506, and the W450 in BRAFR509H/AZ628 shifts closer to R506.   
 
 To evaluate the effect of W450 and R506 on TAK-induced dimerization, we 
performed sedimentation velocity experiments with BRAFW450A, BRAFR506A, 
BRAFW450A/R509H, BRAFR506A/R509H, and BRAFR506A/W450A/R509H mutants alone and in the 
presence of TAK632 (Figure 34a-34b).  We found that TAK632 promotes the complete 
dimerization of BRAFR506A and BRAFW450A, but TAK632 with the double mutants of 
BRAFR509H/W450A and BRAFR506A/R509H showed a peak that is in between that of a monomer 
and a dimer.  The peaks also appear to be slightly broader than those of species that 
sediment as complete monomers or dimers.  We hypothesize that these mutants are able to 
disrupt TAK632-induced dimerization, however not completely, thus giving a mixed 
monomer/dimer peak.  The triple mutant BRAFR509H/R506A/W450A in the presence of TAK632 
sediments less broadly and more closely to that of a monomer peak, indicating that the 
combination of all three mutations disrupts TAK632 induced dimerization more than any 
of the individual mutations.  We confirmed these results with sedimentation equilibrium 
measurements (Figure 34c), where BRAFR509H/R506A gives an estimated ideal molecular 
weight of 58,000 kDa while BRAFR509H/W450A gives an estimated molecular weight of 
57,000 kDa.  BRAFR509H/R506A/W450A leads to the smallest molecular weight of the mutants, 
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47,000 kDa, indicating that while TAK632 binding does still induce dimerization slightly, 
the ability to do so is dramatically decreased due to mutation of the residues that mediate 
dimerization.  These mutants also all show gel filtration curves similar to that of the wild 
type protein, indicating that they are properly folded and not aggregated (not shown).  
While each of these mutants alone is not enough to prevent TAK632-induced dimerization, 
combining them causes conformational changes in the active dimer and combining all three 
prevents the majority of molecules in solution from forming dimers.  Taken together, these 
studies indicate that R509, W450 and R506 play important roles in facilitating the active 
αC-in/αC-in BRAF dimer as well as TAK632-induced dimerization.  The observation that 
TAK632 still efficiently promotes dimers of the single BRAFW450A, BRAFR506A, and 
BRAFR509H mutants but not the BRAFR509H/R506A/W450A mutant suggests that all three 
residues play a coordinated role in “side-to-side” αC-in/αC-in configuration dimerization, 
which is further reinforced by TAK632 binding.    
3.2.6 Type II αC-in and Type I αC-out inhibitors promote BRAF dimers and monomers, 
respectively 
 To assess whether other Type II αC-in inhibitors are able to induce BRAF 
dimerization in solution, we performed sedimentation velocity experiments with sorafenib, 
another well-known Type II, αC-in inhibitor (Karoulia et al., 2016; Wan et al., 2004). As 
shown in Figure 34d, sorafenib behaves similarly to TAK632, promoting dimerization 
despite the R509H mutation, further reinforcing the finding that Type II αC-in inhibitors 
function by stabilizing the active “side-to-side” αC-in/αC-in BRAF dimer configuration. 
To explore the effects of a Type I αC-out inhibitor, we used vemurafenib as a model αC-
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out inhibitor.  We found that BRAFWT monomers were stabilized and BRAFV600E dimers 
were disrupted upon addition of vemurafenib (Figure 34e).  Taken together, Type II αC-
in inhibitors appear to promote BRAF dimerization, while Type I αC-out inhibitors such 
as vemurafenib promote a disruption of the BRAF dimer.  TAK632 therefore relies on its 
ability to induce dimerization for effective inhibition, unlike αC-out inhibitors such as 
vemurafenib.  
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Figure 34 Sedimentation velocity experiments of dimerization mutants and αC-in/αC-
out inhibitors. 
 (a) Sedimentation velocity experiments of BRAFR509H, BRAFR506A, and BRAFW450A in the 
absence and presence of TAK632 at 15-25 µM. (b) Sedimentation velocity experiments of 
BRAFR509H, BRAFR506A/R509H, BRAFW450A/R509H and BRAFR506A/W450A/R509H in the absence 
and presence of TAK at 25 µM.  (c) Sedimentation velocity experiments of BRAFR509H 
without inhibitor and with 20 µM of both TAK632 and sorafenib. (d) Sedimentation 
velocity experiments of BRAFWT and BRAFV600E with 15 µM vemurafenib. 
 
 
 
  
 
93
3.3 Discussion  
 In this study, we demonstrate that TAK632 promotes inhibition of BRAF by 
inducing dimerization with an αC-in/αC-in configuration.  The mutational and analytical 
ultracentrifugation analyses further highlight the importance of R509, W450, R506, and 
likely also D448 in mediating this dimeric BRAF conformation.  The analysis that we 
present here with the other Type II αC-in inhibitors AZ628 and sorafenib suggests that 
these findings extend to the broader family of αC-in inhibitors. Coupled with the potent 
BRAF inhibitory activity and absence of paradoxical activation activity of such inhibitors, 
these findings support the conclusion that TAK632 and related inhibitors promote 
inhibition of BRAF through the induction of inhibited dimers. 
 While previous studies have highlighted the importance of R509 in stabilizing αC-
in/αC-in BRAF dimers, in this study we have extended the analysis of the molecular basis 
of stabilization of this dimeric BRAF configuration, concomitant with positioning the C-
helix in the αC-in configuration.  We demonstrate that W450, R506 and likely also D448 
play important roles in this activity. Other studies have also proposed the importance of 
R506 in mediating BRAF dimer formation, and we have demonstrated that it plays a similar 
role in inhibitor-induced dimerization as W450 (Karoulia et al., 2016).  
 In contrast to monovalent TAK632, the less potent bivalent TAK inhibitors appear 
unable to promote the αC-in/αC-in dimeric configuration.  This leads to BRAF monomers 
being the predominant species, while monovalent TAK632 is able to induce dimerization 
upon binding.  Comparison of the BRAF activities and multimerization states of BRAF 
complexes with bivalent TAK inhibitors and monovalent TAK632 inhibitors with attached 
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linkers reveals that the second TAK632 molecule of the bivalent TAK inhibitors plays a 
particularly important role in the reduced BRAF kinase activity and promotion of the 
monomeric BRAF state.  The control inhibitors TAK-L and TAK-L-C also demonstrate 
that linker placement does not affect active site binding, indicating a more complex 
mechanism.  Although our data imply that the reduced inhibitor activity of the bivalent 
TAK inhibitors is correlated with their inability to promote BRAF dimers, the molecular 
basis for how the second TAK632 ligand of the bivalent TAK inhibitor destabilizes the 
BRAF dimer configuration that is promoted by TAK632 is unclear.  Limited proteolysis 
and DSC experiments suggest that while bivalent TAK inhibitors can mediate a BRAF 
configuration that is similar to that of TAK632-bound BRAF, their affinities for these sites 
are notably decreased.  We propose that bivalent TAK inhibitors have significantly reduced 
affinities for BRAF because they are unable to assume stable dimeric BRAF 
configurations.   
 In previous studies, we demonstrated that bivalent vemurafenib inhibitors promote 
inactive BRAFV600E/BRAFV600E homodimeric conformations with both protomers 
containing αC-out conformations and with improved potency and selectivity for 
BRAFV600E in vitro relative to vemurafenib (Grasso et al., 2016).    Interestingly, we found 
that bivalent vemurafenib inhibitors were able to induce the same face-to-face αC-out/αC-
out BRAF dimeric configurations, independent of linker length.  This was not the case with 
bivalent TAK inhibitors in this study, in which we found that the bivalent TAK inhibitors 
cannot promote BRAF dimers, resulting in reduced potency relative to monovalent 
TAK632.  To understand the molecular basis for why bivalent TAK inhibitors are unable 
to induce the same dimer face-to-face αC-out/αC-out BRAF dimeric configuration 
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promoted by bivalent vemurafenib inhibitors, we overlayed individual BRAF molecules 
bound to TAK632 with the “face-to-face” conformation of BRAF bound to the bivalent 
Vem-BisAmide-2 inhibitor (Figure 35a).  Although this modeling exercise does not reveal 
any steric clashes between the BRAF molecules in the modeled TAK632-bound inactive 
dimeric configuration,  we observe different configurations of the Vem-BisAmide-2 and 
TAK632-bound BRAF proteins that could destabilize TAK632-bound BRAF dimers in 
this BRAF dimer configuration (Figure 35b).  
 
Figure 35 Superposition of BRAFV600E/Vem-BisAmide-2 with BRAFWT/TAK632. 
 (a) Overlay of BRAFWT co-crystallized with TAK632 (PDB ID: 4KSP) overlayed with the 
αC-out/αC-out “face-to-face” dimer induced by Vem-BisAmide-2 (PDB ID: 5JT2).   (b) 
Comparison of activation segment of BRAFV600E bound to Vem-BisAmide-2 in an active 
conformation (cyan) and the activation segment of BRAFWT bound to TAK632 in an 
inactive conformation (magenta), protruding into the other molecule of the “face-to-face” 
dimer. 
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Specifically, we note that while Vem-BisAmide-2 binding favors the activation segment 
to flip outwards into an active conformation (cyan), the activation segment of BRAF bound 
to TAK632 molecules favors an inactive, inward activation segment conformation 
(magenta).  While the activation segment is mostly unresolved in the BRAF/TAK632 
structure, this dynamic region could form steric clashes with the activation segment of 
another BRAF molecule, making the “face-to-face” dimeric conformation energetically 
unstable.  We therefore propose that it is not possible for bivalent TAK inhibitors to induce 
an inactive, “off-state” BRAF dimer configuration, and this is likely true with other αC-in 
inhibitors such as sorafenib and AZ628.  Instead, we hypothesize that pan-RAF inhibitors 
that favor the αC-out conformation will be more amenable to the preparation of bivalent 
inhibitors with improved BRAF potency and with the ability to counteract transactivation 
of RAFWT/RAFWT homodimers and RAFWT/BRAFV600E heterodimers in melanoma and 
other BRAF-associated cancers.  Interestingly, the pan-RAF inhibitors reported to date all 
appear to stabilize the active αC-in conformation.  We propose that a solution to this is to 
prepare bivalent BRAF inhibitors with highly potent BRAFV600E-specific αC-out 
promoting inhibitors that still retain appreciable affinity for BRAFWT.  Such inhibitors 
could be molecules such as Dabrafenib and BI 882370, which inhibit BRAFWT and 
CRAFWT with potencies similar to pan RAF inhibitors such as TAK632 (Waizenegger et 
al., 2016). Another possibility is a purinylpyridinylamino-based BRAF inhibitor that is 
BRAFV600E-specific, but binds two molecules of a BRAFWT side-to-side dimer with two 
αC-out configurations (Liu et al., 2016).  Taken together, these studies highlight the 
importance of understanding the impact of BRAF inhibitors on kinase dimerization to 
effectively target RAFWT/RAFWT homodimers and RAFWT/BRAFV600E heterodimers with 
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bivalent pan-RAF inhibitors to target paradoxical activation for more durable treatment of 
melanoma. 
3.4 Methods 
3.4.1. Plasmids  
Proteins used for analytical ultracentrifugation sedimentation velocity experiments. DNA 
encoding the BRAF kinase domain residues 448-723 containing 16 solubilizing mutations 
(I543A, I544S, I551K, Q562R, L588N, K630S, F667E, Y673S, A688R, L706S, Q709R, 
S713E, L716E, S720E, P722S, and K723G) was ordered from Epoch Biolabs and cloned 
into a Pet28a(+) vector encoding an N-terminal 6XHis Tag and a thrombin cleavage site 
between the protein and the tag.  This construct was used as a template to create His-tagged 
BRAFV600E, BRAFR509H, BRAFR506A, BRAFW450A, BRAFW450A/R509H, BRAFR506A,R509H, and 
BRAFR506A,R509H,W450A mutants (each harboring the 16 stabilizing mutations noted above).  
These proteins were used in analytical ultracentrifugation sedimentation velocity 
experiments.   
Proteins used for kinase inhibition assays. DNA encoding the BRAF kinase domain 
residues 442-724 was used as a template and cloned into a Pfastbac dual vector with mouse 
p50cdc37 full length as an expression chaperone for protein expression in baculovirus 
infected Sf9 insect cells.  An N-terminal 6X-His tag was inserted into the plasmid, and this 
plasmid was used as a template to create mutant BRAFV600E. Full length human MEK1 
with an N-terminal GST fusion tag and a C-terminal His tag in a pGex-3t vector was 
provided by Dr. Michael Olson (Beatson Institute for Cancer Research, Glasgow, UK) and 
was used as the substrate for the in vitro kinase assays.   
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3.4.2 Protein Purification 
Proteins used for analytical ultracentrifugation sedimentation velocity, limited proteolysis, 
and differential scanning calorimetry experiments. His-tagged BRAF proteins were 
produced as previously described (Grasso et al., 2016).  In brief, proteins were expressed 
in (DE3)RIL bacterial expression cells at 37 oC and induced with 1mM IPTG overnight at 
18 oC, spun down the next day, and lysed in lysis buffer (50mM potassium phosphate pH 
7.0, 250mM NaCl) with 1mM PMSF and DNaseI.  The lysate was spun down at 19000 
rpm for 20 minutes, and the supernatant was added to 7mL of TALON metal affinity resin 
(Takara) and left to incubate at 4 oC for 1 hr.  The supernatant was eluted via gravity 
column, and the resin was washed with 1 L of lysis buffer with 10 mM imidazole.  The 
BRAF proteins were eluted with lysis buffer supplemented with 250 mM Imidazole.  
Protein was dialyzed into dialysis buffer (50 mM potassium phosphate pH 7.0, 5 mM 
EDTA pH 7.5, 1mM DTT (Dithiothreitol)) overnight and then applied to a 5 mL SP 
Sepherose cation exchange column followed by washing in dialysis buffer and elution in 
50 mM potassium phosphate pH 7.0, 1 M NaCl, and 1 mM DTT.   Peak fractions were run 
on an SDS-PAGE gel, pooled, concentrated, and applied to a Superdex S200 gel filtration 
column in a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 5% Glycerol and 10 
mM DTT.  Protein was concentrated to 5-10 mg/mL, flash frozen in liquid nitrogen, and 
stored in -80 oC freezer for future use.  
Proteins used for kinase inhibition assays. BRAFWT and BRAFV600E were overproduced as 
N-terminally His-tagged proteins in insect cells essentially as previously described (Grasso 
et al., 2016). Briefly, protein constructs were co-expressed with p50cdc37, pelleted, 
suspended in lysis buffer 2 (25 mM Tris pH 8.0, 250 mM NaCl, 5 mM Imidazole and 10% 
  
 
99
glycerol) treated with Complete EDTA-free protease inhibitor cocktail tablets (Roche) and 
DNaseI, lysed, centrifuged at 19,000 rpm for 30 minutes, and added to TALON metal 
affinity resin and incubated for 1 hour at 4 oC.  The protein on the resin was washed 
extensively with 1 L of lysis buffer 2 and eluted with 25 mM Tris pH 7.5, 250 mM NaCl, 
250 mM imidazole, and 10% Glycerol.   The protein was diluted into a low salt buffer 
containing 25mM Tris pH 8.0, 1 mM EDTA and 1 mM DTT and run on an SP Sepharose 
cation exchange column, and eluted with a salt gradient from 50 mM NaCl to 1 M NaCl.   
Peak fractions were run on an SDS-PAGE gel and fractions containing protein were 
pooled, concentrated, and applied to a Superdex S200 gel filtration column and stored in a 
final buffer of 25 mM Tris pH 8.0, 300 mM NaCl, 1 mM DTT, and 10% glycerol.  Protein 
was concentrated to ~0.5 mg/mL and flash frozen in liquid nitrogen and stored for later use 
in a -80 oC freezer. 
 
GST-MEK1 fusion protein used as a substrate in ELISA assays was prepared essentially 
as described previously.19 Briefly, the protein was expressed in (DE3) RIL cells at 37 oC 
and induced with 0.5 mM IPTG at 15 oC overnight.  The cells were harvested and 
resuspended in lysis buffer 3 (20 mM HEPES at pH 7.0, 500 mM NaCl, 10 mM BME, 10 
mM imidazole and 5% glycerol) supplemented with 1mM PMSF and DNaseI.  The lysate 
was sonicated and spun down at 19,000 rpm for 30 minutes and the supernatant was added 
to Ni-NTA resin and incubated for 1 hr at 4 oC.  The resin was washed extensively with 
lysis buffer 3 with 20 mM Imidazole instead of 10 mM and eluted with lysis buffer 3 
supplemented with 250 mM imidazole.  Eluted protein was concentrated and loaded onto 
a Superdex S200 16/60 gel filtration column into a final buffer of 20 mM HEPES pH 7.0, 
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150 mM NaCl, 10 mM BME and 5% glycerol.  The protein eluted off the sizing column in 
two separate populations, and the second peak was collected, concentrated to ~20 mg/mL, 
and flash frozen in liquid nitrogen and stored in -80 oC freezer for future use.   
3.4.3. In Vitro Kinase Assay 
 Compound inhibition of BRAFWT and BRAFV600E were performed using an ELISA assay 
described previously (Grasso et al., 2016).  Briefly, GST-MEK fusion protein was diluted 
3:1000 in Tris-buffered saline (25 mM Tris pH 7.5, 140 mM NaCl) treated with 0.05% 
Tween-20 (TBST), and diluted MEK was added to each well of a glutathione coated 96-
well plate (Pierce #15240) and incubated at room temp for 1 hr with shaking.  BRAF was 
diluted from frozen stocks (1:500 dilution for BRAFWT and 1:1000 dilution for BRAFV600E) 
in 50 mM HEPES pH 7.0 and 50 mM NaCl.  2 µL of desired concentration of inhibitor 
was added to 100 µL of diluted BRAF in a 96 well “V” bottom plate (Corning #2897) and 
the inhibitor/protein mixture was incubated for 1 hr at room temp.  Glutathione plates were 
washed extensively with TBST and the protein-inhibitor mixture was added to the plate 
with a 100 µM final concentration of ATP in a buffer containing 50 mM HEPES pH 7.0, 
200 mM NaCl, and 20 mM MgCl2.  The plate was incubated at 37 oC for 30 minutes.  The 
reaction was washed from the plate and the plate was again washed with TBST.  A 1:8000 
dilution of primary antibody (p-MEK1/2 (S217/S221) rabbit antibody (cell signaling)) in 
TBST treated with 0.5% BSA was added to the plate and incubated for 1 hr with shaking.  
The plate was then treated with multiple TBST washes and then incubated with a 1:10,000 
dilution of secondary antibody (goat anti-rabbit IgG (H+L)-HRP (BioRad)) in TBST 
treated with 0.5% BSA for 1 hr with shaking.  The plate was washed extensively with 
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TBST and Supersignal ELISA Pico Chemiluminescent Substrate (Pierce #37069) was 
added.  The plate was read on a Promega GloMAX 96 Microplate Luminometer.  Each 
curve was repeated in duplicate or triplicate, normalized using GraphPad Prism by 
selecting the largest value as the maximum and the lowest value as the minimum, and used 
to calculate IC50 values by using a log (inhibitor) vs response fit on Prism 5.0 (GraphPad).  
Error bars are indicative of the SEM of each point, and 95% confidence intervals are listed 
in the figure legends as calculated by GraphPad Prism.   
3.4.4. Analytical Ultracentrifugation (AUC) 
  Sedimentation velocity AUC was performed with a Beckman Optima XL-I at 42,000 rpm.  
Data were obtained over a period of ~15 hours of centrifugation at 20 oC by monitoring 
absorbance.  Previously frozen stocks of BRAF and all corresponding mutations (R509H, 
V600E, R506A, W450A, R506A/R509H. R509H/W450A, and R506A/R509H/W450A) 
were thawed and diluted to ~10-20 µM depending on the experiment in AUC buffer (25 
mM Tris pH 7.5, 150 mM NaCl) and inhibitor was added to the desired final concentration 
by adding 20 µL of stock concentration of inhibitor in 100% DMSO to 430 µL of protein 
to give a final DMSO concentration of 4.44%.   Samples run without inhibitor had 20 µL 
of DMSO added to give the same 4.44% DMSO concentration as a control.  Data were 
analyzed using SEDFIT to calculate a continuous c(s) distribution with a frictional 
coefficient set to 1.20, and data were graphed using GraphPad Prism.    
 
Sedimentation Equilibrium AUC was performed with the same Beckman Optima XL-I at 
three speeds (9,000 rpm, 12,000 rpm, and 18,000 rpm) at three different concentrations (20 
  
 
102 
µM, 10 µM, and 5 µM) of BRAFR509H supplemented with a 2:1 molar ratio of inhibitor to 
protein at each concentration.  AUC buffer from sedimentation velocity experiments were 
used in sedimentation equilibrium experiments.  Data were analyzed using heteroanalysis 
to calculate an ideal fit molecular weight of the species, and log plots of the data were 
subsequently graphed using GraphPad Prism. Log plots were calculated using the 12,000 
rpm data of each set.  Ideal monomer and dimer fits were calculated using heteroanalysis.    
3.4.5. Limited Proteolysis.   
98 µL of 29 µM BRAFWT in LP Buffer (20 mM HEPES pH 7.0, 150 mM NaCl) were added 
to eppendorf tubes with 1 µL of 0.5 mg/mL trypsin (Sigma-Aldrich, T1426-50MG) and 2 
µL of either DMSO or inhibitor dissolved in 100% DMSO to give a final inhibitor 
concentration of 200 µM.  Inhibitors TAK632, TAK-4-TAK, TAK-L-C, and vemurafenib 
were tested, as well as a control in which no trypsin was added.   After 30 min. of protease 
treatment, 20 µL of the reaction mixture was removed and added to 5 µL of 5X SDS 
loading buffer, boiled and run on a 13.5% Acrylimide gel using SDS-PAGE, followed by 
staining using Coomassie blue.  
 3.4.6. Differential Scanning Calorimetry (DSC) 
  BRAFWT was diluted to a final concentration of 37 µM in DSC Buffer (20 mM HEPES 
pH 7.0, 150 mM NaCl).  50 µL of either DMSO or inhibitor dissolved in 100% DMSO 
was added to 450 µL of BRAFWT and degassed for 3 minutes.   The protein/inhibitor or 
protein/DMSO mixture was then added to a MicroCal VP-Capillary DSC (Malvern) and 
blanked with 450 µL of DSC Buffer and 50 µL of DMSO.   The protein (sample) and buffer 
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(blank) were both heated from 10 oC to 90 oC with a scan rate of 60 oC/hour and a filtering 
period of 10 seconds.  The difference in heat required to raise the temperature of the sample 
as compared to the blank is measured as a function of temperature.  The data was plotted 
using Origin 7.    
3.4.7. Small Molecule Inhibitors   
PLX4032 (Vemurafenib) was purchased from Santa Cruz Biotechnology (cat# sc-
364643).  Sorafenib was purchased from Santa Cruz Biotechnology (cat# sc-220125).  
TAK632 was purchased from BioVision Inc. (cat# 2473-5).   
 
3.4.8. General Chemistry Information  
Solvents used for extraction and purification were HPLC grade from Fisher. Unless 
otherwise indicated, all reactions were run under an inert atmosphere of argon. Anhydrous 
tetrahydrofuran, diethyl ether, and toluene were obtained via passage through an activated 
alumina column.  Merck pre-coated silica gel plates (250 mm, 60 F254) were used for 
analytical TLC.  Spots were visualized using 254 nm ultraviolet light, with either 
anisaldehyde or potassium permanganate stains as visualizing agents.  Chromatographic 
purifications were performed on Sorbent Technologies silica gel (particle size 32-63 
microns).  1H and 13C NMR spectra were recorded at 500 MHz and 125 MHz, or 360 MHz 
and 90 MHz, respectively, in CDCl3, DMSO-d6, or CD3OD on a Bruker AM-500, a DRX-
500, or a DMX-360 spectrometer. Chemical shifts are reported relative to internal 
chloroform (δ 7.26 for 1H, δ 77.0 for 13C), DMSO-d6 (δ 2.50 for 1H, δ 39.5 for 13C), 
or CD3OD (δ 3.31 for 1H, δ 49.0 for 13C). Infrared spectra were recorded on a NaCl plate 
using a Perkin-Elmer 1600 series Fourier transform spectrometer.  High resolution mass 
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spectra were obtained by Dr. Rakesh Kohli at the University of Pennsylvania Mass 
Spectrometry Service Center on an Autospec high resolution double-focusing electrospray 
ionization/chemical ionization spectrometer with either DEC 11/73 or OPUS software data 
system. All compounds were chromatographically homogeneous materials that were 
determined to be >95% pure by 1H and 13C NMR, and where necessary, HPLC. 
 
3.4.9. Synthesis of TAK-X-TAK dimers 
 To diacid 2-6 (Figure 1) (Wittmann, Takayama, Gong, Weitz-Schmidt, & Wong, 1998) 
(0.225 mmol), TAK aminobenzothiazole 1 (Figure ) (Okaniwa et al., 2013) (0.472 mmol), 
and DIPEA (1.3 mmol) in DMF (0.3 M) was added BEP (0.582 mmol). The reaction was 
then stirred at 25 °C for 18 h. The reaction was then quenched with brine and extracted 
with 9:1 ethyl acetate: THF. The combined organic fractions were then washed with brine, 
dried over Na2SO4, filtered and concentrated to afford a crude solid. The crude mixture 
was purified by silica gel column chromatography (MeOH/DCM) and then purified by 
preparative thin layer chromatography (MeOH/DCM) to afford TAK-X-TAK dimers as 
thin films. 
 
 TAK-0-TAK 
 Thin Film; Yield=15%; 1H NMR (500 MHz, Acetone-d6) δ 9.35 (s, 1H), 8.17 (s, 2H), 
7.99 (d, J = 9.0 Hz, 2H), 7.73 (s, 1H), 7.68 (d, J = 7.2 Hz, 2H), 7.63 – 7.52 (m, 3H), 7.31 
– 7.24 (m, 2H), 7.14 (d, J = 8.9, 1.6 Hz, 2H), 6.93 (dd, J = 9.1, 3.7 Hz, 2H), 4.70 (s, 3H), 
3.99 (s, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 170.03, 169.74, 157.46, 156.34, 151.64, 
151.21, 149.30, 149.28, 144.81, 142.46, 139.03, 137.30, 136.30, 133.87, 129.68, 129.64, 
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129.43, 129.19, 127.97, 127.87, 127.18, 126.28, 126.25, 126.22, 126.20, 125.68, 123.76, 
123.73, 123.52, 117.20, 117.11, 116.94, 115.65, 115.59, 114.71, 114.13, 95.83, 70.02, 
42.36 ppm; FT-IR (neat) : 1703, 1663, 1625, 1595, 1545 cm-1; HRMS (ESI) m / z calcd for 
C50H30F8N8O7S2 (M + Na)+  1093.1449; Found 1093.1472. 
 
TAK-2-TAK 
Thin Film; Yield = 6%; 1H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 7.93 (d, J = 9.0 
Hz, 1H), 7.83 (s, 0H), 7.67 (s, 1H), 7.59 (s, 3H), 7.57 – 7.49 (m, 1H), 7.41 – 7.30 (m, 1H), 
7.02 (d, J = 9.0 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 4.34 (s, 2H), 3.88 (s, 2H), 3.79 – 3.72 
(m, 3H), 3.69 – 3.62 (m, 3H) ppm; 13C NMR (126 MHz, DMSO) δ 170.35, 169.34, 
157.14, 155.72, 151.26, 151.24, 150.80, 148.87, 144.42, 136.92, 135.88, 133.48, 129.61, 
129.29, 129.26, 129.04, 128.79, 128.54, 127.57, 127.46, 126.60, 125.90, 125.87, 125.84, 
125.81, 125.30, 123.40, 123.37, 123.34, 123.31, 123.14, 120.97, 116.70, 116.62, 116.52, 
115.20, 115.14, 114.28, 113.75, 113.63, 95.31, 70.38, 69.85, 69.32, 41.97 ppm; FT-IR 
(neat) : 1675, 1596, 1544, 1485, 1460 cm-1; HRMS (ESI) m / z calcd for C54H38F8N8O9S2 
(M + Na)+  1181.1973; Found 1181.1975 
 
TAK-3-TAK 
 Thin Film; Yield = 8%; 1H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 10.18 (s, 1H), 
7.95 (dd, J = 9.1, 4.1 Hz, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.63 – 7.49 (m, 3H), 7.38 – 7.30 
(m, 1H), 7.04 (s, 1H), 6.98 – 6.90 (m, 1H), 4.32 (s, 2H), 3.86 (s, 2H), 3.72 – 3.65 (m, 2H), 
3.60 (s, 4H) ppm; 13C NMR (126 MHz, DMSO) δ 170.26, 169.38, 157.00, 155.83, 151.25, 
150.80, 148.87, 144.43, 136.93, 135.87, 133.52, 129.33, 129.30, 129.26, 129.05, 128.80, 
  
 
106 
128.55, 127.60, 127.49, 126.75, 126.66, 125.92, 125.83, 125.33, 123.38, 123.16, 116.73, 
116.66, 116.57, 115.24, 114.34, 113.80, 113.69, 95.35, 70.52, 69.75, 69.31, 41.98 ppm; 
FT-IR (neat) : 1690, 1596, 1537, 1458, 1431 cm-1; HRMS (ESI) m / z calcd for 
C56H42F8N8O10S2 (M + H)+  1203.2416; Found 1203.2382. 
 
TAK-4-TAK 
Thin Film; Yield = 10%; 1H NMR (500 MHz, Acetone-d6) δ 9.34 (s, 1H), 8.12 (dd, J = 
6.6, 3.1 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.60 – 
7.48 (m, 2H), 7.23 (dd, J = 10.7, 9.0 Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 6.90 (ddd, J = 9.0, 
3.9, 3.1 Hz, 1H), 4.32 (s, 2H), 3.96 (s, 2H), 3.87 – 3.80 (m, 4H), 3.79 – 3.70 (m, 4H) ppm; 
13C NMR (126 MHz, Acetone-d6) δ 171.48, 170.01, 158.00, 157.26, 152.84, 152.82, 
151.44, 149.52, 145.73, 137.75, 137.44, 134.37, 131.22, 130.97, 130.71, 130.46, 130.09, 
129.09, 128.99, 127.38, 127.10, 127.06, 127.03, 127.00, 124.47, 124.45, 124.41, 124.38, 
124.28, 117.50, 117.08, 116.90, 115.68, 115.62, 114.88, 114.02, 97.17, 72.52, 71.45, 
71.11, 70.96, 70.54, 43.56 ppm; FT-IR (neat) : 1684, 1625, 1592, 1538, 11487 cm-1; HRMS 
(ESI) m / z calcd for C58H46F8N8O11S2 (M + Na)+  1269.2497; Found 1269.2457. 
 
TAK-6-TAK 
 Thin Film; Yield = 7%;1H NMR (500 MHz, Chloroform-d) δ 10.67 (s, 1H), 8.11 (dd, J 
= 6.6, 3.1 Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.62 – 7.44 (m, 5H), 7.06 (t, J = 10.4, 8.9 Hz, 
1H), 6.94 (d, J = 9.0 Hz, 1H), 6.80 – 6.74 (m, 1H), 4.30 (s, 2H), 3.84 – 3.69 (m, 11H), 3.66 
– 3.57 (m, 5H) ppm; 13C NMR (126 MHz, CDCl3) δ 169.48, 168.09, 159.11, 156.87, 
156.62, 151.73, 149.96, 148.04, 144.53, 136.96, 134.64, 132.73, 131.33, 131.07, 129.41, 
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127.14, 127.05, 126.25, 126.09, 126.06, 124.85, 124.42, 124.40, 116.16, 115.71, 115.55, 
115.09, 114.03, 112.80, 96.53, 71.56, 70.68, 70.43, 70.39, 70.36, 70.15, 69.90, 43.98 ppm; 
FT-IR (neat) : 1693, 1595, 1537, 1485, 1456 cm-1;  HRMS (ESI) m / z calcd for 
C62H54F8N8O13S2 (M + H)+  1335.3202; Found 1335.3214. 
 
3.4.10. Synthesis of TAK-L 
 To a solution 2-(2-Methoxyethoxy)acetic acid 12 (Figure 5a; 57 μL, 0.504 mmol), TAK 
benzotriazole 1 (Okaniwa et al., 2013) (Figure 5a; 0.232 mg, 0.458 mmol), and  DIPEA 
(0.498 ml, 2.8 mmol) in DMF (1.5 mL) was added BEP (0.169 g, 0.620 mmol). The 
reaction was then stirred at 25 °C for 24 h. The reaction was then quenched with brine and 
extracted with 9:1 ethyl acetate: THF. The combined organic fractions were then washed 
with brine, dried over Na2SO4, filtered and concentrated to afford a crude foam. The crude 
product was purified by silica gel column chromatography (5% MeOH/DCM) and then 
purified by preparative thin layer chromatography (4% MeOH/DCM) to afford TAK-L 13 
(Figure 5a) as a white foam.  
Yield = 0.128 g (44% yield); 1H NMR (500 MHz, Chloroform-d) δ 10.91 (s, 1H), 8.15 
(dd, J = 6.4, 3.1 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.62 – 7.48 (m, 4H), 7.48 – 7.41 (m, 
1H), 7.08 (t, J = 10.5, 8.9 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 6.79 (ddd, J = 8.9, 4.1, 2.9 Hz, 
1H), 4.30 (s, 2H), 3.87 – 3.77 (m, 4H), 3.69 – 3.62 (m, 2H), 3.57 (s, 3H) ppm; 13C NMR 
(126 MHz, CDCl3) δ 170.31, 168.88, 168.81, 156.95, 156.41, 151.84, 150.45, 148.53, 
144.90, 136.73, 136.50, 133.28, 130.24, 129.99, 129.73, 129.48, 129.04, 128.15, 128.05, 
127.96, 127.56, 126.52, 126.00, 125.96, 123.40, 123.36, 116.62, 116.02, 115.85, 114.59, 
114.53, 113.83, 113.06, 96.25, 71.46, 71.18, 69.58, 57.95, 42.56 ppm; FT-IR (neat) : 1686, 
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1533, 1486, 1458, 1429 cm-1; HRMS (ESI) m / z calcd for C28H22N4O5F4S (M + Na)+  
625.1145; Found 625.144. 
3.4.11. Synthesis of TAK-L-C 14: 2-(2-(2-(2-oxo-2-(thiazol-2-
ylamino)ethoxy)ethoxy)ethoxy)acetic acid.   
To 3,6,9-Trioxaundecandioic acid 3 (2.5 g, 11.25 mmol) in DCM (50 mL) was added DCC 
(2.32 g, 11.25 mmol). The reaction was then stirred at 25 °C for 18 h. The resulting 
suspension was then filtered and rinsed with chilled DCM. The filtrate was concentrated 
to afford the crude anhydride, which was taken directly on to the next step. The anhydride 
was dissolved with dry THF and was then treated with 2-aminothiazole (1.12 g, 11.25 
mmol). The reaction was stirred for 3 hrs at 25°C and volatiles then removed by 
evaporation under reduced pressure. The resulting solid was then suspended in Et2O and 
filtered. The solid was then rinsed with chilled Et2O. The crude solid was then purified by 
silica gel column chromatography (2-10% MeOH/DCM) to give 2-(2-(2-(2-oxo-2-(thiazol-
2-ylamino)ethoxy)ethoxy)ethoxy)acetic acid. 
Pale yellow solid; Yield = 1.57 g (46% yield); 1H NMR (500 MHz, Methanol-d4) δ 7.46 
(d, J = 3.7 Hz, 1H), 7.14 (d, J = 3.7 Hz, 1H), 4.29 (s, 2H), 4.11 (d, J = 3.4 Hz, 2H), 3.81 – 
3.71 (m, 8H).; 13C NMR (126 MHz, DMSO) δ 171.68, 168.50, 157.37, 137.65, 113.68, 
70.49, 69.81, 69.75, 69.60, 69.24, 67.59, 40.02, 39.86, 39.69, 39.52, 39.35, 39.19, 39.02.; 
IR (neat) : 3200, 1719, 1689, 1495, 1063 cm-1;  HRMS (ESI) m / z calcd for 
C48H41N6O8F4S2 (M + H)+  305.0822; Found 305.0807. 
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3.4.12 Synthesis of TAK-L-C.  
 To a solution of 2-(2-(2-(2-oxo-2-(thiazol-2-ylamino)ethoxy)ethoxy)ethoxy)acetic acid 
(0.159 mg, 0.524 mmol), TAK aminobenzothiazole2 (0.085 mg, 0.174 mmol) and TEA 
(0.243 ml, 1.74 mmol) in DMF (0.587 mL) was added T3P (0.333 mL, 0.524 mmol) in 
DMF (1:1; v/v) dropwise. The reaction was then stirred at 25 °C for 18 h. The reaction was 
then quenched with brine and extracted with 9:1 ethyl acetate: THF. The combined organic 
fractions were then washed with brine, dried over Na2SO4, filtered and concentrated to 
afford a crude solid. The crude product was then purified by preparative thin layer 
chromatography (3% MeOH/chloroform) to afford TAK-control-2 as a thin film.  
Thin Film; Yield = 0.135g (55% yield); 1H NMR (500 MHz, Chloroform-d) δ 10.55 (s, 
1H), 10.35 (s, 1H), 8.11 (dd, J = 6.5, 3.1 Hz, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.62 (d, J = 3.4 
Hz, 1H), 7.60 – 7.45 (m, 4H), 7.37 (d, J = 3.7 Hz, 1H), 7.06 (t, J = 9.7 Hz, 1H), 6.95 – 6.86 
(m, 2H), 6.76 (dt, J = 8.9, 3.5 Hz, 1H), 4.31 (s, 2H), 4.24 (s, 2H), 4.06 – 3.99 (m, 4H), 3.85 
(dt, J = 4.2, 2.3 Hz, 4H), 3.80 (s, 2H) ppm; 13C NMR (126 MHz, CDCl3) δ 169.38, 168.05, 
157.07, 156.82, 156.63, 151.76, 149.96, 148.04, 144.29, 137.57, 137.38, 136.91, 136.46, 
134.69, 132.74, 131.31, 131.05, 130.80, 129.39, 127.16, 127.07, 126.11, 126.09, 126.06, 
126.03, 124.87, 124.41, 124.38, 122.71, 116.19, 115.68, 115.51, 115.09, 115.02, 114.03, 
113.76, 112.88, 96.47, 71.41, 71.33, 70.42, 69.77, 69.74, 43.97 ppm; FT-IR (neat) : 1692, 
1595, 1533, 1484, 1455 cm-1; HRMS (ESI) m / z calcd for C34H28N6O7F4S2 (M + H)+  
773.1475; Found 773.1464. 
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Chapter 4- A High-Throughput Approach to Identifying Novel 
Small Molecule Inhibitors that Target BRAF/MEK 
Heterodimerization 
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throughput screening. Adam Olia purified NF-κB. 
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4.1 Introduction  
 Finding BRAF inhibitors that can help bypass inhibitor resistance is crucial in the 
field of drug discovery due to the strong correlation of BRAF mutation in melanoma, as 
well as a variety of other cancers (Davies et al., 2002; Wellbrock et al., 2004).   Exploring 
novel methods to inhibit the MAPK pathway to circumvent this resistance can offer insight 
into the underlying mechanisms behind transactivation, as well as lead to unique 
approaches in the field.  While many kinase inhibitors exist that target the MAPK signaling 
pathway, most are Type I and II inhibitors, i.e. ATP-competitive inhibitors (Müller et al., 
2015).   There are some Type III kinase inhibitors that target an allosteric pocket 
somewhere on the enzyme, such as MEK inhibitor Trametinib, but Type I and II inhibitors 
are more common (Müller et al., 2015; Salama & Kim, 2013).  Interestingly, MEK 
mutations have been documented in inhibitor resistant melanoma cell lines (Villanueva et 
al., 2013), and combination therapies of MEK and BRAF inhibitors have shown promise 
in the clinic (Flaherty et al., 2012; Greger et al., 2012; Johnson et al., 2014), although 
inhibitor resistance still ensues.   
 Type IV kinase inhibitors that bind the surface of a protein to block interactions 
with another protein or molecule have emerged as possible therapeutic targets in the MAPK 
signaling pathway. The small molecule Rigosertib has been discovered to bind to Ras 
Binding Domains (RBDs) of the RAF kinases, disrupting RAS-RAF interactions and, in 
turn, inhibiting the activation of ERK (Athuluri-Divakar et al., 2016).  Another study has 
developed bivalent ERK inhibitors that utilize an ATP-competitive ERK inhibitor 
chemically linked to a surface binding inhibitor that blocks the “DRS” site on ERK, which 
is known to recognize and bind numerous ERK partners (Lechtenberg et al., 2017).  This 
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emerging technique is also gaining more traction in other kinase systems, and the potential 
for more Type IV inhibitors within the MAPK signaling pathway could introduce a potent 
and selective mechanism for bypassing BRAF inhibitor resistance.   
 In 2014, the crystal structure of the BRAF/MEK complex was determined, and 
interestingly, the complex was found to have a dissociation constant (KD) of ~43 nM, 
indicating a very strong interaction (Haling et al., 2014).  We hypothesized that targeting 
BRAF-MEK dimerization would represent a potentially powerful strategy for MAPK 
pathway inhibition. Such molecules would also be useful probes for studying the MAPK 
signaling pathway and inhibitor resistance.  Here, we report the development and 
optimization of a high throughput screen of more than 44,000 small molecules to discover 
novel inhibitors that disrupt the protein-protein interaction between BRAF and MEK.  We 
identified 15 small molecules which inhibit BRAF-MEK dimerization and kinase activity 
in the low µM IC50 range.      
 
4.2 Results  
4.2.1 Mutations in the solubilized E. Coli construct of BRAF allows for restoration of 
MEK complex formation and kinase activity in vitro. 
The crystal structure of the MEK/RAF complex demonstrates that BRAF forms its 
canonical dimer with itself, and each BRAF molecule binds MEK, forming a 
heterotetramer (Figure 36a).  The RAF and MEK  kinases also sit in a face to face 
conformation, with their active sites and inhibitor pockets facing one another (Haling et 
al., 2014).  The tight interaction between the two kinases makes it a good target for small 
molecule screening, as relatively low concentrations would be able to produce a signal 
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indicating dimerization.   Their face-to-face conformation also makes this a good target, as 
the chemical linking of vemurafenib to a small molecule inhibitor that binds to either the 
surface of BRAF or MEK would be feasible to add selectivity to this class of inhibitors.   
Before developing and optimizing a screen, we aimed to recapitulate complex formation 
using the E. Coli construct of the kinase domain of BRAF, as yield, purity, and accessibility 
make E. Coli purification much more applicable for high throughput screening quantities 
rather than SF9 protein expression, which was used in the crystal structure (Haling et al., 
2014; Tsai et al., 2008a).  The E. Coli construct of the BRAF kinase domain contains 16 
point mutations on the surface of BRAF to allow for expression and solubility in E. Coli.  
Interestingly, this construct is not active, despite no mutations to key catalytic residues, 
and is still able to bind ATP (and inhibitors) (Tsai et al., 2008).  None of the point mutations 
appear to be key contact residues listed in the literature. However, an alignment of the 
MEK/RAF complex and the E. Coli construct shows that one of the mutations, F667E, 
interrupts a key hydrophobic interaction between the BRA and MEK proteins that could 
lead to a charge-charge repulsion with D315 of MEK (Figure 36b).  Indeed, leaving F667E 
in the E. Coli construct ablates complex formation between BRAF and MEK, whereas an 
E667F mutation in this construct allows BRAF-MEK complex formation to occur (Figure 
37a and b).  This key residue also restored activity in the E. Coli construct, indicating that 
tight complex formation is necessary for BRAF’s activity to phosphorylate MEK in vitro 
(Figure 37c).   
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Figure 36 BRAF and MEK complexation in vitro. 
(a) Crystal structure of BRAF (salmon) bound to MEK (blue), forming a heterotetrameric 
complex.  (b) Overlay of the complex with the wildtype kinase domain of BRAF (salmon) 
and the e. coli expressed construct of BRAF harboring 16 point mutations (grey) shows 
F667E can disrupt a key hydrophobic patch that stabilizes the complex.  
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Figure 37 E667F mutation restores complexation and activity. 
(a) SDS-PAGE gel of BRAFV600E/16mut_E667F complexed with MEK45-393 (∆264-307,replaced with 
SVQSDI linker)   (b) Overlay of BRAFV600E/16mut_E667F alone (black), MEK45-393 (∆264-307,replaced with 
SVQSDI linker) alone (pink), and the complex (blue) on size exclusion chromatography, 
showing the two proteins co-elute when mixed together.  (c) While BRAFV600E_16mut has 
little kinase activity in vitro, mutating back to F667 restores kinase activity.  
 
 4.2.2. Development and optimization of a Time-Resolved Fluorescence Resonance Energy 
Transfer (TR-FRET) assay to identify small molecules disrupting a BRAF/MEK complex.   
  
 
116 
The High Throughput Screen (HTS) to identify novel small molecules disrupting the 
interaction between BRAF and MEK was designed as a Time-Resolved Fluorescence 
Resonance Energy Transfer (TR-FRET) assay.  In this assay, both BRAF and MEK are 
expressed and purified with different affinity tags, in this case a 6X-Histidine tag for MEK 
and a FLAG-tag for BRAF (Hopp & Prickett, 1988).  The MEK construct used was an N-
terminally truncated version, encoding residues 63-393 (Ohren et al., 2004) and BRAF was 
the E. Coli mutated Kinase domain (residues 448-723) with mutation E667 mutated back 
to phenylalanine (E667F) (Tsai et al., 2008a).  The assay was designed using Perkin 
Elmer’s LANCE® TR-FRET assay (Ma, Deacon, & Horiuchi, 2008), in which a LANCE®  
Europium Chelate donor conjugated to an antibody or substrate is paired with an acceptor 
fluorophore such as a ULightTM Dye, also conjugated to an antibody or substrate, and when 
in close proximity, the donor and acceptor can generate a fluorescent signal.   In this assay, 
we used Anti-His conjugated Europium (Eu) chelate (Cat # AD0110) to bind the His tagged 
MEK kinase, and ULightTM Dye conjugated with an Anti-FLAG antibody (Cat # 
TRF0059M) (Figure 38a).  The assay allows for a fluorescent transfer when excited with 
320nm light, and elicits a 665nm emission when the Eu chelate is within 10nm of the 
acceptor.  When screening for small molecules, a loss in signal at 665nm indicates an 
ablation of interaction between MEK and BRAF proteins.  While the readout of the 
fluorescence transfer occurs at 665nm, we use the emission at 620nm (fluorescence of Eu 
fluorophore alone) as a loading control to ensure the signal is due to the FRET signal and 
not an issue with Eu concentration, controlling for possible loading errors.   To further 
elucidate if any hits were false positives due to non-specific interactions between the 
antibodies and the proteins, or signal quenching, a counter-screen was developed in which 
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BRAFE667F with a FLAG-tag and a 6XHis-tag only was used (Figure 38b), as any 
compounds that hit in this screen as well as the primary screen would likely be disrupting 
the assay components, rather than the RAF-MEK interaction.  
 
Figure 38 TR-FRET assay diagrams. 
 (a) primary assay screening for small molecules by disrupting FRET signal between MEK 
and BRAF bound to acceptor and donor conjugated antibodies (b) Counter-screen with 
dual-tagged BRAF to determine false positives.   
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 To optimize screening conditions, we initially did a titration of both proteins to find 
optimal protein concentrations resulting in the highest signal.  The assay is dependent on 
the “hooking effect,” where saturating the acceptor and donor fluorophores past their 
binding capacities results in a decrease, or “hooking” of the signal, as protein unbound to 
fluorophore can begin to compete off bound protein.  Our initial “hooking” experiment 
varied each protein from 30nM to 240nM (Figure 39a), and concentrations past 60nM of 
either protein decreased the signal appreciably, leading us to hypothesize the binding 
capacity is at or close to 60nM.  We then chose to screen at 50nM and moved forward with 
screen optimization. 
 As no positive control small molecule inhibitors exist that completely ablate 
BRAF/MEK dimerization, we chose to use untagged BRAF16mut_E667F to compete off the 
signal.  As a negative control to show selectivity, we used untagged BRAF16mut_E667 to 
ensure signal (and loss of signal) is solely from BRAF/MEK dimerization.  We performed 
a 50/50 plate experiment in which we added both proteins mixed with donor and acceptor 
fluorophore to a 384-well plate, and then added BRAF16mut_E667F to one half of the plate and 
BRAF16mut_E667 to the other half to a final concentration of 2 µM for both in order to test 
our signal window (Figure 39b).  The average signal of the negative control (BRAF16mut) 
is 565.7, while our positive control (BRAF16mut_E667F) is 263.7.  Despite the signal to noise 
ratio being just over 2, the screening window was ideal in regard to the Z factor (Z’).  Z’ is 
a statistical tool to measure effect size and can be used to assess how useful the assay will 
be in determining hits from the data.  By using both the standard deviations and means of 
both the positive and negative controls, Z’ can assess if the difference between the positive 
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and negative controls is statistically significant (J. Zhang, Chung, & Oldenburg, 1999).  A 
Z’ larger than 0.5 is considered an excellent assay for high throughput screening, and the 
50/50 plate experiment gave us a Z’ of 0.671 (n=192), indicating an ideal range for 
screening.  We next established a window for the counter-screen.  For a positive control, 
we used 6X-His tagged protein NF-κB-p65 subunit as this protein does not interact with 
BRAF and will be able to compete off the signal by binding the 6X-His Eu fluorophore.   
At a concentration of 30 µM, this protein was able to decrease the signal from 936.2 to 
277, giving us a large window and a Z’ of 0.841 (n=24) (Figure 39c). 
 Before moving to a larger screen, we performed a pilot screen using the Natural 
Product Collection from MicroSource, which contains 800 purified natural product 
compounds dissolved in DMSO.  We screened at 25 µM final concentration of compounds.  
The screen consisted of three 384-well plates, with rows 1 and 23 representing a negative 
control (2 µM BRAF16mut) and rows 2 and 24 representing a positive control (2 µM 
BRAFE667F).  The third plate was set up the same way, but half of the plate contained 
DMSO only, yielding 1152 wells but only 800 compounds screened (Figure 39d).  We 
performed the pilot screen in full against both the primary screen and the counter-screen to 
rule out any false positives.  Due to the counter-screen being able to rule out many false 
hits, our hit rate was 0.75%.  We classified a “hit” as a compound that was able to have a 
normalized percent inhibition (NPI) above 25% in the primary screen but did not surpass 
5% NPI in the counter-screen.  Table 2 lists the hits and their NPI values for both screens.  
We next verified these hits through reproducing the assay and validation with secondary 
assays.      
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Figure 39 Optimization of high-throughput screen. 
(a) Hooking Effect assay titrating different amounts of FLAG-BRAF16mut_E667F and 6XHis-
MEK63-393 to determine ideal screening concentration.   (b) 50/50 plate experiment 
demonstrating that signal can be selectively competed off with untagged 
BRAFV600E/16mut_E667F but not untagged BRAFV600E and that the screening window is ideal 
for a high throughput format.  (c) Test demonstrating counter-screen of FLAG-6XHis-
BRAF16mut can be competed off with 6XHis-NF-κB and also gives a good screening 
window.  (d) Overlay of Natural Product (MicroSource) Pilot Screen for both primary and 
counter-screen. 
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Natural 
Product Pilot 
Screen 
Primary 
screen 
Counter 
screen 
Compound Name NPI (%) NPI (%) 
Plumbagin 56.6 3.71 
Eseroline fumarate 45.9 4.78 
4-methoxy-4-hydroxy-
dalbergione 
38.3 2.09 
Erythromycin 38.2 4.37 
4,4-dimethoxydalbergione 37.6 1.77 
Thymoquinone 31.1 -0.540 
Menadione 26.9 3.80 
 
Table 2-Natural Product pilot screen results 
A list of the small molecule compounds that hit against the primary screen with a 
normalized percent inhibition (NPI) at 25% or above and did not hit in the counter screen 
(NPI at 5% or below).   
 
4.2.3 Plumbagin and thymoquinone can selectively disrupt a BRAF/MEK complex 
 Of the 7 hits from the pilot screen, four (plumbagin, eseroline fumarate, 
erythromycin, and thymoquinone) were commercially available.  We repeated the TR-
FRET assay, testing all four inhibitors purchased commercially against both the primary 
and counter screens in quadruplicate to test reproducibility (Figure 40a).  Both plumbagin 
and thymoquinone were able to effectively inhibit at 25 µM (58.13% and 62.53% 
inhibition, respectively) and at 50 µM (69.27% and 63.81% inhibition, respectively), 
indicating reproducible inhibition.   Erythromycin and eseroline fumarate inhibited 
dimerization marginally in comparison at 50 µM (15.07% in the primary screen and 8.65% 
in the counter screen for erythromycin and 22.03% in the primary screen and 11.08% in 
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the counter screen for eseroline fumarate), indicating these hits are either false positives or 
not as potent.   
 To further confirm these hits, we tested all four inhibitors in our ELISA-based 
kinase assay, as we have elucidated that BRAF dimerization with MEK is necessary for 
BRAF phosphorylation of MEK (Figure 40b).  In corroboration with our TR-FRET assay, 
both plumbagin and thymoquine inhibited BRAF activity in the low µM range (1.94 µM 
and 2.52 µM, respectively).  While eseroline fumarate did decrease the overall kinase 
activity of BRAF, it was not able to fully decrease activity even at the highest concentration 
of inhibitor (150 µM).  Erythromycin did not decrease activity at all, indicating that this 
inhibitor was a false positive.  Interestingly, plumbagin and thymoquinone have similar 
structures (Figure 40c), with thymoquinone being a 1,4-benzoquinone and plumbagin 
being a 1,4-napthoquinone.   
To further elucidate how these compounds can disrupt the RAF/MEK complex, we 
performed thermal stability assays (Differential Scanning Fluorimetry or DSF) in which 
we heat the protein in the presence of fluorescent dye spyro orange, which binds 
hydrophobic residues and gives off a fluorescent signal as the protein unfolds (R. Zhang & 
Monsma, 2010).  We hypothesized that compound binding would increase the thermal 
stability of the protein to which it binds.  We performed these experiments with both 
BRAFV600E/16mut_E667F and MEK63-393 in the absence and presence of plumbagin at different 
concentrations to determine if it can stabilize either protein (Figure 41a-41b).  
Interestingly, the melting temperature of BRAF shifts from ~33 oC to ~44 oC in the 
presence of 100-300 µM of plumbagin.  MEK, meanwhile, stays at ~43 oC despite the 
addition of 100-300 µM plumbagin, indicating that plumbagin is interacting with BRAF.   
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Figure 40 Confirmation of hits. 
(a) TR-FRET experiments testing 4 hit compounds purchased commercially at 25 µM and 
50 µM concentrations.  (b) ELISA-based kinase assay testing 4 hit compounds against 
BRAF’s ability to phosphorylate MEK. The experiments were performed in duplicate with 
+/- SEM shown.  95% confidence intervals are:  Plumbagin (1.26 µM  to 2.98 µM), and 
Thymoquinone (1.34 µM  to 4.74 µM). (c) Chemical structures of plumbagin (left) and 
thymoquinone (right), indicating both have similar chemical structures.    
 
 
To further validate the DSF results, we performed Differential Scanning 
Calorimetry (DSC) experiments (Figure 41c).  While BRAF16mut without any inhibitor 
added has a melting temperature of 38.06 oC, adding 50-75 µM of plumbagin results in the 
addition of a second peak at ~49 oC, indicating plumbagin is able to bind and stabilize 
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BRAF.  100 µM of plumbagin is able to shift the majority of BRAF to the second, 49 oC 
peak, but addition of higher concentrations of plumbagin (300-400 µM) distorts the peak 
with negative Cp values, indicating aggregation of the sample.  While the addition of 
thymoquinone to BRAF16mut shifted the melting temperature from ~38 oC to ~42 oC 
(Figure 41d), the amplitude of the peak was severely diminished with the addition of small 
molecule, indicating that the molecule is crashing the protein out of solution.  Because of 
the tendencies to aggregate protein, we did not pursue these inhibitors further, although 
plumbagin may warrant further investigation. 
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Figure 41 Confirmation of hits using DSF and DSC. 
 (a) DSF assay of BRAFV600E/16mut_E667F in the presence and absence of plumbagin at 
concentrations ranging from 100-300 µM.  (b) DSF assay of MEK63-393 in the presence and 
absence of plumbagin at concentrations ranging from 100-300 µM.   (c) DSC assay of 
BRAFWT in the presence and absence of plumbagin at concentrations ranging from 50-400 
µM.  (d) DSC assay of BRAF16mut in the presence and absence of thymoquinone at 
concentrations ranging from 50-400 µM.   
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4.2.4 ChemDiv and ChemBridge 136 plate screen set up and analysis   
 With the success of the pilot screen, we decided to move forward with two larger 
screens:  12,000 compounds from ChemDiv’s SMART library, and 32,000 compounds 
from ChemBridge, 20,000 from their CORE set and 12,000 from their ExpressPick set.   In 
order to ensure similar results throughout the entire screen, we expressed and purified 
enough FLAG-BRAF16mut_E667F and 6XHis-MEK63-393 to be used for all 136 plates.  Due to 
the large nature of the screen, we decided to cut down on donor and acceptor fluorophore 
concentrations (from 20 nM donor and 5 nM acceptor to 10 nM donor and 2.5 nM acceptor) 
for cost efficiency.  Figure 42 illustrates that despite the concentration being halved, the 
signal was still robust, and the signal window and Z’ was still ideal for high throughput 
screening techniques.  We altered the positive control from untagged BRAFV600E/16mut_E667F 
to 100 µM plumbagin, as the small molecule was easier to obtain in large quantities than 
recombinant protein, and we showed that it is a selective inhibitor in the TR-FRET assay 
environment.        
 We performed both the ChemBridge and ChemDiv library screens within the span 
of two weeks, performing 20 plates a day within that time span.  Figures 43a and 43b 
show the results of both libraries.  Using an NPI of 25% as our cutoff, the two screens gave 
a total of 148 hits.  ChemDiv gave a total of 70 hits, and a hit rate of 0.625%.  ChemBridge 
gave a total of 78 hits and a hit rate of 0.241%.  As noted in the results, a number of small 
molecules also “activated” dimerization, indicated by a stronger fluorescent signal and, in 
turn, a negative NPI.  However, this could have been due to interference with the FRET 
signal.  We sorted the 148 hits into “chemotypes” and selected one or two molecules from 
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each group with the best NPI out of the group, giving us a total of 49 compounds, 22 from 
ChemDiv and 27 from ChemBridge for futher testing.           
  
 
Figure 42 Fluorophore concentrations halved. 
Halving the working concentrations of the donor and acceptor fluorophores in the screen, 
as well as using 100 µM plumbagin as a positive control, results in a Z’ value suitable for 
high throughput screening (0.901).   
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Figure 43 44,000 compound screen results. 
 (from previous page) (a) ChemDiv screen results, giving 70 hits with a cutoff of 25% 
NPI.  (b) ChemBridge screen results, giving 78 hits with a cutoff of 25% NPI.   
 
We ordered new stocks of each of the 49 compounds and prepared an automated 
dose response assay of each compound ranging from 46 nM to 100 µM against both the 
primary screen and the counter screen.  Some compounds were not commercially available, 
and others did not fully dissolve in DMSO, taking the full list of testable compounds to 41.  
In performing the dose response assays, we looked for compounds that were able to hit the 
primary screen and not the counter screen.  Table 3 lists the results, including which 
compounds were not commercially available and which were not soluble in DMSO.  Table 
4 lists the IUPAC names of the compounds in Table 3, in the same order.  The total list of 
compounds that were able to be selective against the primary screen were 15, which are 
listed in Table 5.  It should be noted that CD10 did hit the counter screen, but its IC50 was 
appreciably lower in the counter screen than in the primary screen.  In selecting compounds 
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to move forward, we aimed for compounds that hit the primary screen with a max signal 
close to the positive control of plumbagin (listed as “max” and is the normalized max 
inhibition shown).  We also avoided compounds with high Hill slopes, as this is indicative 
of a compound that can aggregate the protein in question (Feng et al., 2007).  This left us 
with 8 compounds, and we next decided to repeat the dose response assay by hand with 
these compounds, increasing the concentration range of inhibitors to 300 µM to 586 nM to 
obtain a more accurate representation of IC50 values and Hill slopes (Figure 44).  All 8 
compounds hit the primary screen with IC50 values ranging from 2 µM to 34 µM.  All of 
the compounds were also shown to be ineffective in the counter screen up to a 
concentration of 300 µM, except for CD10, which was able to inhibit BRAF with an IC50 
of 205 µM.  
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Supplier ID Initial NPI Available Soluble Primary Counter Name Chemotype 
ChemBridge 7532833 82.83773 Yes Yes Yes No CB1 thiophene
ChemBridge 95877291 41.78127 Yes Yes No No CB25 pyrazole
ChemBridge 38667363 30.79267 Yes Yes Yes Yes CB24 imidazole
ChemDiv K029-0062 76.5445 No N/A N/A N/A N/A imidazole
ChemBridge 9018218 47.59549 Yes Yes Yes Yes CB10 1,2,4-triazole
ChemBridge 9283140 72.48091 Yes Yes No No CB21 1,2,3-triazole
ChemBridge 9153534 47.21289 Yes Yes Yes No CB20 1,2,3-triazole
ChemDiv M564-0134 49.60175 Yes Yes No No CD16 1,2-oxazole
ChemDiv C201-1987 51.57056 Yes Yes Yes No CD8 1,2,4-oxadiazole
ChemBridge 9017718 90.30982 Yes mostly Yes No CB9 1,3,4-thiadiazole
ChemDiv K783-6707 81.66144 Yes Yes Yes No CD14 1,3,4-thiadiazole
ChemBridge 7903556 88.90437 Yes Yes Yes No CB3 thioamide
ChemBridge 7916412 92.09573 Yes Yes Yes No CB4 thioamide
ChemDiv 0655-0099 59.22873 Yes Yes Yes No CD1 cyclic thioamide
ChemDiv C201-1499 63.53421 Yes Yes Yes No CD7 cyclic thioamide
ChemDiv C301-7412 62.83147 Yes Yes No No CD9 urea
ChemDiv M509-0433 26.07941 Yes Yes Yes Yes CD15 urea
ChemDiv 8018-1737 66.5581 Yes Yes No No CD4 thiourea
ChemDiv K783-5213 46.57137 Yes Yes Yes No CD13 thiourea
ChemDiv D284-0238 93.24313 Yes Yes Yes No CD11 cyclic thiourea
ChemDiv K241-0225 43.87642 Yes Yes No No CD12 cyclic thiourea
ChemDiv 1494-0327 31.23913 Yes Yes No No CD3 cyclic thiourea
ChemDiv 8014-2247 89.27625 No N/A N/A N/A N/A cyclic thiourea
ChemDiv 8019-0869 45.41068 Yes Yes No No CD5 cyclic thiourea
ChemDiv C200-3441 76.31184 No N/A N/A N/A N/A 1,4,8-triazaspiro[4.5]dec-3-ene-2-thione
ChemDiv C200-3443 83.35142 Yes Yes No No CD6 1,4,8-triazaspiro[4.5]dec-3-ene-2-thione
ChemBridge 9144997 53.32442 Yes Yes No No CB19 7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
ChemBridge 9104745 104.5595 Yes Yes Yes Yes CB13 benzothiazole
ChemBridge 9122006 82.91343 Yes Yes Yes Yes CB15 Thieno[2,3-b]pyridine
ChemBridge 9116291 42.0284 Yes Yes Yes No CB14 Thieno[2,3-b]pyridine
ChemBridge 27065701 28.61002 Yes Yes Yes Yes CB23 1H-Pyrrolo[2,3-b]pyridine
ChemBridge 79024647 105.1373 No N/A N/A N/A N/A 1H-Pyrrolo[2,3-b]pyridine
ChemDiv T499-0675 118.2352 Yes Yes No No CD18 Various nitrogen-containing 6-5 ring systems
ChemDiv P814-4725 41.6299 Yes Yes Yes Yes CD17 Various nitrogen-containing 6-5 ring systems
ChemDiv C430-0042 120.0072 Yes Yes Yes Yes (lower) CD10 isoindole
ChemBridge 7954896 30.22385 Yes Yes Yes Yes CB6 isoindole
ChemDiv 0263-0418 41.07984 No N/A N/A N/A N/A benzimidazole
ChemBridge 9157817 39.96184 Yes Yes Yes No CB21 quinazoline
ChemBridge 7697494 30.78429 Yes Yes Yes No CB2 quinazoline
ChemBridge 9131456 58.80107 Yes Yes Yes Yes CB18 quinoline
ChemBridge 76251720 37.21705 No N/A N/A N/A N/A quinoline
ChemBridge 7958461 33.89854 Yes No N/A N/A CB7 4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine
ChemBridge 7961079 63.35647 Yes mostly Yes Yes CB8 4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine
ChemBridge 9126762 55.58708 Yes Yes No No CB16 4-oxo-1,4-dihydropyrido[1,2-a]pyrrolo[2,3-d]pyrimidine
ChemDiv 1391-0614 82.2714 Yes Yes Yes Yes CD2 benzopyrones
ChemBridge 9023017 39.59888 Yes Yes No No CB11 benzopyrones
ChemBridge 9128342 36.35136 Yes No N/A N/A CB17 unstructured
ChemBridge 9103442 95.37924 Yes Yes No No CB12 unstructured
ChemBridge 7928988 100.872 Yes Yes No No CB5 unstructured
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Table 3. ChemBridge and ChemDiv screen results (from previous page). A list of the 
49 compounds that hit in the initial screen and were pulled out by chemotype.   Their 
activity in both the primary and counter screen is listed, as well as company, ID number, 
initial NPI, availability, solubility, chemotype, and shorthand name.   
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supplier_ID IUPAC name 
7532833 methyl 2-amino-5-phenyl-3-thiophenecarboxylate 
95877291 
2-[1-(2-chlorophenyl)-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-cyclopropyl-N-[(1-
methyl-1H-pyrazol-4-yl)methyl]acetamide 
38667363 2-methyl-5-(2-pyridin-4-yl-1H-imidazol-1-yl)phenol 
K029-0062 4-(4-methoxyphenyl)-1H-imidazole-1,2-diamine 
9018218 N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-3-(4H-1,2,4-triazol-4-yl)benzamide 
9283140 [5-methyl-1-(3-methylphenyl)-1H-1,2,3-triazol-4-yl]acetic acid 
9153534 
5-amino-1-(4-methylphenyl)-N-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-1H-1,2,3-triazole-4-
carboxamide 
M564-0134 1-[4-(5-amino-1,2-oxazol-3-yl)piperidin-1-yl]-3-(4-methoxyphenyl)propan-1-one 
C201-1987 2-{3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl}ethanethioamide 
9017718 N-[5-(1,1-dimethylpropyl)-1,3,4-thiadiazol-2-yl]cyclohexanecarboxamide 
K783-6707 5-(4-fluorophenyl)-1,3,4-thiadiazol-2-amine 
7903556 1-(4-fluorophenyl)-4-[(2-methoxyphenyl)carbonothioyl]piperazine 
7916412 4-{[3-chloro-5-methoxy-4-(2-propyn-1-yloxy)phenyl]carbonothioyl}morpholine 
0655-0099 5-ethyl-4,6-dimethyl-2-sulfanylidene-1,2-dihydropyridine-3-carbonitrile 
C201-1499 6-[4-(2-methoxyphenyl)piperazin-1-yl]-2,3-dihydropyridazine-3-thione 
C301-7412 3-(2H-1,3-benzodioxol-5-yl)-1-(2,4-dihydroxypyrimidin-5-yl)urea 
M509-0433 3-(2-{1-propyl-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)-1-[3-(trifluoromethyl)phenyl]urea 
8018-1737 3-[(2E)-1-methyl-1,2-dihydropyridin-2-ylidene]-1-phenylthiourea 
K783-5213 3-benzyl-N-(3,5-dichlorophenyl)imidazolidine-1-carbothioamide 
D284-0238 3-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-ethyl-4,5-dihydro-1H-1,2,4-triazole-5-thione 
K241-0225 4-tert-butyl-1-(4-chlorophenyl)-2,3-dihydro-1H-imidazole-2-thione 
1494-0327 4-phenyl-3-(phenylamino)-4,5-dihydro-1H-1,2,4-triazole-5-thione 
8014-2247 3-amino-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-5-thione 
8019-0869 5-benzyl-1-(6-methylpyridin-2-yl)-1,3,5-triazinane-2-thione 
C200-3441 8-methyl-3-phenyl-1,4,8-triazaspiro[4.5]dec-3-ene-2-thione 
C200-3443 3-phenyl-8-(propan-2-yl)-1,4,8-triazaspiro[4.5]dec-3-ene-2-thione 
9144997 6-(1H-indol-3-yl)-3-(4-methylphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
9104745 methyl 2-[(3-pyridinylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate 
9122006 ethyl 5-{[(3-aminothieno[2,3-b]pyridin-2-yl)carbonyl]amino}-2-chlorobenzoate 
9116291 3-amino-N-(3-chloro-4-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide 
27065701 5-[6-(cyclopentylamino)-1H-pyrrolo[2,3-b]pyridin-4-yl]nicotinamide 
79024647 N-piperidin-4-yl-4-(1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-6-amine 
T499-0675 
1-(5-chlorothiophene-2-carbonyl)-3-[3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridin-2-
yl]pyrrolidine 
P814-4725 9-[1-(furan-2-carbonyl)pyrrolidin-3-yl]-8,9-dihydro-7H-purin-8-one 
C430-0042 1-hydroxy-2-(2-methoxyethyl)-3-oxo-2,3-dihydro-1H-isoindole-5-carboxylic acid 
7954896 2-(5-methyl-3-isoxazolyl)-1,3-dioxo-N-1,3-thiazol-2-yl-5-isoindolinecarboxamide 
0263-0418 2-(4-aminophenyl)-5-chloro-1H-1,3-benzodiazol-6-amine 
9157817 
3-[(4-oxo-3,4-dihydro-2-quinazolinyl)methyl]-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-
4(3H)-one 
7697494 N-(6,7-dimethoxy-4-oxo-1,4-dihydro-2-quinazolinyl)benzamide 
9131456 N-[4-(aminocarbonyl)phenyl]-4-hydroxy-3-quinolinecarboxamide 
76251720 8-methoxy-5-[5-(pyrrolidin-1-ylcarbonyl)-2-furyl]quinoline 
7958461 
9-methyl-N-(5-methyl-3-isoxazolyl)-4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-2-
carboxamide 
7961079 N-1,3-benzodioxol-5-yl-4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-2-carboxamide 
9126762 1-benzyl-N-methyl-4-oxo-1,4-dihydropyrido[1,2-a]pyrrolo[2,3-d]pyrimidine-2-carboxamide 
1391-0614 3-{imidazo[1,2-a]pyridin-2-yl}-2H-chromen-2-one 
9023017 2,4-dimethoxy-N-(2-oxo-2H-chromen-6-yl)benzamide 
9128342 N-(4-chloro-2,5-dimethoxyphenyl)-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide 
9103442 4-oxo-4-[(3-propoxyphenyl)amino]butanoic acid 
7928988 2-{[1-(2-amino-5-ethyl-6-methyl-4-pyrimidinyl)-1H-diaziren-3-yl]thio}acetamide 
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Table 4. ChemBridge and ChemDiv screen results IUPAC names (from previous 
page). Chemical names of hits from ChemBridge and ChemDiv screen, listed in the same 
order as in Table 3.    
 
 
 
Name ID Min Max Hill Slope IC50 (µM) 
CD10 C430-0042 0.000 157 1.94 29.3 
CD8 C201-1987 -1.38 152 1.86 98.5 
CD1 0655-0099 0.430 55.5 1.75 39.4 
CD7 C201-1499 2.02 7580 0.910 Ambiguous 
CD11 D284-0238 0.210 74.1 2.05 37.0 
CD14 K783-6707 2.29 89.0 3.75 16.8 
CD13 K783-5213 0.990 83.7 3.15 22.4 
CB9 9017718 -1.64 80.4 2.56 4.36 
CB20 9153534 -4.59 43.0 1.09 57.3 
CB2 7697494 -2.33 40.4 21.7 12.8 
CB21 9157817 -3.37 44.5 2.69 32.8 
CB14 9116291 -0.820 107 1.42 80.0 
CB3 7903556 -0.970 3804 1.96 Ambiguous 
CB4 7916412 -1.43 84.0 2.38 28.0 
CB1 7532833 -1.59 80.2 2.92 23.1 
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Table 5 Initial hits (from previous page). A list of the 15 compounds that hit in the initial 
screen and hit the primary screen in the dose response assay but not the counter screen.  
The ID number, Min, Max, IC50 and Hill slope from the dose response against the primary 
screen of each compound is listed.  Max is the normalized maximum inhibition shown, 
while min is the normalized minimum inhibition shown.  Compounds whose Max values 
were close to 100, had unambiguous IC50 values, and initial Hill slopes between 1 and 5 
are listed in bold.   
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Figure 44 Dose response repeat. 
 (from previous page).  (a) Primary screen dose response assay of 8 initial hit compounds, 
with IC50 values and Hill slopes listed, tested in duplicate.  95% confidence intervals for 
IC50 values are:  CB1 (21.0 µM to 28.3 µM), CB4 (13.7 µM to 16.3 µM), CB9 (2.08 µM 
to 2.37 µM), CD8 (29.6 µM to 38.4 µM), CD10 (8.97 µM to 11.0 µM), CD11 (20.9 µM to 
31.1 µM) CD13 (16.6 µM to 20.9 µM), and CD14 (7.42 µM to 10.1 µM).  95% confidence 
intervals for Hill slope values are:   CB1 (1.53 to 2.69), CB4 (3.39 to 6.13), CB9 (2.66 to 
4.21), CD8 (1.71 to 3.00), CD10 (1.19 to 1.57), CD11 (1.15 to 2.10) CD13 (1.98 to 3.68), 
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and CD14 (1.68 to 4.81).  (b) Counter screen dose response assay of the 8 initial hit 
compounds, showing only CD10 hit against the counter screen.    95% confidence intervals 
for IC50 values are as follows:  CD10 (70.8 µM to 591 µM).  95% confidence intervals for 
Hill slope values are as follows:  CD10 (0.621 to 1.31).   
 
4.3 Discussion 
In conclusion, we have developed a high-throughput method for identifying small 
molecules that can disrupt the interaction between BRAF and its substrate, MEK.  We have 
also developed a counter screen useful in determining whether these small molecules are 
non-specific inhibitors that affect the specific technology of the screen or if these inhibitors 
are specific towards the RAF/MEK interaction.   In developing this screen, we have utilized 
a point mutation to make E. coli expressed BRAF able to interact with MEK in vitro and 
also have restored kinase activity in BRAF through this mutation.  Finally, we have 
developed secondary assays useful in further confirming lead compounds and have 
identified chemotype structures that can be further analyzed for determining mode of 
inhibition.    
 
 Using secondary assays used for plumbagin and thymoquinone such as Differential 
Scanning Calorimetry (DSC), Differential Scanning Fluorimetry (DSF), ELISA based 
activity assays, and Analytical Ultracentrifugation (AUC) can help further confirm these 
compounds as lead hits that can be optimized to target MAPK signaling and, possibly, 
inhibitor resistant melanoma cell lines.  While any compounds that inhibit the BRAF-MEK 
interaction will not be able to differentiate basal level MAPK signaling from BRAF-mutant 
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MAPK signaling, using chemical linking techniques such as those described in Chapter 2 
and Chapter 3 of this thesis would be able to add selectivity to these compounds.  
Chemically linking vemurafenib, a BRAFV600E-selective compound, to a compound that 
can bind to the surface of BRAF or MEK and hinder dimerization between these two 
proteins could have therapeutic benefits in inhibitor resistant cell lines and be more 
effective than in normal cells due to the selectivity of the vemurafenib inhibitor.  We have 
shown that bivalent vemurafenib molecules are not potent in BRAFWT cells (Grasso et al., 
2016), and this added selectivity could make these compounds powerful therapeutic tools 
in the clinic.   BRAF-MEK dimerization inhibitors alone can also be powerful probes in 
exploring the effects of disrupting BRAF-MEK dimerization in vitro and in cells.   Further 
confirming if these compounds affect BRAF signaling in vitro and testing their effects on 
MEK phosphorylation of ERK could help elucidate the binding mode of these compounds 
as well as elucidate the intricacies of the BRAF/MEK complex.  Testing these inhibitors in 
cells to determine if resistant pathways could develop is also a use that can enlighten the 
field on further directing melanoma therapy.    
 
 
4.4 Methods 
4.4.1. Plasmids  
DNA encoding the BRAF kinase domain residues 448-723 containing 16 solubilizing 
mutations (I543A, I544S, I551K, Q562R, L588N, K630S, F667E, Y673S, A688R, L706S, 
Q709R, S713E, L716E, S720E, P722S, and K723G) was ordered from Epoch Biolabs and 
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cloned into a Pet28a(+) vector encoding an N-terminal 6XHis Tag and a thrombin cleavage 
site between the protein and the tag.  This construct was used as a template to create 6XHis-
BRAF16mut_V600E, 6XHis-BRAF16mut_E667F, 6XHis-BRAFV600E/16mut_E667F, FLAG-tagged 
BRAF16mut_E667F, and 6XHis-FLAG-BRAF16mut. This construct was also cloned into a 
PRSF vector with a GST-tag to create untagged BRAF16mut_V600E and BRAFV600E/16mut_E667F. 
These proteins were used in the TR-FRET assay, the ELISA based assay confirming that 
the E667F mutation restores kinase activity in the E. coli construct, DSF experiments, and 
DSC experiments. 
A cDNA library for full length MEK was purchased from Dharmacon (Catalog # MHS 
6278-211690391) and residues 63-393 were cloned into a pET-Duet vector containing a 
TEV protease cleavable N-terminal 6XHis tag.  This construct was used in TR-FRET 
assays and thermal shift assays.  The MEK construct spanned residues 45-393 and with 
replacement of the flexible linker region 264-307 with a 6-residue sequence SVQSDI, 
which was a gift from Dr. Donita Brady (University of Pennsylvania) and used for in vitro 
complexation of BRAF and MEK via size exclusion chromatography.   Full length human 
MEK1 with an N-terminal GST fusion tag and a C-terminal His tag in a pGex-3t vector 
was provided by Dr. Michael Olson (Beatson Institute for Cancer Research, Glasgow, UK) 
and was used as the substrate for the BRAF in vitro kinase assays.   
DNA encoding the BRAF kinase domain residues 442-724 was used as a template and 
cloned into a Pfastbac dual vector with mouse p50cdc37 full length as an expression 
chaperone for protein expression in baculovirus infected Sf9 insect cells.  An N-terminal 
6X-His tag was inserted into the plasmid, and this plasmid was used as a template to create 
mutant BRAFV600E.  
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DNA encoding mouse NF-κB p65 residues 191-291 with an N-terminal 6XHis-tag was 
cloned into a pET-Duet vector.  This construct was used in TR-FRET assays.   
4.4.2 Protein Purification 
6XHis-tagged BRAF16mut proteins were produced as previously described (Grasso et al., 
2016). In brief, proteins were expressed in (DE3)RIL bacterial expression cells at 37 oC 
and induced with 1mM IPTG overnight at 18 oC, spun down the next day, and lysed in 
lysis buffer (50mM potassium phosphate pH 7.0, 250mM NaCl) with 1mM PMSF and 
DNaseI.  The lysate was spun down at 19000 rpm for 30 minutes, and the supernatant was 
added to 7mL of TALON metal affinity resin (Takara) and left to incubate at 4 oC for 1 hr.  
The supernatant was eluted via gravity column, and the resin was washed with 1 L of lysis 
buffer with 10 mM imidazole.  The BRAF proteins were eluted with lysis buffer 
supplemented with 250 mM Imidazole.  Protein was dialyzed into dialysis buffer (50 mM 
potassium phosphate pH 7.0, 5 mM EDTA pH 7.5, 1mM DTT (Dithiothreitol)) overnight 
and then applied to a 5 mL SP Sepherose cation exchange column followed by washing in 
dialysis buffer and elution in 50 mM potassium phosphate pH 7.0, 1 M NaCl, and 1 mM 
DTT.   Peak fractions were run on an SDS-PAGE gel, pooled, concentrated, and applied to 
a Superdex S200 gel filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM 
NaCl, 5% Glycerol and 10 mM DTT.  Protein was concentrated to 5-10 mg/mL, flash 
frozen in liquid nitrogen, and stored in an -80 oC freezer for future use.  6XHis-FLAG-
tagged BRAF was purified in the same manner.    
FLAG-tagged BRAF16mut proteins were expressed in (DE3)RIL bacterial expression cells 
at 37 oC and induced with 1mM IPTG overnight at 18 oC, spun down the next day, and 
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lysed in lysis buffer (50mM potassium phosphate pH 7.0, 250mM NaCl) with 1mM PMSF 
and DNaseI.  The lysate was spun down at 19000 rpm for 30 minutes, and the supernatant 
was added to 15mL of M2 Anti-FLAG resin affinity resin (Sigma-Aldrich) and left to 
incubate at 4 oC for 2 hr.  The supernatant was eluted via gravity column, and the resin was 
washed with 1 L of lysis buffer.  The BRAF proteins were eluted with lysis buffer 
supplemented with 5 mL of 0.5 mg/mL 3X FLAG peptide (Sigma Aldrich).  The resin was 
then washed with lysis buffer and the eluent was collected and monitored using Bradford 
reagent (Sigma Aldrich) until protein elution was complete.  Protein was dialyzed into 
dialysis buffer (50 mM potassium phosphate pH 7.0, 1mM DTT (Dithiothreitol)) overnight 
and then applied to a 5 mL SP Sepherose cation exchange column followed by washing in 
dialysis buffer and elution in 50 mM potassium phosphate pH 7.0, 1 M NaCl, and 1 mM 
DTT.   Peak fractions were run on an SDS-PAGE gel, pooled, concentrated, and applied to 
a Superdex S200 gel filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM 
NaCl, 5% Glycerol and 10 mM DTT.  Protein was concentrated to 3-5mg/mL, flash frozen 
in liquid nitrogen, and stored in an -80 oC freezer until future use.  
GST-tagged BRAF16mut proteins were expressed in bacteria as described for the His-tagged 
proteins, lysed in lysis buffer (50 mM KPi pH 7.0 and 250 mM NaCl) and incubated on 
Glutathione Resin at 4 oC for 1 hr.   The protein on resin was then washed with 1L of lysis 
buffer and left on the resin and cleaved with TEV protease overnight and eluted the next 
morning in lysis buffer with 25 mM NaCl, run over both SP Sepharose and Q Sepharose 
ion exchange columns in tandem and the flow through collected.  The protein was run over 
Ni-NTA resin pre-equilibrated with lysis buffer and the flowthrough was collected. The 
protein was then concentrated using a 10kDalton cutoff centrifugal filter unit (Millipore) 
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and chromatographed on a Superdex S200 gel filtration column in a final buffer of 20 mM 
HEPES pH 7.0, 150 mM NaCl, 10 mM Dithiothreitol and 5% glycerol.  Protein eluted as 
a mixture of dimer and monomer and both species were pooled together, concentrated to 
10mg/mL (~320 μM) and flash frozen in liquid nitrogen and stored for later use in a -80 oC 
freezer. 
MEK63-393 with an N-terminal 6XHis tag was expressed in DE(3) RIL bacterial expression 
cells at 37 oC, induced with 1mM IPTG overnight at 16 oC, spun down the next day, and 
lysed in lysis buffer 2 (25 mM Tris pH 7.5, 500mM NaCl, 5mM BME) supplemented with 
1mM PMSF and DNAseI.  The lysate was spun down at 19,000 rpm for 30 minutes and 
the supernatant was added to 10 mL of Ni-NTA metal affinity resin (Thermo Scientific) 
and left to incubate at 4 oC for 1 hr.  The supernatant was then eluted via gravity column 
and the resin was washed with 1L of lysis buffer 2 treated with 20mM imidazole.  The 
MEK protein was eluted with lysis buffer 2 supplemented with 300 mM imidazole.  Protein 
was dialyzed into dialysis buffer (25 mM Tris pH 7.5, 25mM NaCl, 5 mM BME) overnight 
and then applied to a 5 mL Q Sepharose cation exchange column followed by washing in 
dialysis buffer and elution in 25 mM Tris pH 7.5, 5 mM BME,  and 1 M NaCl.   Peak 
fractions were run on an SDS-PAGE gel, pooled, concentrated using a 30k Dalton cutoff 
centrifugal filter unit (Millipore), and applied to a Superdex S200 gel filtration column in 
a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 5% Glycerol and 5 mM BME.  
Protein was concentrated to 5-10 mg/mL (200 µM), flash frozen in liquid nitrogen, and 
stored in an -80 oC freezer for future use.   
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MEK45-393 (∆264-307/SVQSDI linker) with an N-terminal 6XHis tag was expressed in DE(3) RIL 
bacterial expression cells at 37 oC, induced with 1mM IPTG overnight at 17 oC, spun down 
the next day, and lysed in lysis buffer 2 (25 mM Tris pH 7.5, 500mM NaCl, 5mM BME) 
supplemented with 1mM PMSF and DNAseI.  The lysate was spun down at 19,000 rpm 
for 30 min. and the supernatant was added to 10 mL of Ni-NTA metal affinity resin 
(Thermo Scientific) and left to incubate at 4 oC for 1 hr.  The supernatant was then eluted 
via gravity column and the resin was washed with 1L of lysis buffer 2 treated with 20mM 
imidazole.  The MEK protein was eluted with lysis buffer 2 supplemented with 300 mM 
Imidazole.  Protein was dialyzed into dialysis buffer (25 mM Tris pH 7.5, 25mM NaCl, 5 
mM BME) overnight while incubated with TEV protease in dialysis and then applied to a 
5 mL SP Sepharose cation exchange column followed by washing in dialysis buffer and 
elution in 25 mM Tris pH 7.5, 5 mM BME, and 1 M NaCl.   Peak fractions were run on an 
SDS-PAGE gel, pooled, concentrated, and applied to Ni-NTA resin pre-washed with lysis 
buffer 2.  The flow through was collected, concentrated using a 30kDalton cutoff 
centrifugal filter unit (Millipore), and loaded onto a Superdex S200 gel filtration column 
in a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 5% Glycerol and 5 mM BME.  
Protein was concentrated to 5-10 mg/mL (200 µM) and then added to already purified 
untagged BRAFV600E/16mut_E667F.  This complex was then loaded onto a Superdex S200 gel 
filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 5% Glycerol 
and 5 mM BME and only the fractions containing stoichiometric amounts of BRAF and 
MEK were pooled together, concentrated to 5-10 mg/mL, and then flash frozen in liquid 
nitrogen and stored in an -80 oC freezer for future use.   
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BRAFWT and BRAFV600E kinase domains were overproduced as N-terminally His-tagged 
proteins in insect cells. Briefly, protein constructs were coexpressed with p50cdc37, pelleted, 
suspended in lysis buffer 3 (25 mM Tris pH 8.0, 250 mM NaCl, 5 mM Imidazole and 10% 
glycerol) treated with Complete EDTA-free protease inhibitor cocktail tablets (Roche) and 
DNaseI, lysed, centrifuged at 19,000 rpm for 30 min., and added to TALON metal affinity 
resin and incubated at 4 oC for 1 hr.  The protein on the resin was washed extensively with 
1 L of lysis buffer 3 and eluted with 25 mM Tris pH 7.5, 250 mM NaCl, 250 mM imidazole, 
and 10% Glycerol.   The protein was diluted into a low salt buffer containing 25mM Tris 
pH 8.0, 1 mM EDTA and 1 mM DTT and run on an SP Sepharose cation exchange column 
and eluted with a salt gradient from 50 mM NaCl to 1 M NaCl.   Peak fractions were run 
on an SDS-PAGE gel and fractions containing protein were pooled, concentrated, and 
applied to a Superdex S200 gel filtration column and stored in a final buffer of 25 mM Tris 
pH 8.0, 300 mM NaCl, 1 mM DTT, and 10% glycerol.  Protein was concentrated to ~0.5 
mg/mL and flash frozen in liquid nitrogen and stored for later use in an -80 oC freezer. 
 
GST-MEK1 fusion protein used as a substrate in ELISA assays was expressed in (DE3) 
RIL cells at 37 oC and induced with 0.5 mM IPTG at 15 oC overnight.  The cells were 
harvested and resuspended in lysis buffer 4 (20 mM HEPES at pH 7.0, 500 mM NaCl, 10 
mM BME, 10 mM imidazole and 5% glycerol) supplemented with 1mM PMSF and 
DNaseI.  The lysate was sonicated and spun down at 19,000 rpm for 30 min. and the 
supernatant was added to Ni-NTA resin and incubated at 4 oC for 1 hr.  The resin was 
washed extensively with lysis buffer 4 with 20 mM instead of 10 mM imidazole and eluted 
with lysis buffer 4 supplemented with 250 mM imidazole.  Eluted protein was concentrated 
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and loaded onto a Superdex S200 16/60 gel filtration column into a final buffer of 20 mM 
HEPES pH 7.0, 150 mM NaCl, 10 mM BME and 5% glycerol.  The protein eluted off the 
sizing column in two separate populations, and the second peak was collected, concentrated 
to ~20 mg/mL (~250 µM), and flash frozen in liquid nitrogen and stored in an -80 oC freezer 
for future use.   
NF-κB p65 residues 191-291 with an N-terminal 6XHis-tag was expressed in DE(3) RIL 
bacterial expression cells at 37 oC, induced with 1mM IPTG overnight at 22 oC, spun down 
the next day, and lysed in lysis buffer 5 (25 mM HEPES pH 7.5, 500 mM NaCl, 5mM 
BME) supplemented with 1 mM PMSF and DNAseI.   The lysate was spun down at 19,000 
rpm for 30 min. and the supernatant was added to 10 mL of Ni-NTA metal affinity resin 
(Thermo Scientific) and left to incubate at 4 oC for 1 hr.  The supernatant was then eluted 
via gravity column and the resin was washed with 1L of lysis buffer 5 treated with 20mM 
imidazole.  The MEK protein was eluted with lysis buffer 5 supplemented with 300 mM 
imidazole.  Protein was dialyzed into dialysis buffer (25 mM HEPES pH 7.5, 150 mM 
NaCl, 5 mM BME) overnight and concentrated the next day to ~600 µM and flash frozen 
in liquid nitrogen and stored in an -80 oC freezer for future use.   
 
4.4.3. In Vitro Kinase Assay 
Compound inhibition of BRAFWT and BRAFV600E were performed using an ELISA assay.  
Briefly, GST-MEK fusion protein was diluted 3:1000 in Tris-buffered saline (25 mM Tris 
pH 7.5, 140 mM NaCl) treated with 0.05% Tween-20 (TBST), and diluted MEK was added 
to each well of a glutathione coated 96-well plate (Pierce #15240) and incubated at room 
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temp for 1 hr. with shaking.  BRAF was diluted from frozen stocks (1:500 dilution for 
BRAFWT and 1:1000 dilution for BRAFV600E) in 50 mM HEPES pH 7.0 and 50 mM NaCl.  
2 µL of desired concentration of inhibitor was added to 100 µL of diluted BRAF in a 96 
well “V” bottom plate (Corning #2897) and the inhibitor/protein mixture was incubated for 
1 hr. at room temp.  Glutathione plates were washed extensively with TBST and the 
protein-inhibitor mixture was added to the plate with a 100 µM final concentration of ATP 
in a buffer containing 50 mM HEPES pH 7.0, 200 mM NaCl, and 20 mM MgCl2.  The 
plate was incubated at 37 oC for 30 min.  The reaction was washed from the plate and the 
plate was again washed with TBST.  A 1:8000 dilution of primary antibody (p-MEK1/2 
(S217/S221) rabbit antibody (cell signaling)) in TBST treated with 0.5% BSA was added 
to the plate and incubated for 1 hr. with shaking.  The plate was then treated with multiple 
TBST washes and then incubated with a 1:10,000 dilution of secondary antibody (goat 
anti-rabbit IgG (H+L)-HRP (BioRad)) in TBST treated with 0.5% BSA for 1 hr. with 
shaking.  The plate was washed extensively with TBST and Supersignal ELISA Pico 
Chemiluminescent Substrate (Pierce #37069) was added.  The plate was read on a Promega 
GloMAX 96 Microplate Luminometer.  Each curve was repeated in duplicate or triplicate, 
normalized using GraphPad Prism by selecting the largest value as the maximum and the 
lowest value as the minimum, and used to calculate IC50 values by using a log (inhibitor) 
vs response fit on Prism 5.0 (GraphPad).  Error bars are indicative of the SEM of each 
point, and 95% confidence intervals are listed in the figure legends as calculated by 
GraphPad Prism.   
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4.4.4 Differential Scanning Fluorimetry (DSF) assays 
Frozen aliquots of BRAFV600E/16mut_E667F and MEK63-393 proteins were thawed and diluted 
in DSF Buffer (25 mM Hepes  pH 7.0, 150 mM NaCl) to a final concentration of 5 μM 
(0.2 mg/mL) and 15 μL were added to the selected wells of a MicroAmp Optical 384 well 
plate (Applied Biosystems).   Sypro Orange (5000X stock, ThermoFisher Scientific) was 
diluted 1:300 and 4 μL of that diluted stock was added to each well.  1 μL of inhibitor in 
100% DMSO was added to each well to a final concentration of 100-300 μM and the plate 
was spun down and heated from 20 oC to 95 oC using a qPCR (ABI 7900 RealTime PCR) 
with a 1% ramp rate.   Melting curves were generated from this data and analyzed by taking 
the first derivative of the curve.  Data were analyzed and plotted using GraphPad.  Each 
data set was performed in quadruplicate.  One representative curve for each data point is 
shown in Figure 40.   
 
4.4.5 Differential Scanning Calorimetry (DSC) assays 
  BRAF16mut was diluted to a final concentration of 37 µM in DSC Buffer (20 mM HEPES 
pH 7.0, 150 mM NaCl).  50 µL of either DMSO or inhibitor dissolved in 100% DMSO 
was added to 450 µL of BRAF16mut and degassed for 3 min.   The protein/inhibitor or 
protein/DMSO mixture was then added to a MicroCal VP-Capillary DSC (Malvern) and 
blanked with 450 µL of DSC Buffer and 50 µL of DMSO.   The protein (sample) and buffer 
(blank) were both heated from 10 oC to 90 oC with a scan rate of 60 oC/hour and a filtering 
period of 10 seconds.  The difference in heat required to raise the temperature of the sample 
as compared to the blank is measured as a function of temperature.  The data was plotted 
using Origin 7.    
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4.4.6 Time Resolved- Fluorescence Resonance Energy Transfer (TR-FRET) assay 
“hooking experiment”  
Frozen aliquots of FLAG-BRAF16mut_E667F and 6XHis-MEK63-393 were thawed and each 
were diluted to 4X final concentrations in TR-FRET buffer (20 mM Tris pH 7.5, 140 mM 
NaCl, 0.05% Tween-20, and 0.2% BSA) and 2.5 µL of each protein were added to each 
well in a 384 well Proxi-Plate (Perkin Elmer).  LANCE Eu-W1024-anti6XHis (AD011, 
Perkin Elmer) was diluted to 40 nM and mixed with 10 nM LANCE Ultra ULight Anti-
FLAG (TRF0059M, Perkin Elmer) in TR-FRET buffer and 5 µL of fluorophore mixture 
was added to each well.   The plate was then covered and left to sit at room temperature for 
60 minutes and then read on a PerkinElmer EnVision Xcite plate reader at both 665 nm 
and 620 nm.   The 665 nm emission signal was divided by the 620 nm emission and 
multiplied by 1000 to control for Europium loading.    
 
4.4.6 TR-FRET assay 50:50 screen 
 Frozen aliquots of untagged BRAF16mut_V600E and BRAFV600E/16mut_E667F were thawed and 
1 µL of 22µM BRAF16mut_V600E was pipetted into half of a 384-well Proxi plate (Perkin 
Elmer) and 22 µM BRAFV600E/16mut_E667F was added to the other half using the Janus 
Modular Dispensing Tool (MDT) P30 head (Perkin Elmer).  Frozen aliquots of FLAG-
BRAF16mut_E667F  and 6XHis-MEK63-393 were thawed and each were diluted to 50 nM final 
concentrations in TR-FRET buffer (20 mM Tris pH 7.5, 140 mM NaCl, 0.05% Tween-20, 
and 0.2% BSA) along with 20 nM LANCE Eu-W1024-anti6XHis (AD011, Perkin Elmer) 
and 5 nM LANCE Ultra ULight Anti-FLAG (TRF0059M, Perkin Elmer).   10 µL of 
protein-fluorophore mixture was then dispensed into 384 well plates using a MultiDrop 
  
 
148 
Combi reagent dispenser (Thermo Fisher).   The plate was then left at room temperature 
for 90 min. and read on a Perkin Elmer EnVision XCite.  The data was analyzed as 
described above.    
 
 
4.4.6 TR-FRET assay Natural Product Pilot Screen 
A frozen aliquot of untagged BRAFV600E/16mut_E667F was thawed and 1 µL of 22µM 
BRAFV600E/16mut_E667F was pipetted into rows 2 and 24 of three 384-well Proxi plates (Perkin 
Elmer) using the Janus MDT P30 head.  Frozen aliquots of FLAG-BRAFE667F  and 6XHis-
MEK63-393 were thawed and each were diluted to 50 nM final concentrations in TR-FRET 
buffer (20 mM Tris pH 7.5, 140 mM NaCl, 0.05% Tween-20, and 0.2% BSA) along with 
20 nM LANCE Eu-W1024-anti6XHis (AD011, Perkin Elmer) and 5 nM LANCE Ultra 
ULight Anti-FLAG (TRF0059M, Perkin Elmer).   10 µL of protein-fluorophore mixture 
was then dispensed into 384 well plates using a MultiDrop Combi reagent dispenser 
(Thermo Fisher).  50nL of 5mM small molecules from the Natural Product Pilot Screen 
were pipetted to the 384 well plates using the Janus MDT PinTool.  The plate was then left 
at room temperature for 60 min. and read on a Perkin Elmer EnVision XCite.  This was 
repeated for the counter screen, except FLAG-6XHis-BRAF16mut was added at a final 
concentration of 50 nM to 20 nM LANCE Eu-W1024-anti6XHis (AD011, Perkin Elmer) 
and 5 nM LANCE Ultra ULight Anti-FLAG (TRF0059M, Perkin Elmer) in TR-FRET 
buffer.  Also, 1 µL of 300 µM NF-κB was added to rows 2 and 24 of each of the counter 
screen plates using the Janus MDT P30 head. The data was analyzed as described above 
and normalized by using positive (plumbagin) and negative (DMSO) controls. Any 
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inhibitors that hit with an NPI above 25% and did not hit the counter screen with more than 
5% NPI were considered hits.   
 
4.4.9 Dose Response assays by hand 
Frozen aliquots of FLAG-BRAF16mut_E667F and 6XHis-MEK63-393 were thawed and each 
were diluted to 50 nM final concentrations in TR-FRET buffer (20 mM Tris pH 7.5, 140 
mM NaCl, 0.05% Tween-20, and 0.2% BSA) along with 10 nM LANCE Eu-W1024-
anti6XHis (AD011, Perkin Elmer) and 2.5 nM LANCE Ultra ULight Anti-FLAG 
(TRF0059M, Perkin Elmer).   10 µL of protein-fluorophore mixture was then added into a 
384 well plate and 1 µL of inhibitor in 100% DMSO was added to each of the wells ranging 
from 586 nM to 300 µM for each inhibitor.  Each inhibitor titration was performed in 
duplicate.   Data was normalized with DMSO as a control and data was analyzed using 
GraphPad Prism using a nonlinear regression (curve fit) (log (agonist) vs response (variable 
slope)).   
 
4.4.10 High Throughput screening 
Compounds (50 nL) were transferred to low volume 384-well assay plates (Perkin Elmer 
6008280) containing 5uL of assay buffer (25mM Tris pH7.5, 140mM NaCl, .05% Tween, 
and 0.2% BSA) using a 384, 50 nL slotted pin tool (V&P Scientific) and a JANUS 
Automated Workstation (Perkin Elmer). Compounds were added to a final concentration 
of 50 uM in 0.5% DMSO with negative control (DMSO) in columns 1 and 23, and positive 
control (100uM Plumbagin) in columns 2 and 24. Five microliters of premixed BRAF-
MEK (50nM: 50nM ratio), protein-bead complex in assay buffer was added to the assay 
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plates using a MultidropTM Combi Reagent Dispenser (Thermo Scientific). Assay plates 
were incubated for 90 minutes at room temperature and fluorescence was measured on an 
EnVision Xcite Multilabel Plate Reader (PerkinElmer), using the TR-FRET measurement 
technology (Ex 320 nM and Em 620 and 665 nm, 300 us window, 60us delay). 
  
4.4.11 Data Analysis using Tibco Spotfire Software 
The EM665:Em620 ratio from DMSO and Plumbagin control wells were aggregated, 
respectively, and used to calculate z’-factors for each assay plate, as a measure of assay 
performance and data quality, with a z’-factor >0.5 representing acceptable data.  Em665: 
Em620 values of sample wells were normalized to aggregate values from DMSO and 
Plumbagin plate control wells and expressed as normalized percent inhibition [NPI = 
((DMSOavg-test well) / (DMSOavg - Plumbaginavg) x 100)] and Z-score [Z= (DMSOavg-Test 
well) / (DMSOstddev]. 
 
For dose response experiments, Normalized Percent Inhibition (NPI) and log10 
transformed drug concentration values were fit to a non-linear model with variable slope 
to define the IC50 values, Hill slope, and Area Under Curve (AUC). 
 
4.4.12 Inhibitors 
Plumbagin (P7262-250MG) and Thymoquinone (274666-1G) were purchased from Sigma 
Aldrich.  Eseroline Fumarate (sc-202155) was purchased from Santa Cruz Biotechnology.  
Erythromycin (AC227330050) was purchased from Acros Organics.   All hits from 
ChemBridge and ChemDiv were purchased directly from their respective companies.    
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4.4.13 Library 
We screened ~44000 compounds from the 3 independent libraries, designed with 
assistance from medicinal and computational chemists. These 44,000 compounds were 
vetted from an initial set of 500,000 compounds for early stage lead-like characteristics 
(i.e. modified Lipinski rules, including MW<625 Da, LogP/LogD, Hydrogen bond 
donor/acceptors, chiral centers and PSA, functional groups, etc.).  Additional substructure 
filters were applied to remove reactive groups (e.g. Michael acceptors) and compounds 
predicted to be PAINS. Lead Finder Clustering and MACCS fingerprinting was used to 
select a set of compounds to perform property based selection of a 50,000 compound set 
of which 43,000 were readily available from commercial vendors. The final library is 
comprised of 800 purified Natural Products (Microsource) with annotated biological 
activities, 11,137 compounds from ChemDiv’s SMART library, 20,000 compounds from 
Chembridge’s Core set, and 12,000 compounds from Chembridge’s Express Pick set.  The 
compound composition of the library can be characterized by an average MW of 350 Da, 
LogP/LogD of 2.5, Hydrogen Bond donors of 1, hydrogen bond acceptors of 4, chiral 
centers <1, and a PSA of 60, with ~25% of the library enriched with compounds with 
known pharmacophore content. Compounds are suspended in DMSO, arrayed in columns 
3-22 of 384 well microplates, and stored at -20oC.  Library plates are thawed a maximum 
of 10X to maintain compound integrity. 
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Chapter 5- Conclusions and Future Directions 
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 While the experiments within help elucidate important mechanisms in inhibitor 
resistance within the MAPK signaling pathway, there is still much work to be done in 
discovering a novel class of inhibitors that can bypass paradoxical activation.  While the 
bivalent vemurafenib inhibitors were able to stabilize BRAFV600E in an inactive, artificially 
induced dimeric conformation, these inhibitors were ineffective against resistance in cells 
(Grasso et al., 2016).   We hypothesize that this affect is due to BRAFV600E’s ability to 
activate BRAFWT in cells (Heidorn et al., 2010; P. I. Poulikakos et al., 2010), indicating 
that our bivalent inhibitor must be further adapted to target BRAFWT while not losing 
selectivity.   Our initial efforts were focused on chemically linking pan RAF inhibitor 
TAK632 with vemurafenib, creating an asymmetric RAF inhibitor capable of inhibiting 
activated BRAFWT while still maintaining selectivity towards mutant cells with 
vemurafenib.   However, when this was tested with proof-of-principle bivalent TAK 
inhibitors, these inhibitors were found to drastically reduce TAK’s potency in vitro. 
Monovalent TAK632, however, was able to induce the biologically relevant dimeric 
conformation of BRAF in vitro, even in the presence of surface mutations that are known 
to disrupt the dimer (Rajakulendran et al., 2009).   These discoveries led us to believe that 
a chemically linked TAK/vemurafenib heterodimeric inhibitor would not be successful, 
because the chemical linking has drastically different effects depending on whether an αC-
helix IN (TAK) or an αC-helix OUT (vemurafenib) inhibitor is used.  Based on our 
experiments detailed above, focusing on chemically linking αC-helix OUT inhibitors will 
be more successful in stabilizing an inactive form.   However, this is complicated by αC-
helix OUT inhibitors being more specific towards BRAFV600E rather than BRAFWT or 
CRAFWT.  In moving forward, discovering inhibitors that can hit BRAFWT while not 
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inducing an αC-helix IN conformation would be integral in discovering a chemically 
linked RAF inhibitor that can “trap” RAF molecules and disrupt any possible 
transactivation.  A bioluminescence resonance energy transfer (BRET) system has been 
developed for determining BRAF dimerization effects of various inhibitors (H Lavoie et 
al., 2013), and this can be used in conjunction with the ELISA based activity assay 
described above to determine if inhibitors can inhibit BRAFWT but not induce dimerization 
to the same effect as TAK632.  Using these two techniques to monitor existing RAF 
inhibitors in the literature could lead to a new useful target to chemically link to 
vemurafenib, as well as help characterize existing inhibitors further to give a clear 
predictive model for whether inhibitors will induce paradoxical activation and inhibitor 
resistance. 
 While these methods are able to predict the effects of inhibitors within a cell, the 
field is limited by the lack of easily expressing and purifying full length BRAF.  
Furthermore, it is currently unknown how the N-terminal RBD and CRD domains of BRAF 
are able to interact with the kinase domain and inhibit activity.   The N-terminus of BRAF 
is known to be able to inhibit the kinase domain in trans (Dent et al., 1995; Hugo Lavoie 
& Therrien, 2015), and using X-ray crystallography to elucidate how the N-terminus blocks 
the kinase domain is integral.  The RBD of BRAF is able to be expressed and purified in 
vitro (Athuluri-Divakar et al., 2016), and I propose adapting this construct and expanding 
it to encompass regions that are then able to inhibit RAF kinase activity in vitro would give 
a good construct for crystallization.   This can then be complexed with BRAF16mut_E667F 
purified in E. coli and subjected to crystallization screens.   These structural studies could 
help give the field a more in-depth picture at how transactivation functions.     
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 While the TR-FRET screen was productive in determining hit compounds that are 
able to specifically disrupt the RAF/MEK signal, these inhibitors need to be further 
confirmed using ELISA based activity assays, DSF and DSC assays, and AUC studies to 
elucidate if they affect RAF or MEK kinase activity, which protein they are binding, and 
if they are truly disrupting the complex formation.   These inhibitors are also just a subset 
of various inhibitors within group chemotypes, and further exploring the successful 
chemotypes can lead to a novel family of type-IV kinase inhibitors that can disrupt the 
interaction between BRAF and MEK (Müller et al., 2015).  X-Ray crystallography can also 
be used to perform structure-based drug design to improve these inhibitors.   They can then 
be chemically linked to vemurafenib to develop a selective class of kinase inhibitor that 
can be selective towards BRAFV600E while disrupting proliferation of the phosphorylation 
cascade in a synergistic fashion.   The MEK/RAF heterodimerization can also further be 
exploited by developing chemically linked heterodimeric inhibitors that can target both 
BRAF and MEK at the same time.  The crystal structure demonstrates that their dimer 
interface places the active site of BRAF within close proximity of the allosteric site of 
MEK (Haling et al., 2014).   Chemically linking vemurafenib or another inhibitor to an 
allosteric MEK inhibitor such as cobimetinib can provide further diversity within MAPK 
pathway inhibitors that can target transactivation.    
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